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CHAPTER 1 
INTRODUCTION 
и 

INTRODUCTION 
Ultrafiltration 
Glomerular ultrafiltration is a complex process, whereby through the transcapillary 
passage of plasma fluid an ultrafiltrate is formed, which is virtually devoid of blood cells 
and the major plasma proteins. This process is regulated by hemodynamic factors 
(glomerular plasma flow rate and hydrostatic pressure), oncotic factors (predominantly the 
protein concentration of the plasma) and intrinsic biochemical and biophysical properties 
of the glomerular capillary wall (GCW) [1,2]. Tracer studies performed in the last two 
decades have shed light on the permeability characteristics of the GCW. These results 
indicate that the GCW behaves like a sieve, since small molecules, like inulin, can pass 
the GCW without any restriction, but with increasing molecular size the passage into the 
urinary space decreases progressively [3]. This phenomenon is called the size-dependent 
permeability of the GCW. Subsequently, the significance of the charge of filtered 
molecules was discovered to be a major determinant of glomerular filtration. Independent 
observations indicate that the GCW retards the filtration of circulating polyanions, 
whereas the filtration of polycations was enhanced [4-7]. This is called the charge-depen-
dent permeability of the GCW (Fig.l). 
FRACTIONAL 
CLEARANCE 
Fig. 1. Fractional clearances of 
diethylaminoethyl (DEAE) dex-
tran, neutral dextran, ami dex-
tran sulfate, plotted as a fiinction 
of effective molecular radius (À) 
in normal rats. With increasing 
radius, the fractional clearance 
decreases (size-dependent perme-
EFFECTIVE MOLECULAR RADIUS (Â) ability). For the same size, the 
fractional clearance of DEAE dextran (positively charged) is facilitated, whereas the 
fractional clearance of dextran sulfate (negatively charged) is retarded compared to 
neutral dextran (charge-dependent permeability). Reproduced with permission from: 
Kanwar YS. Lab Invest (1984): 51:7-21. 
• ZO 22 24 Μ 2 · 30 52 54 3« M 40 42 44 
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These findings indicate the presence of fixed negative charges within the GCW. 
Although originally the negatively charged sialoglycoprotems on the cell membranes of 
epithelial cells were thought to be the major determinants of the charge selective proper­
ties of the GCW [8], nowadays most attention is focussed on heparan sulfate (HS). This 
molecule is the negatively charged glycosaminoglycan side chain of heparan sulfate 
proteoglycan (HSPG), which is constitutively present in the glomerular basement 
membrane (GBM) of the GCW [9,10]. The structure of the GCW and the presence of 
anionic sites on cell membranes of epithelial cells as well as in the GBM are illustrated in 
Fig.2. 
Fig. 2. A: Anionic cell surface sialoglycoproteins (SGP) covering the epithelial foot 
processes (fp) are stained with colloidal iron. B: Structure of the GCW. It is made up of 
epithelial foot processes (fp) with intervening slit diaphragms (Sd), GBM, and fenestrated 
(fn) endothelium (En). GBM consist of lamina densa (LD) and lamina rara interna (LRI) 
and externa (LRE). C: Heparan sulfate-associated anionic sites of the GBM are decorated 
with groups of ferritin particles (arrowheads) in LRE and LRI. US = urinary space (A 
and C, χ 50,000; Β, χ 60,000). Reproduced with permission from: Kanwar YS. Lab Invest 
(1984): 51:7-21. 
Heparan sulfate proteoglycan 
Proteoglycans are produced by most eukaryotic cells and are components of pericellular 
and extracellular matrices (ECM) [11,12]. They consist of a core protein to which one or 
more glycosaminoglycan side chains are attached [13-15]. Glycosaminoglycans are 
unbranched chains of repeating disaccharide units, which, with the exception of keratan 
sulfate, contain an uronic acid and an hexosamine. The characteristics of the different 
classes of glycosaminoglycan disaccharide units are summarized in Table I . 
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Table I. General composition of the glycosaminoglycans (general formula: (A-B)J 
Glycosarmno- Sulfate (moles Mr range 
glycan A В /disacchande) Linkage (kDa) 
A-»B B-»A 
Hyaluronan 
Chondroitm 4-
sulfate 
Chondroitm 6-
sulfate 
Dermatan sulfate 
Heparan sulfate 
Heparin 
Keratan sulfate 
GlcA1 
GlcA 
GlcA 
IdoA 
IdoA/GlcA 
IdoA/GlcA 
Gal 
GlcNAc 
GalNAc 
GalNAc 
GalNAc 
GlcNAc 
GlcNAc 
GlcNAc 
0 
0.2-1.0 
0.2-1.3 
1 0-2.0 
0.2-3.0 
2.0-3.0 
0.9-1.8 
641-3) 
1H1-3) 
ß-(l-.3) 
α-(1-3) 
a/ß-(l-*4) 
a/ß-(l-4) 
ß-(l-»4) 
β-(1-*4) 
ß-(l-4) 
ß-(l-4) 
ß41-4) 
o,-(l-4) 
eKl-M) 
ß-(l-3) 
'Abbreviations: GlcA = Glucuronic acid; IdoA = Iduronic acid; Gal = Galactose; 
GlcNAc = N-acetyl-glucosamine; GalNAc = N-acetyl-galactosamine 
The glycosaminoglycan chains (with the exception of heparin and hyaluronic acid) are 
mostly covalently bound to a serine residue of the protein core by a trisaccharide, with 
the general structure of: | 
- D-Gal - D-Gal - D-Xyl - Serine 
I 
The basic repeating disacchande unit of heparan sulfate is formed by an l-*4 linked 
sequence of glucosamine and uronic acid. The glucosamine residues are either N-
acetylated or N-sulfated. N-sulfation is only found in HS and heparin. The amino sugars 
can also be ester (O)-sulfated at the C-6, C-4 and C-3 position. Uronic acid residues are 
glucuronic acid and its C-5 epimer, iduronic acid and can be O-sulfated at C-2 (Fig.3) 
[16]. The presence of sulfate groups together with the carboxyl groups of the uronic acid 
residues are responsible for the highly negative charge of HS at physiological pH. It is 
important to realize that extensive sequence variability can be generated by different 
arrangements of the sugar components. 
60-10,000 
5-50 
5-50 
15^0 
5-12 
7-16 
4-19 
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Fig. 3. The carbohydrate composition of heparan 
sulfate (for abbreviations see Table I). The disaccha-
rides are shown in three forms; an N-acetylated type 
(i) and two N-sulfated types (ii) and (Hi). In each 
example R may be SO/ or H. GlcNS03 may be pre­
sent as a 3-0-sulfated or 6-O-sulfated derivative and 
also as a di-O-sulfated component. Reproduced with 
permission from: Gallagher et al.. Biochem J (1986): 
236:313-325. 
lui) GlcNSOja1-4ldUAa1-4 
Despite the fact that HS and heparin are made up of identical disaccharide units (Table 
I), there are several differences. Heparin is a highly sulfated mast cell product that 
contains mostly N-sulfated hexosamines (>80% of N-glucosamine units) and shows 
always a molar excess of O-sulfation over N-sulfation. In HS there is a significant 
variation in the number of O-sulfate groups and about 50% of N-glucosamine units are 
sulfated. Moreover, heparin has a higher percentage of iduronic acid than HS [16]. 
In general, there are two classes of HSPGs, one class is present on the cell membrane 
of many cell types, the other class is expressed in the ECM and more specifically in 
basement membranes (BMs) [16]. Cell surface-associated HSPGs are either integral 
plasma membrane components, like the syndecan family [17-24], peripheral components 
covalently bound to the cell surface via a glycosyl phosphatidylinositol-membrane anchor, 
like glypican [25], or non-covalently via their glycosaminoglycan chain or core protein to 
recepte»· structures present in the cell membrane (Fig.4) [26]. 
CH,OR 
со, H 
он 
H ÒH 
~CHi 
(il GlcNAca! *4GlcUA01-4 
lul GlcNSOja1-4GlcUA01-4 
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Glycosaminoglycan 
Core protein / 
Ca) Cb) (с) Cd) 
Fig. 4. The attachment of cell surface-associated HSPGs to the cell membrane. The HSPG 
molecule may be an integral plasma membrane component anchored via a hydrophobic 
peptide segment like syndecan (a) or covalently linked to an inositol-containing phospholi­
pid like glypican (b). Alternatively, the core protein (c) or the glycosaminoglycan side 
chains (d) may be non-covalently bound to a receptor which is itself an integral plasma 
membrane component. Reproduced with permission from: Fransson L-À. TIBS (1987): 
12:406-411. 
BM-associated HSPGs can be secreted into the extracellular space, where they bind to 
and interact with other BM components. HSPGs can bind a large amount of water and 
thereby occupy a large space relative to their weight [13], which may influence the 
general chemical and physical properties of BMs or ECM. Table II summarizes the main 
characteristics of HSPGs. 
Table П. General characteristics of heparan sulfate proteoglycans 
• consist of a core protein carrying one or more HS-side chains 
9 are present on cell membranes and in basement membranes 
• carry a highly negative charge 
• occupy a large volume in aqueous solutions 
Both classes of HSPGs, mentioned above, are immunologically and structurally 
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completely different. Antibodies against one HSPG class do not cross-react with the other 
[27,28]. Moreover, the primary structures of HSPGs belonging to the syndecan family 
[17-24] or glypican [25] completely differ from that of the large BM HSPG [29-31]. Also 
their chromosomal localization is different. The gene coding for the human cell surface 
HSPG fibroglycan is located on chromosome 8 [23], whereas the gene for the human BM 
HSPG has been demonstrated on chromosome 1 [32-34]. 
Heparan sulfate - protein interactions 
HSPGs can bind to a wide variety of biologically active proteins. Many of these 
interactions are mediated by the HS component [35]. The HS-protein interaction may 
require specific sugar sequences (as is the case with heparin/HS with antithrombin III) or 
may be primarily charge-charge dependent (as is the case with the binding of HS to 
various ECM molecules and growth factors). Most of these proteins bind to HS by 
regions containing multiple basic amino acids [35]. However, not all HSPG-protein 
interactions are mediated by the glycosaminoglycan component. For example, the core 
protein of ECM-HSPG binds specifically to fibronectin [36]. It is however, beyond the 
scope of this introduction to discuss in detail the significance of all HSPG-protein 
interactions. A list of the most important proteins binding to HS, are given in Table III. 
Some of the studies mentioned in this Table, have been carried out with heparin, but in 
general also apply for HS. 
Functions of cell surface HSPGs 
From the characteristics of HSPGs (Table II) together with the existence of many HS-
binding proteins (Table III), it is clear that HSPGs play a role in many biological 
processes. 
Cell surface HSPGs have been strongly implicated with a role in cell-cell and cell-
matrix interactions, and with the growth, adhesion and differentiation of cells [26,37-42]. 
Moreover, cell membrane-associated HSPGs on endothelial cells have been shown to bind 
and activate very effectively antithrombin III, thereby providing an anti-thrombogenic 
barrier at the inner side of vessel walls [43,44]. Detailed information about the functions 
of cell surface HSPGs are given in references 26, 37 and 38 and will not be discussed 
further in this overview. 
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Table Ш. Proteins binding to heparan sulfate1 
• Proteins involved in hemostasis 
antithrombin III [43-46] 
thrombin [46,47] 
platelet factor IV [48-50] 
• Proteins involved in lipid metabolism 
low-density lipoproteins [46,51] 
lipoprotein lipase [52-55] 
• Basement membrane components 
fibronectin [56,57] 
laminin [58-61] 
collagen type IV [62] 
• Transcription factors [35,63] 
• Growth factors 
basic FGF2 [25,64-66] 
acidic FGF [67,68] 
GM-CSF [69] 
IL-3 [69] 
• Others 
viral coat proteins [70,71] 
histones [72,73] 
'References are given in parentheses 
abbreviations: FGF = fibroblast growth factor 
GM-CSF = granulocyte macrophage colony stimulating factor 
IL-3 = interleukin 3 
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Basement membranes 
Basement membranes are thin, sheet-like ECM structures found beneath epithelium and 
endothelium or completely surrounding muscle and fat cells and peripheral nerve fibers. 
On electron microscopy BMs consist of an electron-lucent lamina rara and an electron-
dense lamina densa. Ultrastructural studies revealed that BMs are organized into a 
network, formed by fibrils or cords. These cords are closely packed in the lamina densa 
and moore loosely arranged in the lamina rara [74-78]. BMs contain a panel of unique 
components, such as laminin, collagen type IV, entactin/nidogen and HSPG [79]. Some 
components such as osteonectin/BM-40/SPARC are not exclusively present in BMs 
[80,81], while other components like fibronectin [79] and serum amyloid Ρ component 
[82-84] are derived from the circulation and probably bind to HS. The precise localizati­
on of the different BM constituents within the ultrastructural framework of the different 
BMs will not be detailed here, but for the GBM there are indications that the HSPG-core 
protein in mainly located in the lamina densa, whereas the HS side chains protrude in the 
laminae rarae [85]. Excellent reviews are available, dealing with the development, 
(ultra)structure, function and pathology of BMs [75,79,86-88]. The GBM is a special type 
of BM, since early in embryogenesis, a fusion takes place between two BMs: one beneath 
the vascular endothelium and one beneath the visceral epithelial cells, thereby forming the 
three-layered GBM [89,90]. 
Functions of BM HSPGs 
As will be outlined below, BM-associated HSPGs are thought to be responsible for the 
charge-dependent permeability of BMs (especially the GBM), for the assembly and 
integrity of BMs by interactions with other BM components, for the hydration of BMs, 
for the intimate BM-cell interactions and for the modulation of the availability of growth 
factors. Much of the initial work on GBM HSPG has been done by the group of Kanwar 
and Farquhar, who in 1979 reported the presence of HS in the GBM [10,91]. In the 
following years, they provided evidence for the role of GBM HS in the charge-dependent 
permeability, since after enzymatic degradation of HS by heparitinase, the GCW did not 
restrict anymore the transcapillary passage of anionic ferritin and of albumin into the 
urinary space [92,93]. At the same time they could show that after neutralization of the 
charge of the GCW, plasma proteins could enter the GBM, leading to a reduction of the 
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glomerular nitration rate. They also found that the HSPG-associated, anionic sites of the 
GCW had an anti-clogging effect on the glomerular transcapillary flow of solutes by 
keeping the GBM hydrated [94]. The findings of Kanwar and Farquhar were supported by 
several other investigators who neutralized the anionic charges of the GCW by intrave-
nous or intrarenal injection of cationic molecules and found an increased GBM permeabi-
lity [95-99]. All the studies, mentioned above, suggest a relationship between the HS-
associated anionic charge of the GBM and the permeability of the GCW. Therefore, 
several investigators tried to relate the status of GBM HSPG to the onset or existence of 
proteinuria in many types of glomerulopathies [100]. Firstly, with cationic probes, both in 
human and in experimental glomerulopathies, a reduction of GBM anionic sites was found 
in systemic lupus erythematosus [101-103], minimal change disease [8], membranous 
glomerulonephritis (GN) [104-108], congenital nephrotic syndrome [109], IgA nephropa-
thy [110,111], diabetic nephropathy [112-114] and aminonucleoside nephropathy [114]. 
Secondly, with biochemical and immunochemical methods HSPG alterations were 
observed in membranous GN [116], polycystic kidney disease [117] and diabetic 
nephropathy [118-122]. However, in most of these studies the methods used (cationic 
probes, 3SS-sulfate incorporation) are not specific for HS and a number of controversies 
still exists, that hamper a clear interpretation [123-129]. Finally, some reports dealt with 
a semi-quantitative immunohistochemical examination of the HSPG-core protein in several 
glomerulopathies [130-136], but the amount of HSPG-core protein does not necessarily 
reflect the amount of GBM HS. Despite this, the general conclusion is that a decreased 
GBM HS content is accompanied by an increased permeability of the GCW, especially 
for anionic molecules like albumin. 
In vitro experiments on the molecular interaction between isolated BM components 
suggest a structural role for BM HSPG, since it increased the precipitation of laminin, 
particularly in the presence of type IV collagen [137]. Moreover, the simultaneous 
incubation of laminin, type IV collagen and HSPG at 350C yielded BM-like structures as 
determined ultrastructurally [138]. In the model of BM assembly described by Yurchenco 
[76,88], HSPG binds to itself to form core oligomers, and so induce a peripheral 
orientation of the HS chains, which bind to laminin molecules present in a lattice-like 
framework. These studies indicate that BM HSPG is actively involved in the assembly 
and integrity of the three-dimensional structure of BMs. 
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Two studies provided some evidence for a role of BM HSPG in the intimate BM-cell 
interactions. Clément et al [139] identified a cell surface-binding protein for the core 
protein of BM HSPG on several cell lines, for instance rat kidney epithelial cells. This 
binding protein had an apparent molecular weight of 38 kDa. They also reported the 
presence of a cationic 80 kDa HS-binding protein on the cell surface of rat hepatocytes 
[140]. Another study [141] demonstrate the presence of BM HSPG and fibronectin in 
ECM fibers at the substrate adhesive surfaces of cultured stationary fibroblasts. They 
suggested that the appearance of BM HSPG in these ECM fibers might stabilize the 
fibronectin-containing cell-substrate contacts. 
Like other proteoglycans, BM HSPGs can function as modulators of growth factors 
[142]. For instance, basic fibroblast growth factor (FGF) is normally sequestered in ECM 
and BMs by binding to HS. Release of this HS-bound basic FGF by heparin-like 
molecules or HS-degrading enzymes leads to the growth of new capillaries in normal and 
pathological situations [143]. Furthermore, Gordon et al [67] isolated HSPGs from the 
ECM of human endothelial cells in vitro, which could modulate the mitogenicity of acidic 
FGF. 
Heterogeneity in basement membrane HSPG 
In recent years, several types of BM HSPG have been described. They could be 
categorized into two groups: one group of high density, low-molecular-weight HSPGs, 
mainly of glomerular/GBM origin [131,144-148], and a second group of low-density, 
high-molecular-weight HSPGs, purified from the murine Engelbreth-Holm-Swarm (EHS) 
sarcoma or from other sources, but immunologically related to it [85,149-152]. The 
relationship between both types of HSPGs is at present unknown. Some investigators 
suggest that the large HSPG is a precursor of the small HSPG [153]. However, the 
glomerular localization of both types of BM HSPGs, as detected by indirect immunofluo-
rescence on human kidney cryostat sections using monoclonal antibodies is quite different 
(Fig.5), and suggests two different HSPG molecules. Recently, a novel HSPG was 
characterized, which was purified from liver extracellular matrix, and was shown to be 
different from the other BM HSPGs described above [154]. 
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Fig. 5. Indirect immunofluorescence on human kidney cryostat sections with monoclonal 
antibodies against (A) the large EHS HSPG which cross-react with human HSPG 
(antibody kindly provided by Dr. John R. Couchman, University of Alabama, Birming­
ham, U.S.A.) or against (B) the small human GBM HSPG (mAb JM-72). Note the 
difference in the glomerular staining pattern; in (A) predominantly a mesangial staining 
and in (B) a strong GBM staining (A and Β, χ 400). 
The complete DNA sequence of the murine EHS HSPG, called perlecan, and of its 
human homologue from a human fibrosarcoma (HT1080) and colon carcinoma cell line 
were published [29-31]. In both species the total HSPG molecule consisted out of five 
different domains, most of which contain internal repeats (Fig.6). The major differences 
between mouse and human perlecan are found in domain IV, which contains Ig repeats: 
seven additional repeats are found in the human protein inserted in the middle of the 
second repeat in the mouse sequence [29]. At present, no DNA data are available on the 
other BM HSPGs mentioned above, so the relationship between the several BM HSPGs is 
still open. 
The heterogeneity of HSPG expression in BMs is not unique, since it has been 
described for other BM components like collagen type IV, that Can be build up from at 
least 5 different α-chains, and laminin that also can be assembled out of 5 different chains 
[155]. 
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Fig. 6. Molecular model of the human perlecan protein core. Reproduced with permission 
from: Murdoch et al.. J Biol Chem (1992): 267:8544-8557. 
Aim of this study 
Monoclonal antibodies (mAbs) against epitopes on the HSPG-core protein as well as on 
the HS-side chains can be of great value to evaluate the role of HSPG in glomerular 
filtration and renal disease. The major aim of this study was to develop such mAbs. With 
these antibodies it became possible to study whether HSPG or HS are nephritogenic 
targets and whether intravenous injection of these antibodies into experimental animals 
can induce alterations in glomerular filtration. Moreover, these antibodies could be used 
to study the localization of HS and HSPG-core in normal tissues and their expression in 
renal diseases by immunohistochemical methods. Furthermore, such antibodies might be 
used to quantify immunochemically the HSPG-core and/or the HS content of tissue 
extracts and biological fluids, and of HS(PG)-containing fractions during purification 
procedures. In this thesis the production, characterization and some applications of mAbs 
against the HSPG-core protein and the HS-side chain are described. 
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Production and Characterization of a 
Monoclonal Antibody Against Human 
Glomerular Heparan Sulfate 
J. VAN DEN BORN, L. P. W. J. VAN DEN HEUVEL, Μ. Α. Η. BAKKER, J. Η. VEERKAMP, 
К. J. M. ASSMANN, AND J. H. M. BERDEN 
Departments of Medicine, Division of Nephrology, Biochemistry, and Pathology, University of 
Nijmegen, Nijmegen, The Netherlands 
After immunization with heparan sulfate proteoglycan (HSPG) isolated from human glomeruli, 
two mouse monoclonal antibodies (mAbs) against heparan sulfate (HS) were obtained. Both mAbs 
were of the IgM isotype and showed identical specificity. One of these, mAb JM-13 is described in 
detail. In enzyme-linked immunosorbent assay and Western blotting, reactivity was found with 
human glomerular basement membrane HSPG and HS. No binding occurred to the core protein of 
HSPG obtained after removal of HS with trifluoromethanesulfonic acid. In enzyme-linked immu­
nosorbent assay, mAb JM-13 did neither bind to other proteoglycans, nor to other basement 
membrane components like collagen type IV, laminin, or fibronectin. In indirect immunofluores­
cence on cryostat sections of human kidneys, a restricted staining of tubular basement membranes 
was observed along with staining of the vascular basement membranes. In the glomerulus, a weak, 
fine granular staining was seen along the capillary wall and in the mesangium. MAb JM-13 bound 
also to the basolateral cell membranes of proximal tubular cells, to the cell membranes of cultured 
human and rat glomerular visceral epithelial cells, rat mesangial cells, human hepatocytes in 
culture, and in liver cryostat sections, indicating also a recognition of cell surface-associated HS. 
Pretreatment of the sections with heparitinase abolished binding of JM-13, whereas treatment 
with chondroitinase ABC had no effect. Inhibition studies in enzyme-linked immunosorbent assay 
as well as in indirect immunofluorescence corroborated the HS specificity of mAb JM-13. In 
conclusion, mAb JM-13 binds to an epitope on the HS chains of glomerular, tubular, and cell 
surface-associated HSPG. 
Additional key words: Heparan sulfate proteoglycan, Glomerular basement membrane, Cell 
surface. 
Heparan sulfate (HS) plays a crucial role in glomerular 
permselectivity, since its anionic moieties are the major 
determinants of the negative charge of the glomerular 
basement membrane (GBM). These negative charges are 
held responsible for the charge-dependent permeability 
of the GBM (9,10). After enzymatic removal of HS from 
the GBM, the glomerular capillary wall loses its ability 
to restrict the passage of albumin (44). Intrarenal от 
intravenous injection of various polycationic probes, that 
neutralize the negative charge of the GBM, results in an 
increased permeability of the GBM for circulating 
plasma proteins (3, 5, 24, 28, 50, 56). In several experi­
mental models of proteinuria (puromycin aminonucleo-
side nephrosis, anti-GBM nephritis, remnant kidney 
model, diabetes mellitus), an association has been found 
between reduction of anionic sites and proteinuria (10, 
11, 15, 26, 34, 40). In humans, a reduction of HS-associ-
ated polyanionic sites has also been held responsible for 
the proteinuria in the congenital nephrotic syndrome 
(57) and diabetes mellitus (41, 49). Besides its function 
in glomerular permeability, there is also evidence that 
GBM HS can serve as an acceptor for cationic antigens, 
antibodies and immune complexes, that can result in 
proteinuria (7, 21, 27, 46, 48). Recent evidence suggests 
that HS can also act as an epitope for antibody binding, 
as was demonstrated by Fillit et al. (17) in patients with 
poststreptococcal glomerulonephritis. We showed that 
anti-DNA antibodies from systemic lupus erythematosus 
patients can bind to HS (14). However, the precise 
relationship between the HS content of the GBM and 
proteinuria is not clear yet and needs further elucidation 
(6,18, 20, 32, 51). To study the function and distribution 
of renal HS, well-characterized antibodies can be an 
important tool. We therefore attempted to produce 
monoclonal antibodies (mAb) against HS. We hereby 
report the production of two of these mAb, and describe 
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one of them, mAb JM 13, in detail With this mAb, a 
distribution study in the human kidney was performed 
that showed a restricted basement membrane (BM) 
staining along the nephron 
EXPERIMENTAL DESIGN 
For the production of anti-HS mAbs, mice were im 
mumzed with various antigenic preparations After im 
mumzation of mice with heparan sulfate proteoglycan 
(HSPG) isolated from human glomeruli, two mAbs were 
obtained that were directed against HS One of these 
mAbs, JM-13 is described in detail HS specificity of 
mAb JM-13 was demonstrated by enzyme-linked im 
munosorbent assay (ELISA), Western blotting, inhibí 
tion studies and indirect immunofluorescence by using 
specific glycosaminoglycan-degrading enzymes The lo 
calization of the epitope recognized by this anti HS mAb, 
was studied in the normal human kidney using indirect 
immunofluorescence (IIF) The precise localization of 
the restricted tubular basement membrane (TBM) stain 
ing was further defined by double staining with mAb 
JM 13 and antibodies that identify specific segments of 
the nephron The faint granular staining in the glomeruli 
was studied by incubating glomerular cells in culture 
with mAb JM 13 
RESULTS AND DISCUSSION 
PRODUCTION OF MAB AFTER DIFFERENT 
IMMUNIZATION PROCEDURES 
After immunization of female BALB/c mice with HS, 
HS complexed to methylated bovine serum albumin 
(3SA), HS coupled to EAH Sepharose, or hepann-Seph 
arose no antibody response against HS could be observed 
m the serum of these mice as assessed by ELISA and IIF 
on kidney cryostat sections After fusion of the spleen 
cells of these mice with the SP2/03 mouse myeloma, no 
HS specific mAbs were obtained 
After immunization of female BALB/c mice with hu 
man glomerular HSPG, we obtained two mAb against 
this immunogen Both mAb were of the IgM isotype and 
showed identical specificity The characteristics of one 
of the antibodies, mAb JM-13, are presented in detail 
REACTIVITY OF MAB JM-13 
In ELISA, mAb JM 13 bound to intact GBM HSPG, 
but showed no reactivity with the core protein of HSPG 
obtained after removal of HS with tnfluoromethanesul-
fomc acid (TFMS) It also bound to isolated HS chains 
obtained after /J-elimination of human GBM HSPG with 
alkaline NaBH4 and to HS from bovine kidney (Fig 1) 
These results indicate that mAb JM 13 recognizes an 
epitope on the HS chain of GBM HSPG Western blot-
ting (Fig 2) confirmed these ELISA data MAb JM 13 
stained intact GBM HSPG (Fig 2A, lane 4), but not the 
core protein obtained after treatment with heparitinase 
(Fig 2Λ, lane 2) or after treatment with HNO,. (Fig 2A, 
lane 3) or TFMS (Fig 2A, lane 1) Control experiments 
showed staining of the same HSPG preparations using 
JM 72, a mAb directed against an epitope on the core-
protein of GBM HSPG The latter mAb reacted with the 
intact proteoglycan (Fig 2B, lane 4) as well as with the 
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A 450 nm 
Ajg mAb/ml 
Fir. 1 Reactivity of mAb JM 13 in ELISA with GBM HSPG 
(—V—) the core protem of GBM HSPG obtained after removal of 
the HS chains by TFMS ( - S - ), HS isolated from GBM HSPG 
after alkaline NaBHi treatment (—0—) and HS from bovine kidney 
(—Π—) Τ he results are expressed in absorption units at 450 nm 
(A450) 
core protein obtained after the various deglycosylation 
treatments (Fig 2ß, lanes 1 to 3) This indicates that no 
degradation of the core protein has occurred during the 
various deglycosylation procedures The intact proteo-
glycan had a molecular mass of 200 to 400 kilodaltons 
(kd) (Fig 2A and B, lane 4) Treatment of the proteogly-
can with TFMS (which cleaves HS and all О and JV-
hnked oligosaccharides from the core protein) resulted 
in a decrease in its molecular mass to a main band of 120 
kd (Fig 2B, lane 1), whereas HNO2 and heparitinase 
treatment, which cleave the N-sulfated part of the HS 
chain and the total HS-chain, respectively (Fig 25, lanes 
3 and 2), resulted in a less substantial decrease m molec­
ular mass than TFMS hydrolysis The decrease in stain­
ing intensity from lanes 1 to 3 in Fig 2B probably results 
from this decreasing extent of deglycosylation The re­
moval of negative charges enhances the blotting effi­
ciency No staining of the blot was seen after incubation 
of the intact proteoglycan or the core proteins with 
nonrelevant mAbs of the IgM or IgGl subclass (not 
shown) 
In ELISA, the binding of mAb JM 13 to coated HS 
could be inhibited in a dose dependent manner by GBM 
HSPG, but not by the core protem obtained after hy­
drolysis with TFMS Preincubation of the antibody with 
HS did not inhibit its binding to coated HS If HS was 
complexed to protamine chloride however, it inhibited 
very effectively the binding of mAb JM-13 to HS, 
whereas protamine chloride without HS was not inhibi­
tory at all (Fig 3) The same results were obtained in 
IIF Inhibition of JM 13 binding to the sections occurred 
after preincubation of JM 13 with intact GBM HSPG 
and HS complexed to protamine chloride, whereas no 
mAb JM-13 
В 
mAb JM-72 
100 7 
' 
- 205 -
116 
97.4 
66 
45 
- 29 -
0.1 1 10 100 
concentration inhibitor (ug/ml) 
FIG. 3. Dose-dependent inhibition of the binding of mAb JM-13 in 
ELISA (using HS as coated antigen) by GBM HSPG (—·—j and HS 
complexed to protamine chloride (—С—). No inhibition occurred by 
GBM HSPG core protein, protamine chloride or not complexed HS 
(—V—). The results are expressed as the percentage inhibition of the 
ELISA signal obtained without inhibitor. 
1 2 3 4 1 2 3 4 
FIG. 2. Western blotting with intact GBM HSPG or the core pro­
tein of this proteoglycan prepared in different ways. A, Blot incubated 
with anti-HS mAb JM-13. B, Blot incubated with JM-72, an anti-
GBM HSPG-core mAb. Lanes i to 4 are identical for A and В Lane I, 
Core protein obtained after treatment with trifluoromethanesulphonic 
acid (TFMS). Lane 2, Core protein obtained after treatment with 
heparitinase. Lane 3, Core protein obtained after treatment with HNO2. 
Lane 4, Intact GBM HSPG. 
inhibition occurred with HSPG core protein, non-com-
plexed HS, and protamine chloride. 
To test whether mAb JM-13 reacted with other gly-
cosaminoglycans, binding was tested in ELISA with der-
matan sulfate-, chondroitin sulfate-, and keratan sulfate-
proteoglycan. In none of these assays was reactivity 
found, which indicates that mAb JM-13 does not recog­
nize epitopes on chondroitin sulfate A and C, dermatan 
sulfate, or keratan sulfate. In addition, mAb JM-13 
showed no reactivity with other basement membrane 
components like laminin, fibronectin, or collagen type 
IV. These results indicate that mAb JM-13 is specific for 
HS. 
IMMUNOFLUORESCENCE STUDIES WITH MAB JM-13 
In IIF on cryostat sections of human kidneys, mAb 
JM-13 gave a weak and faint, fine granular staining of 
the glomerulus (Fig. 4A) and bound to certain parts of 
the TBM along the nephron (Fig. 4B). The precise 
localization of the TBM staining was analyzed by double 
staining with both mAb JM-13, and with monoclonal 
and polyclonal antibodies that identified certain seg­
ments of the nephron (Fig. 5). The BM of the convoluted 
and straight parts of the proximal tubules, identified 
with mAb BB-10 (Fig. 5B), were negative or showed a 
weak, segmental staining with JM-13 (Fig. 5A). The 
loops of Henle with their characteristic butterfly-like 
appearance, as seen with mAb RCK-105 (Fig. 5D), did 
not show reactivity for mAb JM-13 (Fig. 5C). The thick 
ascending limb identified with anti-Tamm Horsfall pro­
tein (Fig. 5F), stained clearly with mAb JM-13 (Fig. 5E). 
The connecting tubules, containing the 28-kd calcium 
binding protein in their cytoplasm (Fig. 5Я) were mostly 
negative for JM-13 (Fig. 5G). The collecting ducts, pos­
itive for cytokeratin 7, showed in the cortex (Fig. 5J) a 
negative staining with JM-13 (Fig. Ы) and in the medulla 
(Fig. 5L) a moderate reactivity with mAb JM-13 (Fig. 
5K). By comparing these double-staining experiments, 
we found by exclusion that mAb JM-13 most strongly 
stains the BM of distal convoluted tubules and to a lesser 
extent, the BM of the thick ascending limb of Henle and 
of the medullary collecting ducts. It did not stain the 
descending and thin ascending limb of Henle's loop, the 
connecting tubules and collecting ducts of the cortex. 
The BM of the endothelium of the peritubular capillaries, 
arteries, arterioles, and venules also stained with mAb 
JM-13 (Fig. 6Л ), as indicated by the double staining with 
the lectin Ulex europaeus I (Fig. 6B). 
The mAb did not only react with BM-associated HS 
but also with cell surface-associated HS. First, we dem­
onstrated staining of the basolateral parts of many prox­
imal tubular epithelial cells (Fig. 7Л). Secondly, mAb 
JM-13 also stained in vitro human and rat visceral epi­
thelial and rat mesangial cells in a granular pattern on 
the cell membranes (Fig. ΊΒ). These findings suggest 
that the glomerular staining is due to the binding of mAb 
JM-13 to cell surface-associated HS present on glomer­
ular epithelial and mesangial cells. Whether mAb JM-13 
bound to endothelial cell surface-associated HS could 
not be ruled out because there was no glomerular endo-
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FIG. 4. Indirect immunofluorescence 
of mAb JM-13 on cryostat sections of 
human kidney. A, glomerulus, B, tubules. 
Note the restricted staining of the TBM. 
Figure 4Λ, X430; B, X330. 
thelial cell line available. In addition, we could demon­
strate the binding of mAb JM-13 to cell surface-associ­
ated HS present on human hepatocytes in culture and 
cryostat sections (Fig. 7C). All staining disappeared after 
pretreatment of the sections for 30 minutes at 37° С with 
1 unit/ml heparitinase, whereas after digestion with 
chondroitinase AB, ABC or hyaluronidase, staining was 
not altered. Pretreatment of the sections with other 
enzymes or dissociative agents (see the "Methods" sec­
tion) did not alter the staining pattern of mAb JM-13. 
No staining could be observed after incubation of the 
sections with a nonrelevant IgM mAb with the same 
immunoglobulin concentration as JM-13, indicating the 
specificity of our staining. In most other tissues, JM-13 
bound to the basement membranes in a fine granular 
pattern. IIF on rat kidney sections showed very similar 
staining patterns, indicating the cross-reactive recogni­
tion of rat HS (data not shown). 
DiSCUSSION 
In this study, we describe an IgM mAb (JM-13), ob­
tained after immunization with human glomerular 
HSPG, which is directed against an epitope present in 
several tubular and vascular BM as well as in glomerular 
and some tubular cell membranes. The following data 
indicate that mAb JM-13 is directed against HS. In 
ELISA and on Western blot, our mAb bound to intact 
HSPG, but not to the isolated core protein, obtained 
after hydrolysis of HS by TFMS, cleaving off all N- and 
O-linked polysaccharides (13), whereas JM-13 bound to 
the isolated HS chains, obtained after /3-elimination of 
GBM HSPG with NaBHi. The epitope is presumably 
located in the region in which Λί-sulfated groups are 
clustered, since the binding in the Western blot disap­
peared already after treatment of HSPG with HNO2 
(Fig. 2/1, lane 3), which cleaves off the ЛГ-sulfated parts 
of HS. Intact HSPG, but not the core protein without 
HS, could inhibit in a dose-dependent manner, the bind­
ing of mAb JM-13 to HS in ELISA. HS in the fluid 
phase however, inhibited JM-13 binding to HS after 
complexation of HS with protamine chloride. This mol­
ecule is also used in the HS-ELISA as precoating to 
obtain sufficient binding of the anionic HS to the micro-
titer plates. Apparently, mAb JM-13 recognizes an epi­
tope that becomes expressed or accessible if HS is either 
part of the HSPG molecule, or complexed with the highly 
cationic protamine chloride. These findings are in ac­
cordance to those reported by Gitel et al (19), who found 
that antibodies directed against heparin (structurally 
closely related to HS) could only be inhibited by heparin 
if it was complexed to a cationic macromolecule like 
protamine sulfate. The HS specificity was corroborated 
in ELISA in which no reactivity was found with chon-
droitin sulfate-, dermatan sulfate-, and keratan sulfate-
proteoglycans nor with the other BM components lami-
nin, collagen type IV and fibronectin. Furthermore, HS 
specificity was confirmed in IIF, in which the staining 
disappeared after pretreatment of the sections with 
FIG. 5. Peripheral part of the figure: IIF with mAb JM-13 (A, C, £, 
G, ƒ, and K) on cryostat sections of human kidney double labeled with 
anti-brush border mAb BB-10 (S), with anti cytokeratin 7 mAb RCK-
105 (D, J, and L), with a polyclonal antiserum against the Tamm-
Horsfall protein {F), and with a polyclonal antiserum against the 28-
kD calcium-binding protein (Я). Central part of the figure: schematic 
distribution of JM-13 binding to distinct parts of the TBMs. Intensity 
of shading corresponds to the intensity of staining in the IIF 1 = 
Bowman's capsule. 2 = convoluted and straight parts of proximal 
tubule. 3 = descending part of Henles loop. 4 = ascending thin part of 
Henle's loop. 5 = ascending thick limb, 6 = distal convoluted tubule, 7 
= connecting tubule, 8 = cortical collecting duct, 9 = medullary col 
lecting duct. Figure 4Л and B, X430; С and D, X540: E and F, X270; G 
and H, X540; / and J, X680; К and L, X680. 
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FIG. 6. Double staining with mAb JM-13 (Л) or the lectin Ulex euwpaeus I (B). Note that the BMs of the structures, positive with Ulex, 
stain with mAb JM-13 (arroufs). 
heparitinase but not after pretreatment with chondroi-
tinase AC, ABC, or hyaluronidase. 
In IIF on cryostat sections of human kidneys, the 
staining of the TBM by JM-13 was not uniform, but 
restricted to certain parts of the nephron. With double 
staining, using antibodies that identified certain tubular 
segments of the nephron, we could locate the epitope in 
the BM of the distal convoluted tubule, the thick ascend­
ing limb, the medullary collecting tubule, and to a lesser 
extent, the proximal tubule. The epitope in the proximal 
tubules could not only be visualized in the BMs, but also 
in the basolateral parts of the cell membranes. In the 
vascular compartment, the epitope was predominantly 
present in BM of the peritubular capillaries and larger 
vessels. In contrast to the distinct presence of the epitope 
in several tubular and vascular BM, glomerular localiza­
tion was rather faint. The glomerular staining does not 
suggest a binding to the GBM, although the character­
ization of mAb JM-13 clearly demonstrates HS specific­
ity and a strong reactivity with isolated GBM HSPG. 
Based on the binding studies with glomerular (mesangial 
and visceral epithelial) cells in culture, the faint, fine 
granular staining in the glomerulus as seen in the IIF, 
could be due to binding of JM-13 to HS present on the 
cell membranes of these glomerular cells. 
The heterogeneity of BM staining can be explained by 
variations in the macromolecular composition of several 
BMs with variable interactions between the various in­
trinsic BM components. HS binding domains have been 
demonstrated on collagen type IV, laminin as well as 
fibronectin (52). It is conceivable, that binding of the 
HS-chains of HSPG to one or more of these BM com­
ponents interferes with the binding of mAb JM-13 to its 
epitope. After purification of HSPG from the GBM 
under dissociative conditions, all such macromolecular 
interactions are disrupted, which may set free the JM-
13 epitope. Although some investigators were able to 
unmask hidden epitopes in BMs (23), others failed to do 
so (1, 25, 47, 58). Our attempts, using pretreatment of 
the sections with several enzymes or dissociative agents 
also failed to enhance the binding of mAb JM-13. Such 
a selective epitope expression or accessibility within BMs 
is not unique, since it has been previously described for 
two other BM components. MAbs to laminin revealed a 
considerable heterogeneity of BM staining along the 
nephron, as well as between the GBM and TBM (1, 23, 
25, 33) and mAb against collagen type IV have also 
demonstrated a selective BM localization (47). Our re­
sults, showing a selective BM staining with an anti-HS 
mAb confirm this concept of BM heterogeneity (12). 
Whether the difference in staining of the TBM of the 
various tubular segments is related to differences in 
function is not known yet. Another possibility is that the 
make-up of the BM is related to the orientation, orga-
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FIG. 7. Binding of mAbJM-13 to cell 
surface-associated HS in IIF. {A); Stain­
ing of the basolateral cell membranes of 
proximal tubular epithelial cells; (B): 
granular staining on the cell surface of 
cultured human visceral epithelial cells; 
(C): staining of the cell membranes of 
hepatocytes in cryostat sections of a hu­
man liver. Arrows indicate the cell sur­
face-associated binding in A and С Fig­
ure 7Л, X430; В, X430; С, X800. 
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nization, and differentiation of the adjacent tubular ep­
ithelium. Recent evidence indicates that extracellular 
matrix proteins provide a substratum for cell adhesion 
by interacting with cell surface receptors. This contact 
induces signals for polarity, position, differentiation, and 
possibly growth of the cells involved (4, 39,45). Although 
it was demonstrated that HSPG is involved in cell-matrix 
interaction (31), it is not known whether the observed 
heterogeneity with respect to JM-13 staining is related 
to this function. Future studies centering on the dynamic 
interaction between cells and BMs, could provide impor­
tant information on the role of BM-HS in this interac­
tion. 
Earlier attempts, using GBM HSPG as immunogen, 
yielded only mAbs against epitopes of the HSPG core 
protein (J. van den Born, unpublished data). This is in 
accordance with findings of Kemeny et al. (29), who also 
generated only anti-GBM HSPG-core mAbs after im­
munization with bovine GBM HSPG. Attempts in which 
we immunized mice with HS, HS complexed to methyl­
ated BSA, heparin-Sepharose or HS coupled to EAH-
Sepharose, also failed to produce mAbs against HS. 
Apparently, immunization with HS without protein does 
not generate antibodies against HS. For the production 
of JM-13, we used glomerular HSPG that had a protein-
GAG ratio of 0.59, whereas the GBM HSPG preparations 
that yielded anti-HSPG core protein mAbs had a much 
higher protein-GAG ratio of 3.2. This lower ratio of 
glomerular HSPG is probably due to a limited proteolysis 
occurring during isolation. Whether this partial prote­
olysis of the HSPG molecule enhances the induction of 
an anti-HS response remains to be determined, but is a 
tempting explanation. 
Whether antibodies against HS have a pathogenetic 
significance in vivo is not yet known. Fillit et al. (17) 
reported the existence of antibodies against HS in the 
sera from patients with poststreptococcal glomerulo­
nephritis. However, the presence of anti-HS antibodies 
in the circulation does not prove a causal relationship 
with the glomerulonephritis. Abrass and Cohen (2) in­
vestigated the role of anti-HS antibodies in the devel­
opment of glomerular injury, by immunizing rats with 
HS. They demonstrated that the binding of anti-HS 
antibodies induced a mild inflammatory reaction in the 
glomerulus, along with a reduction in the glomerular 
filtration rate, but without proteinuria. They immunized 
however with commercially obtained HS, that contained 
contaminants like a 60 kd protein band. Miettinen et al. 
49 
(37) and Makino et al (35) studied the glomerular injury 
induced by a single, intravenous gift of polyclonal anti­
bodies against rat GBM HSPG A mild form of anti-
GBM-like nephritis occurred with (37) or without (35) 
the development of albuminuria The seventy of the 
disease could be increased by preimmunizmg the rats 
with normal rabbit IgG (36) The antibodies used in 
these studies were however, directed against the core 
protein of GBM HSPG It is not known whether anti-
HS antibodies, that bind to the GBM m situ, will have a 
more pronounced effect on GBM permeability. Although 
mAb JM-13 is cross-reactive with rat HS, this antibody 
is not suited for in υινο experiments, because the JM-13 
epitope on HS, m situ embedded in the GBM matrix, 
appeared to be hardly accessible for mAb JM-13 MAb 
JM-13 may however be useful for immunochemical and 
immunohistochemical studies of renal diseases, in which 
HSPG might be involved 
METHODS 
ISOLATION OF ANTIGENS, IMMUNIZATION PROCEDURES, 
A N D H Y B R I D O M A P R O D U C T I O N 
Isolation of Glomerular and GBM HSPG Human glomerular 
and GBM HSPG were isolated and characterized as previously 
described (53, 54) Briefly, human glomerular HSPG was iso­
lated by extraction of whole glomeruli, followed by ion ex­
change chromatography, DNase-, RNase-, and chondroitinase 
ABC treatment and CsCl density centnfugation Cellulose ace­
tate electrophoresis of the glycosaminoglycans, obtained after 
alkaline NaBH« treatment proved the presence of only HS 
The glomerular HSPG preparation had a protem-GAG ratio of 
0 59 GBM HSPG was isolated by extraction of human GBM, 
ion-exchange chromatography and gel permeation chromatog­
raphy (53) The isolated proteoglycan had a molecular mass of 
200 to 400 kd and HS chains of 18 kd The GBM HSPG 
preparation had a protem-GAG ratio of 3 2 The core protein 
of GBM HSPG was prepared according to the procedure of 
Edge et ai (13) with some minor modifications using TFMS as 
deglycosylatmg agent (53) In addition, HNO2 oxidation and 
hepantinase (Seikagaku Kogyo, Tokyo, Japan) treatment of 
HSPG were used to remove HS side chains as described before 
(53) HS chains were isolated from GBM HSPG using alkaline 
NaBHi treatment according to Parthasarathy and Spiro (41) 
Coupling of HS to Carriers HS from bovine kidney (Seika­
gaku Kogyo, Tokyo, Japan) was complexed with methylated-
BSA (Sigma Chemical Company, St Louis, Missouri) according 
to the procedure of Fiedel et ai (16) in a weight ratio of 1 4 
Under this condition both components are totally complexed 
In addition HS was coupled to EAH-Sepharose 4B (Pharmacia, 
Uppsala, Sweden) according to the manufacturer's instructions 
(1 mg HS/ml swollen gel), using N-ethyl N'-(3 dimethylami 
nopropyl)carbodiimide hydrochloride as coupling agent 
[mmumzation with HS HS (1 mg/ml), HS-methylated BSA 
complexes (1 mg complexes/ml of phosphate buffered saline 
(PBS)), HS coupled to EAH Sepharose 4B, or heparin Sepha-
rose (Pharmacia, Uppsala, Sweden), 1 1 diluted in PBS were 
emulsified m an equal volume of complete Freund's adjuvant 
Female BALB/c mice were immunized intrapentoneally every 
week with 0 2 ml of these emulsions during 3 months Four 
days after the last immunization, fusion was carried out as 
described below 
Immunization with Glomerular HSPG Female BALB/c mice 
were immunized intrapentoneally at days 0 and 30, with 50 |ig 
glomerular HSPG in 0 2 ml of PBS emulsified with 0 2 ml 
complete Freund's adjuvant At days 60, 61, and 62 the mice 
were boosted intravenously with 15 μg of human glomerular 
HSPG in 0 15 ml of PBS At day 63, the spleen cells were 
isolated and fused with the nonproducing mouse myeloma cell 
line, SP2/03 according to Kohier and Millstein (30) Syngeneic 
peritoneal macrophages (10,000 to 20,000 cells/well) were used 
as feeder layer Wells with growing hybndomas were screened 
in ELISA for anti HSPG and anti-HS reactivity, and by IIF 
on human kidney cryostat sections 
Cell Cultures After HAT selection, screening and expansion, 
cell cultures were transferred to HEPES buffered RPMI-1640 
culture medium containing 10% fetal calf serum, gentamycin 
(40 Mg/ml), pyruvate (110 Mg/ml) and glutamin (292 μg/ml), 
and cultured in an humidified incubator at 37° С with 95% air 
and 5% CO2 Selected wells were recloned by limiting dilution 
until all subclones showed the same reactivity pattern 
CHARACTERIZATION OF MAB 
Isotype Determination of mAb The antibody subclass was 
determined in ELISA Briefly, flatbottom microliter plates 
(Costar, Cambridge, Massachusetts), were coated with goat 
anti-mouse Ig, 12 5 μg/ml, 100 μΐ/well in PBS, overnight at 4° 
С After washing with PBS containing 0 05% Tween 20 (PES­
TI, nonspecific binding was blocked with PBS 1% gelatin for 
2 hours at 37° С After washing, the wells were incubated for 1 
hour at 37° С with 100-μ1 culture supernatant of the mAb 
After washing, the plates were developed with anti-mouse iso-
type-specific antibodies, conjugated with peroxidase (Nordic, 
Tilburg, The Netherlands), 1 500 in PBS-1% gelatin, 1 hour at 
37° С After washing, 100 μί of freshly prepared substrate 
solution (0 8 mg/ml 5 aminosalicylic acid in 50 т м phosphate 
buffer, pH 6 0, containing 0 8 Mg/ml, 30% vol/vol H2O2) were 
added to each well After 30 minutes, the signal was measured 
at 450 nm in a Titertek multiscan 
ELISA Studies Anti-HS ELISA was performed as previously 
described (14) Briefly, polystyrene microtiter plates (Costar) 
were precoated with 150 μ\ of 0 5 mg/ml protamine chloride 
(Kabi AB, Stockholm, Sweden) per well during a 2-hour incu­
bation at room temperature After washing with PBS, 100 μί of 
HS (Seikagaku Kogyo, Tokyo, Japan), 50 Mg/ml was added and 
incubated overnight at room temperature The plates were then 
washed five times with PBS To avoid nonspecific binding, the 
plates were subsequently coated for 2 hours at 37° С with 1% 
wt/vol gelatin dissolved in PBS, and then washed five limes 
with PBS, containing 0 05% vol/vol Tween 20 (PBS T) MAb 
was diluted in PBS, containing 1% gelatin in 2-fold dilution 
steps (final volume 100 μί) After 1 hour incubation at 37° C, 
the plates were washed five times with PBS-T The bound 
antibodies were detected by 100 μί of peroxidase conjugated 
rabbit anti-mouse Ig (Miles, Elkhart, Indiana) diluted 1 500 in 
PBS containing 1% gelatin After a 1-hour incubation at 37° 
C, the plates were washed five times with PBS-T followed by 
a 1 hour incubation at 37° С of peroxidase-conjugated goat 
anti rabbit Ig (Miles, Elkhart, Indiana) diluted 1 500 in PBS 
containing 1% gelatin The plates were washed five times with 
PBS-T and 100 μί of freshly prepared substrate solution (0 8 
mg/ml 5-aminosalicylic acid dissolved in 50 mM phosphate 
buffer, pH 6 0, containing 0 8 Mg/ml 30% vol/vol H2O2) was 
added to each well After 30 minutes, the signal was measured 
at 450 nm in a Titertek multiscan Supernatants were also 
tested in ELISA for antibody reactivity against HSPG and 
various other proteoglycans as previously described (53), and 
against lamimn (from mouse EHS tumor), fibronectin (from 
human plasma) and collagen type IV (from human placenta) 
according to Rennard (43) Dermatan sulfate proteoglycan from 
bovine lung was kindly provided by Dr A van Kuppevelt 
(Department of Biochemistry, University of Nijmegen, the 
Netherlands) and isolated as previously described (55) Chon-
droitin, dermatan, and keratan sulfate proteoglycan from hu-
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man and bovine hyaline cartilage were a generous gift of Dr R 
van der Stadt (J van Breemen Institute, Amsterdam, the 
Netherlands) Laminin, fibronectin and collagen type IV were 
commercially obtained from Sigma 
Western Blotting Intact GBM HSPG or its core protein 
obtained after the various deglycosylation procedures were run 
on 3 to 20% sodium dodecyl sulfate Polyacrylamide gels and 
blotted overnight to nitrocellulose as described (53) After 
incubation with mAb and development with peroxidase conju­
gated goat anti-mouse IgG (heavy and light chain), blots were 
stained with 4-chloro-l naphtol (22) 
Inhibition Experiments A constant amount of anti-HS mAb 
JM 13, giving 50% of the maximal ELISA signal, was added to 
an increasing concentration of inhibitor (GBM HSPG, GBM 
HSPG core protein, HS, HS-protamme chloride complex, pro­
tamine chloride) and incubated for 1 hour at 37° C, and sub­
sequently overnight at 4° С to optimalize immune complex 
formation Thereafter, this mixture was added to ELISA plates, 
coated with HS after precoating with protamine chloride 
Bound antibodies were developed identically as in the HS-
ELISA Percentage inhibition was calculated as 1 — (A450 + 
inhibitor / A450 - inhibitor) X 100% In other experiments, 
the antibody antigen complexes were transferred to cryostat 
sections IIP was performed as described below Inhibition was 
scored visually 
Positive Controls Positive controls, used in the ELISA stud­
ies and/or Western blotting were mAb JM-72 against the core 
protein of human GBM HSPG (J van den Born, unpublished 
data), mAb against human laminin (Calbiochem, La Jolla, 
California), mAb FN-15 against human fibronectin (Sigma), 
mAb CS-56 against chondroitin sulfate (Bio-Makor, Rehovot, 
Israel), mAb 1042 and mAb 1043 against human collagen type 
IV, a polyclonal antiserum against human collagen type IV and 
a polyclonal antiserum against mouse (EHS) laminin (all do 
nated by Dr J Ρ M Cleutjens, Department of Pathology, 
University of Maastricht, The Netherlands), and a polyclonal 
antiserum against dermatan sulfate proteoglycan, which was 
kindly donated by Dr A H M S M van Kuppeveld (Depart­
ment of Biochemistry, University of Nijmegen, The Nether­
lands) 
MORPHOLOGICAL STUDIES 
Indirect Immunofluorescence (HF) IIP was performed on 2-
μτα croystat sections of human kidneys Sections were fixed for 
5 minutes in acetone and washed with PBS For the double 
staining with the anti 28-kd calcium-binding protein antiserum, 
kidney tissue fixed by perfusion with a mixture of penodate-
lysine-2% paraformaldehyde was used, because the 28 kd pro­
tein could not be demonstrated in acetone fixed cryostat sec­
tions The sections were incubated with 100 μΐ of primary 
antibody, diluted in PBS containing 1% BSA and 0 05% sodium 
azide for 30 minutes at 20° С After washing with PBS, binding 
was visualized by incubating the sections for 30 minutes at 20° 
С with 100 μΐ of fluorescein isothiocyanate (FITC)- or tetra 
methylrhodamine isothiocyanate (TRITC)-labeled secondary 
antibody, also diluted in PBS containing 1% BSA and 0 05% 
sodium azide Sections were washed with PBS, embedded in 
AquaMount and examined with a Leitz Ortholux light micro­
scope fitted for fluorescence microscopy 
The restricted BM staining was investigated by double stain­
ing mAb JM-13 (ascites containing 2 mg IgM/ml, dilution 1 40) 
with one of the following antibodies or reagents FITC-labeled 
lectin Ulex europaeus Ι (Ε Y Laboratories, San Mateo, Califor­
nia) specific for human endothelium (38), anti-Tamm Horsfall 
Protein antiserum (Cappel-Organon Teknika, Turnhout, Bel­
gium) recognizing the thick ascending limb of Henle, anti-
brush border mAb BB-10 recognizing the convoluted and 
straight part of the proximal tubules, anti-28-kd calcium-bind-
ing protein antiserum recognizing predominantly the connect 
ing tubules (8), and mAb RCK-105 against cytokeratin 7 (42) 
recognizing the descending and ascending thin limb of Henle's 
loop and the cortical and medullary collecting ducts (42) Bind 
ing of mAb JM 13 was visualized by goat anti mouse IgM (Fc) 
coupled to FITC or TRITC (Nordic, Tilburg, The Netherlands), 
mAb BB-10 by goat anti mouse IgGl-FITC (Nordic), the 
Tamm Horsfall protein antiserum by rabbit anti goat IgG-
TR1TC (Cappel-Organon Teknika, Turnhout, Belgium), the 28 
kd calcium-binding protein antiserum by swine anti rabbit IgG-
TRITC (Dakopatts, Copenhagen, Denmark), mAb RCK-105 
by goat anti mouse IgGl-TRITC (Nordic) Each double staining 
experiment included the following controls (a) omitting the 
first antibody, (b) incubating the first antibody with the con­
jugate used for the detection of the other antibody in the double 
staining All control experiments were negative 
Pretreatment of the sections was performed by incubating 
unfixed cryostat sections for 30 minutes at 37° С in the appro­
priate buffer with one of the following enzymes or agents 
trypsin (100, 10, or 1 Mg/ml), pronase (100, 10, or 1 Mg/ml), 
collagenase (100, 10, or 1 Mg/ml), hepantinase (1 unit/ml), 
chondroitinase AC (0 2 units/ml), chondroitinase ABC (0 5 
units/ml), hyaluromdase (50 units/ml), 7 м urea (pH 6 8 or pH 
3 5), 4 M guamdine-HCl (pH 6 8) or 1 mM sodium periodate 
(pH 4 1, 5 2, 6 3, or 7 4) After washing with PBS, IIF with 
mAb JM-13 was performed as described above Unfixed, viable 
cultured human hepatocytes and human and rat glomerular 
cells were incubated sequentially with mAb JM-13 and goat 
anti mouse IgM (Fc) FITC at 4° С to prevent capping There­
after, cells were fixed in ice-cold methanol, embedded and 
examined as described above IIF on 2 jim acetone fixed cryo­
stat sections of a human liver was performed as described above 
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CHAPTER 3 
A MONOCLONAL ANTIBODY AGAINST 
GBM HEPARAN SULFATE INDUCES AN ACUTE 
SELECTIVE PROTEINURIA IN RATS 
J. van den Bom, L.P.W.J. van den Heuvel, M.A.H. Bakker, 
J.H. Veerkamp, K.J.M. Assmann, and J.H.M. Berden 
Published in: Kidney Int. 1992: 41; 115-123 
55 

A monoclonal antibody against GBM heparan sulfate induces 
an acute selective proteinuria in rats 
J A C O B V A N D E N B O R N , L A M B E R T P.W.J, V A N D E N H E U V E L , M A R I N K A A . H . B A K K E R , 
J A C Q U E S H. V E E R K A M P , K A R E L J .M. A S S M A N N , and Jo H . M . B E R D E N 
Departments of Medicine, Division of Nephrology, Biochemistry and Pathoiogy, University of Nijmegen. Nijmegen, The Netherlands 
A monoclonal antibody against GBM heparan sulfate Induces an acute 
selective profeinuria In rats. After immunization of mice with partially-
purified heparan sulfate proteoglycan (HSPG) isolated from rat glomer-
uli, a monoclonal antibody (mAb JM-403) was obtained, which was 
directed against heparan sulfate (HS), the glycosaminoglycan side chain 
of HSPG. In ELISA it reacted with isolated human glomerular base-
ment membrane (GBM) HSPG, HS and hyaluronic acid, but not with 
the core protein of human GBM HSPG, and not with chondroitin sulfate 
A and C, dermalan sulfate, keratan sulfate and heparin. Furthermore, it 
did not bind to laminin, collagen type IV or fibronectin. Specificity of 
JM-403 for HS was also suggested by results of inhibition studies, which 
found that inlact HSIO and HS, but not the core protein, inhibited the 
binding of JM-403 to US. In indirect immunolluorcscence on cryostat 
sections of rat kidney, a fine granular to linear staining of the GBM was 
observed, along with a variable staining of the other renal basement 
membranes. Pretrealmcnl of the sections with heparitinase completely 
prevented the binding of mAb JM-403, whereas pretreatment with 
chondroitinase ABC or Hyaluronidase had no effect. The precise 
binding site of mAb JM.403 was investigated by indirect immunoelec-
tron microscopy. It revealed a diffuse staining of the whole width of the 
GBM. One hour after intravenous injection of JM-403 into rats, the 
mAb was detected along the glomerular capillary wall in a fine granular 
pattern, which shifted towards a more mesangial localization after 24 
hours. No binding was observed anymore by day 15. Intravenous 
injection induced a dose-dependent, transient and selective proteinuria 
that was maximal immediately after the injection. Administration of 2 
mg of JM-403 increased the urinary albumin excretion within the first 24 
hours after injection from (mean ± so) 177 ± 19 to 20,755 i- 10,310 
Mg/24 hr (ƒ• < 0.01); the urinary IgG excretion increased from 5.8 ± 2.9 
to 236.1 ± 132.2 ng/24 hr {P < 0.03); the selectivity index (clearance 
IgG/clearance albumin) decreased from 0.33 ± 0.12 to 0.12 ± 0.05 {P < 
0.004). 
Heparan sulfate (HS) is thought to play an important role in 
the permsclective properties of the glomerular basement mem-
brane (GBM) [1-3]. In several clinical and experimental glomer-
ulopathies an increased permeability of the GBM is associated 
with a diminished HS content of the GBM [4-9]. Moreover, 
enzymatic removal of HS from the glomerular capillary wall 
increases the passage of native ferritin and albumin into the 
urinary space [10, 11]. These data were corroborated by inves-
tigations which showed that after intrarenal or intravenous 
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injection of calionic molecules, GBM permeability increased 
due to the neutralization of HS-associated anionic sites of the 
glomerular capillary wall (12-161. However, the significance of 
HS for the permseleclivity of the GBM and for the induction of 
proteinuria is still not completely understood, and a number of 
controversies still exist [17-20]. 
To study the impact of HS for the permselective properties of 
the GBM in more detail, antibodies against HS can be an 
important tool. There are some reports with regard to the 
nephritogenic potential of polyclonal antibodies against the core 
protein of GBM heparan sulfate proteoglycan (HSPG) [21-24]. 
However, at present there are no studies which describe the 
nephritogenic effects of antibodies against HS, the glycos-
aminoglycan (GAG) side chain of HSPG. This is probably due 
to the difficulty to raise anti-HS antibodies because of the low 
immunogenicity of these polysaccharide struclurcs. Kure and 
Yoshie [25] described a syngeneic monoclonal antibody (mAb) 
to murine mcth-A sarcoma which recognizes HS. The prepara-
tion of an mAb against HS of Engelbreth-Holm-Swarm (EHS) 
tumor proteoglycan was also reported [26]. It was recently 
applied in studies on cerebral amyloid deposits [27, 28]. 
In this paper, we describe the production and characteriza-
tion of an mAb against GBM HS. After intravenous (i.v.) 
injection in rats an immediate, transient binding of mAb to the 
GBM occurred with a concommitant development of a selective 
proteinuria. 
Methods 
Partial purification of rat glomerular HSPG 
All procedures were carried out at 4°C, in the presence of a 
mixture of proteinase inhibitors (I тм phenylmethanesulpho-
nyl fluoride, 5 тм benzamidinc hydrochloride, 10 тм N-elhyl-
malcimide, 0.1 м 6-aminohexanoic acid, 5 тм iodocetamide 
and 10 тм EDTA). Rat glomeruli (9.3 g) were isolated from rat 
kidney cortices (715 g) by the differential sieving technique 
according to Meezan et al [29]. The glomerular suspension was 
maintained for more than 85% of glomeruli and was only 
contaminated with a few tubular fragments, but not with 
interstitial tissue. Glomeruli were homogenized using a Sorvall 
omnimixer, and extracted twice overnight in 150 ml 4 м 
guanidine HCI/50 тм sodium acetate buffer, pH 5.8. The 
combined supematants obtained after centnfugation al 40,000 g 
for 30 minutes, were concentrated to 35 ml by ultrafiltration on 
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Flg. 1. Chromatography of the extract of rat 
glomeruli on DE 52 cellulose Elution took 
place with 7 м urea/10 тм Tns buffer, pH 
7 6, followed by a gradient starting at fraction 
40 of 0 to 2 M NaCl in the same buffer 
Fractions were analyzed for protein (A280) 
(- -O- -) and sulfated GAGs (A525, Famdale 
assay) (-»-) Fractions 69-75 (indicated by the 
bar) were pooled and dialy/ed against PBS 
an Amicon XM-50 filter, and extensively dialyzed against 7 м 
urea/10 т м Tns-HCl buffer, pH 6 8 After centnfugation 
(40,000 g for 30 mm) the supernatant was punfied on a DE-52 
cellulose column (2 5 x 20 cm) equilibrated with 7 м urea/10 
т м Tns-HCl buffer, pH 6 8 The bound material was eluted by 
a linear 0 to 2 M sodium chloride gradient The protein content 
of the fractions was determined spectrophotometncally at A280 
and the glycosaminoglycan (GAG) content by the Farnddle 
assay [30] During elution, two protein peaks appeared, the first 
containing one Famdale-positive peak, the second comprising 
two Famdale-positive peaks (Fig I) This elution profile was 
completely identical to that obtained during purification of 
human glomerular extracts From this previous analysis, for 
which we used human specific anti-HSPG antibodies [31], we 
knew that HSPG was only present in the middle Farndale-
positive peak For that reason fractions 69 to 75 were pooled 
and dialyzed extensively against PBS Companson of the 
protein/GAG ratio of the 7 м urea extract before DE-52 
chromatography of 51 5 with that of 4 3 of the pooled fractions 
69 to 75 after DE-52 chromatography shows an evident ennch-
ment for HSPG, as indicated by this decreased protein/GAG 
ratio This ratio is of the same order as for isolated human GBM 
HSPG [31] This crude glomerular HSPG preparation was used 
for immunizations 
Hybndoma production 
Female BALB/c mice were immunized intrapentoneally at 
days 0 and 30 with 50 μg of the glomerular HSPG preparation 
dissolved in 150 μΐ PBS and emulsified with an equal volume of 
complete Freund's adjuvant At days 60, 61 and 62 the mice 
received an intravenous booster injection of 15 μ« of the same 
immunogen in 0 15 ml PBS At day 63 the mice were sacrificed, 
their spleens were removed, and splenocytes were fused with 
the non-producing SP2/0 mouse myeloma cell line, according to 
the pnnciples of Kohier and Millstein [32] Syngeneic pentoneal 
macrophages (10,000 to 20,000 cells/well) were used as feeder 
cells Wells with growing hybndomas were screened in ELISAs 
with either the immunogen or HS as coated antigen, and by 
indirect immunofluorescence (IF) on rat kidney cryostat sec­
tions After HAT selection, screening and expansion, cell 
cultures were transferred to HEPES-buffered RPMI-1640 cul­
ture medium containing 10% fetal calf serum, gentamycin (40 
/¿g/tnl), pyruvate (110 /¿g/ml) and glutamine (292 /ig/ml) Se-
lected wells were recloned by limiting dilution until all sub-
clones displayed the same reactivity pattern All cells were 
cultured in an humidified incubator at 37°C with 95% air and 5% 
CO, The antibody subclass was determined in ELISA using 
subclass-specific antibodies conjugated to peroxidase (Southern 
Biotechnology Associates Ine , Birmingham, Alabama, USA) 
Ten to twelve weeks old, pnstane (2,6,10,14 tetramethylpenta-
decane, Janssen Chimica, Beerse, Belgium) pnmed, male 
BALB/c mice received 3 χ 106 viable hybndoma cells intraper-
itoncally After one to three week ascites was drained, left to 
clott overnight at 4°C, centnfuged, filtered through 0 2 /im 
filters, aliquoted and stored at -20°C until use The IgM 
concentration of the ascites was determined by the single 
diffusion technique according to Mancini, Carbonara and Her-
emans [33], using punfied mouse IgM (Bionetics, Kensington, 
Maryland, USA) as the standard and goat anti-mouse IgM 
(Sigma Chemical Co , St Louis, Missoun, USA) as antibody 
Characterization ofmAb 
ELISA studies Anti-glycosaminoglycan (GAG) reactivity 
was measured in ELISA as desenbed [34] using protamine 
chlonde precoating to ensure sufficient binding of the negatively 
charged GAGs to the plates The following GAGs were used 
HS isolated from bovine kidney (Seikagaku, Tokyo, Japan), 
chondroitin sulfate A and С isolated from whale cartilage 
(Sigma), dermatan sulfate isolated from porcine skin (Sigma), 
keratan sulfate isolated from calf cartilage (from Dr R van de 
Stadt, Jan van Breemen Institute, Amsterdam, The Nether­
lands), heparin (Thrombohquine, Organon Текшка, Oss, The 
Netherlands), and hyaluronic acid (HA) isolated from human 
umbilical cord (Sigma) The ELISA for determination of anti­
body reactivity against glomerular HSPG (pool 69-75), human 
GBM HSPG (isolated as desenbed previously [31]), and its core 
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protein [obtained after treatment of GBM HSPG with tnfluo-
romethane sulphonic acid (TFMS) [31]]. laminin (from the 
mouse EHS tumor; Sigma), collagen type IV (from the mouse 
EHS tumor, Collaborative Res. Inc., Bedford, Massachusetts, 
USA) and fibronectin (from rat plasma, Calbiochem, La Jolla, 
California, USA) was carried out according to Rcnnard el al 
[35]. As positive controls in the ELISAs were used: serum of 
the mouse selected for fusion (positive control for pool 69-75), 
rabbit ami-EHS laminin (GIBCO Europe, Breda, The Nether­
lands), rabbit anti-mouse collagen type IV (Collaborative Res. 
Inc.) and goat anti-rat fibronectin (Calbiochem). The inhibition 
ELISA was earned out with the different GAGs and with 
isolated human GBM HSPG or its core protein as inhibitor. For 
this inhibition ELISA, mAb JM-403 was diluted to a concen­
tration giving 80% of the maximal ELISA signal and preincu-
bated with an equal volume of 60 μΙ inhibitor at concentrations 
ranging from 0.2 to 100 /¿g/ml for one hour at 37°C and 
subsequently for one hour at 4°C and tested in the ELISA with 
HS as coated antigen. Results are expressed as % inhibition of 
the ELISA signal calculated as: [I - (A450 + inhibitor/A450 -
inhibitor)] x 100%. 
Immunofluorescence (IF). Indirect IF was performed on 2 
μπι cryostat sections of rat kidneys, which were incubated with 
25 μΙ of primary antibody (culture supernatant of hybndoma 
cells) for 30 minutes at 20°C. Incubation of the sections with a 
non-relevant mAb served as a negative control After washing 
with PBS, binding was visualized by incubating the sections for 
30 minutes at 20°C with 25 /¿1, 1:500 diluted FITC-labeled 
F(ab)2 fragments of sheep anti-mouse IgG, heavy and light 
chains specific (Cappel, Organon Гекпіка, Turnhout, Belgium) 
or with FITC-labcled goat anti-mouse IgM, Fc specific (Nordic, 
Tilburg, The Netherlands), 1:50 diluted in PBS containing 1% 
bovine serum albumin (BSA), 0.05% sodium azide and 5% 
normal rat serum. Direct IF was performed on 2 μιπ cryostat 
sections of rat kidneys snap frozen in liquid nitrogen. Sections 
were incubated for 30 minutes with FITC-labeled goat anti-
mouse IgM, Fc specific, 1:50 diluted m PBS containing 1% 
BSA, 0.05% sodium azide and 5% normal rat serum. Sections 
were washed with PBS, embedded in Aqua Mount (pH 7.0) and 
examined with a Leitz fluorescence microscope equipped with 
a Ploemopak epi-illuminator. Pretreatment of the sections was 
performed by incubating unfixed cryostat sections for 30 min­
utes at 37°C in the appropriate buffer with 1 U/ml hepantinase 
(Seikagaku, Tokyo, Japan), 0.5 U/ml chondroitmase ABS (Sig­
ma) or 50 U/ml hyaluromdasc (Sigma). After washing with PBS. 
indirect IF with mAb JM-403 was performed. As a positive 
control, goat antibodies against human GBM HSPG-core pro­
tein were used, which cross react with rat GBM HSPG. Indirect 
IF was performed as desenbed above, using FITC-labeled 
rabbit anti-goat IgG (Kallestad, Chaska, Minnesota, USA) to 
detect the bound goat antibodies. Inhibition studies in indirect 
IF on kidney sections were carried out by incubating mAb 
JM-403 in the presence of GBM HSPG, its core protein, 
different GAGs or the monosaccharide components of HS and 
HA, N-acetyl-glucosamine and glucuronic acid in a concentra­
tion of 100 Mg/ml. 
Immunoeletlron microscopy (IEM). For indirect I EM, rat 
kidneys were perfused for 10 minutes via the retrograde aortic 
route with PBS, followed by perfusion with a mixture of 
periodate-lysine-2% paraformaldehyde (PLP) fixative for 10 
minutes Small pieces of renal cortex were further immersed in 
the same fixative for an additional three hours, cryoprotectcd in 
2.3 M sucrose for 45 minutes, and snap frozen in liquid nitrogen. 
Twenty-five μτη cryostat sections were incubated with mAb 
JM-403, diluted 1:30 in PBS containing 1% BSA, for 18 hours at 
4°C and washed several times with PBS afterwards. For the 
direct IEM, rats were injected i.v. with one ml JM-403 ascites. 
After one hour, the kidneys were perfused and fixed, cryopro-
tected and stored as desenbed for the indirect IEM. Twenty-
five μπι cryostat sections were cut Sections for the direct as 
well as for the indirect IEM were incubated with a peroxidase-
labeled rabbit anti-mouse Ig (Dakopatts, Copenhagen, Den­
mark), diluted 1:20 in PBS-1% BSA for 90 minutes. After 
several washes in PBS, the sections were preincubated in 0 05% 
diaminobcnzidinc (DAB) medium containing 0.6% TRIS for 10 
minutes, followed by the same medium with addition of 10 μΐ of 
30% H 2 0 2 for 10 minutes. After washing in H 2 0 for 18 hours, 
the sections were post-fixed in 0.1 M phosphate buffered 1% 
OsOj pH 7.4 for 30 minutes at room temperature, dehydrated, 
and embedded m Epon 812. Thin sections were prepared on a 
LKB Ultratome, and examined in a Philips 300 electron micro­
scope. 
Nephritogemcily of mAb JM-403 
Animals. The nephntogcnic properties of mAb JM-403 were 
investigated in male Wistar rats of 200 g, bred at our animal 
laboratory. Dunng the cxpenments rats were placed in individ­
ual metabolic cages, with free access to water and standard 
chow. 
Experimental design. In the first expenment, rats were in­
jected i.v. in the tail vein under ether anaeMhesia with one ml of 
JM-403 ascites (containing 1 mg IgM/ml). Rats were sacrificed 
one hour, 24 hours and 14 days after injection. Kidneys were 
removed, snap frozen in liquid nitrogen and used for direct IF 
as described above. In the second experiment, five groups of 
five rats were used. Rats were injected i.v. with respectively 
0.032, 0 125, 0.5 and 2 mg IgM (JM-403 ascites, in PBS with a 
final volume of 2 ml). In control experiments rats received 2 ml 
ascites in PBS containing 2 mg of a non-relevant IgM mAb 
(anti-human B-cell idiotype). After injection rats were placed in 
individual metabolic cages and 24-hour urine specimens were 
sampled during 10 days. Thereafter, a blood sample was taken 
from each rat. In the third experiment 10 rats received 0.5 ml 
JM-403 ascites (containing 0.5 mg IgM) i.v. Immediately after 
injection rats were placed in metabolic cages and unne was 
sampled every two hours, during 24 hours. 
Urine analysis. Unnary albumin concentrations were deter­
mined by rocket Immunoelectrophoresis according to Laurell 
[36], using goat anti-rat albumin and rat albumin as the standard 
(both from Nordic, Tilburg, The Netherlands). Unnary IgG 
concentrations were determined in a capture ELISA, using rat 
IgG (Nordic), 2 to 2000 ng/ml as the standard. Polystyrene 
microliter plates (Greiner) were coated overnight at room 
temperature with affinity-purified goat anti-rat IgG, heavy and 
light chains specific (Cappel), 1:500 in 0.05 M carbonate buffer, 
pH 9.6, 100 μΙ/well. After washing with PBS containing 0.05% 
Tween-20 (PBS-T), urines were diluted 1:4 to 1:4096 in PBS-T 
containing 0.2% BSA, 100 μΐ/well. Plates were incubated for 
one hour at 370C. After washing with PBS-T, 100 μ| peroxidase 
conjugated, affinity-purified goat anti-rat IgG, (Cappel), 1.500 
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Fig 2 Antigen ¡peufiulv of mAb JW^Wi A. 
Reaumly of mAb JM 403 in bLISA MAb 
JM 403 bound lo HS (-*-) and НА (-О-) but 
not to the other GAGs (chondroitin sulfate A 
and С dermatan sulfate keratan sulfate and 
heparin) (-О-) Binding also occurred to 
isolated human GBM HSPG (-V-) whereas 
its core protein was not recognized (-Δ-) B. 
Dose dependent inhibition of mAb JM 403 in 
ELISA HS was used as coated antigen 
Inhibition was found with intact human GBM 
HSPG (-V-) with US (-*-) and with HA 
(-D-) but not with the other GAGs (-О-) or 
the HSPG core protein (-Δ-) 
in PBS-T, 0 2% BSA were added to the wells and incubated for 
another hour at 37°C Finally, after washing with PBS-T, 100 μΐ 
freshly prepared substrate solution (0 8 mg/ml 5-aminosalicylic 
acid in 50 т м phosphate buffer, pH 6 0, containing 0 8 /il/ml 
30% vol/vol H 2 0 2 ) were added to each well After 30 minutes 
the absorbance was measured at 450 nm in a Titertek multiscan 
Serum albumin and IgG concentrations were determined as 
descnbed above for unne The selectivity index was defined as 
clearance IgG/clearance albumin 
Statistical analysis 
For statistical analysis of results with a normal distnbution 
the paired r-test was used, for not normally distnbuted data the 
Wilcoxon's test Probability values < 0 05 were regarded as 
significant All values are expressed as mean ± so 
Results 
Production of monoclonal antibodies 
After immunization of female BALB/c mice with the glomer­
ular HSPG preparation and fusion of the splenocytes with the 
non-producing SP2/0 myeloma cell line, growing hybndomas 
were screened m indirect IF on rat cryostat kidney sections and 
in ELISA on the immunogen and HS After this screening 
procedure one out of 700 clones was positive This hybndoma, 
called JM-403, was subcloned twice until all subclones dis­
played the same reactivity pattern MAb JM-403 belongs to the 
IgM class Ascites contained 1 mg IgM/ml 
Characteristics of mAb JM-403 
ELISA studies The reactivity pattern of mAb JM-403 in 
ELISA with different GAGs is shown in Figure 2A A clear 
reactivity was observed with HS and hyaluronic acid (HA), but 
no binding occurred to chondroitin sulfate A and C, dermatan 
sulfate, keratan sulfate or heparin Since mAb JM-403 cross 
reacted with human tissues (not shown), we tested its binding to 
isolated human GBM HSPG and its core protein in ELISA The 
core protein was obtained after treatment with TFMS, a method 
known to cleave all sacchande units [31] Figure 2A also shows 
that mAb JM-403 bound to human GBM HSPG in ELISA, but 
not to its core protein The GAG specificity of mAb JM-403 was 
confirmed by the inhibition ELISA shown in Figure 2B Both 
HS and HA were able to inhibit the binding of mAb JM-403 to 
HS in a dose dependent manner None of the other GAGs, even 
at the highest concentration (100 /ug/ml), showed any inhibition 
Cellulose acetate electrophoresis of HA used in our expen-
ments did nol show any contamination of HA with HS, which 
excluded impunty of the HA preparation as a cause of this 
binding Figure 2B also showed that the intact HSPG molecules 
were able to inhibit the binding of mAb JM-403 to HS in ELISA 
m a dose-dependent manner, whereas the core protein did not 
inhibit at all This lack of inhibition of the core protein was due 
to the removal of HS-side chains and not to denaturation or 
degradation of the core protein by the TFMS treatment, since 
the core protein inhibited equally effectively as intact HSPG for 
the binding of an anti-HSPG core mAb to HSPG (data not 
shown) All results corroborated the HS specificity of mAb 
JM 403 In ELISA mAb 1M-W1 did not bind to other basement 
membrane components, (hat is, laminin, collagen type IV or 
fibronectin (data not shown) 
Histologu al studies By indirect IF on 2 μπι cryostat sections 
of a rat kidney, mAb JM-403 bound strongly to the GBM and 
Bowman s capsule in a fine granular to linear pattern (Fig ЗА) 
Also the basement membranes of endothelial cells and of 
smooth muscle cells in arteries and arterioles were positive as 
well as some tubular basement membranes (TBMs), although 
this staining was much weaker and had a vanable intensity (Fig 
3B) The staining pattern of the glomerulus corresponded very 
well to that of antibodies directed against the core protein of 
GBM HSPG (Fig 3D) The HS specificity of mAb JM-403 was 
further substantiated by the finding that binding was completely 
prevented by pretreatment of the sections with hepantmasc, an 
enzyme which degrades HS (Fig 3C) This pretreatment did not 
degrade the core protein of HSPG, since antibodies against the 
HSPG core protein still bound (Fig 3D) No alterations in 
staining pattern were observed after pretreatment of the sec­
tions with chondroitinase ABC or hyaluronidase Binding of 
mAb JM-403 to the sections could also be inhibited by the 
addition of 100 ^g/ml human GBM HSPG, HS or HA to the 
mAb before incubation of the sections, but not by the addition 
of the other GAGs or the core protein of human GBM HSPG, 
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Fig. 3. indirect IF of a rat Udncy NMUfl mAb 
JM-t03 Ι А, В and C) and a poke lomil 
antibody аяшпм the CiBKÍ HSPCr-íore prolein 
(D) Sections shown in photomicrographs С 
and D were pretrcated with hepanlmase. Note 
the absence of staining with mAb JM-40^ after 
hepantinase pretreatment (C). whereas 
binding of the anti-HSPG-core antibodies was 
unaltered (D) ΙΑ χ WS. Β χ 254; С х 422; D 
χ 264). 
Fig. 4. ІЬМ plioíomnrotfroph\ Hlustratìng the 
in vitro and in vivo binding of mAb JM^ÍOÍ 
A. Indirect ΙΕΜ showed a clear staining of 
the whole GBM. B. Direct IEM of a capillary 
wail prepared one hour after I.V. injection of I 
ml JM-403 ascites li mg IgM/ml) Reaction 
product was located m the lamina rara interna 
of the GBM and its border adjacent to the 
endothelium. In some but not all glomeruli, a 
faint staining was observed of the endolheli.il 
cell membranes (A χ 13.000; В x 18.8501. 
nor by the addition of the monosaccharide components of HS 
and HA, N-acetyl-glucosamine and glucuronic acid. Tissues 
known to contain large amounts of HA (skin and umbilical vein) 
only revealed a basement membrane staining in indirect IF. 
Moreover, this staining was completely abolished after pre­
treatment of the sections with heparitinase, whereas hyaluroni-
dase did not alter the staining pattern, indicating that mAb 
JM-403 did not recognize HA in situ. In indirect IEM, mAb 
JM-403 bound diffusely to the whole width of the GBM (Fig. 
4A). Occasionally staining was observed of the cell membranes 
of endothelial cells and the foot processes of epithelial cells. It 
is difficult to distinguish whether this is due to binding to the cell 
membrane or to a diffusion artifact. 
Nephlitogenicily of anli-HS mAb JM-403 
After intravenous injection mAb JM-403 immediately local­
ized predominantly along the GBM, as indicated by direct IF 
one hour after injection (Fig. 5A). A finegranular staining of the 
GBM was observed along with some staining of the mesangium. 
Twenty-four hours after injection, the staining pattern had 
shifted towards a more mesangial localization, while the stain­
ing in the GBM had decreased considerably (Fig. 5B). Two 
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Fig. 5. Direct IF of ral kidneys obtained one hour (A), twenty-four hours (B) or two weeks (C) after i.v. injection of 500 μχ mAb JM-403- There 
was a shift from GBM binding at one hour (A) to a more mesangial localization at twenty-four hours (B). After two weeks no mAb was detectable 
in the glomeruli (С) (А, В and С x 380). 
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Fig. 6. Urinary· protein excretion per 24 hours after i.v. injection of 0.032 (-Π-Ι. 0.125 (-Δ~). 0.5 (-О-) and 2 f-·-) m)> mAb JM-403. Each group 
consisted out of 5 rats. Day 0 gives baseline levels before injection of mAb. Graph A shows the course of the albuminuria (solid lines) and the 
urinary IgG excretion (dashed lines), both expressed as ;xg/24 hours. Graph В shows the course of the selectivity index of the proteinuria (clearance 
IgG/clearance albumin). Urinary IgG excretion and selectivity indexes are given for the rats that received 0 5 and 2 mg mAb. 
weeks after injection, hardly any antibody could be detected in 
the glomerulus, however, a weak staining of Bowman's capsule 
remained (Fig. 5C). These immunohistological data indicate a 
direct, transient binding of anti-HS mAb JM-403 along the 
GBM. 
Direct IEM visualized the bound mAb JM-403 mainly at the 
inner side of the GBM one hour after i.v. injection (Fig. 4B) 
Sometimes, reaction products were also observed on endothe­
lial cells, but not in every glomerulus. No binding occurred to 
epithelial cells. Additional staining was observed in the parame-
sangtal areas. This staining pattern corresponded well to the IF 
staining depicted in Figure 5A 
To test whether this GBM binding of JM-403 could alter the 
permeability of the GBM, groups of five rats were injected i.v. 
with different doses of mAb, respectively 0.032, 0.125, 0.5 and 
2 mg. A dose-dependent albuminuria was induced after 0.5 and 
2 mg mAb, which w^s maximal at day 1 and declined thereafter 
(Fig. 6A). To investigate whether the induced proteinuria was 
selective, urinary excretion of IgG was also measured. The 
urinary IgG excretion followed the same pattern as the albumin 
excretion, although at a lower level (Fig. 6A). If we calculated 
the selectivity index (clearance IgG/clearance albumin) we 
found that the proteinuria was selective (Fig. 6B). The values 
for the mean (± SD) of the urinary albumin and IgG excretion in 
the first 24 hours after the i.v. injection of either 0.5 or 2 mg 
mAb JM-403 and the corresponding selectivity indexes, to­
gether with the baseline values for the different parameters are 
given in Table I. Control studies m five rats, receiving ascites 
containing 2 mg of a non-relevant IgM mAb (anti-human B-cell 
idiotype) i.v.. did neither show any glomerular localization of 
mouse IgM, nor development of albuminuria. Since the albu­
minuria was maximal at day 1. we analyzed in 10 rats the 
kinetics of the albumin excretion in two-hour urine samples 
during the first 24-hours after injection of 0.5 mg mAb JM-403. 
Figure 7 shows that the albumin excretion is maximal in the first 
two hours after injection with a gradual decline thereafter. The 
magnitude of the albuminuria paralleled the glomerular binding 
of the mAb as seen by direct IF (Fig. 5). 
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Table 1. Mean (± so) unnary albumin and IgG excretion after ι ν injection of a 2 ml dilution of JM 403 ascites containing either 0 5 or 2 mg 
IgM in the first 24 hours after ityeclion (day I) compared with the normal excretion (baseline) 
Albumin excretion 
μίΙ24 hr 
IgG excretion 
ßg/24 hr 
Selectivity index 
baseline 
284 ± 120 
5 7 ± 15 
0 37 * 0 20 
0 5 mg ι ν 
day 1 
6,486 ± 4 640 
58 6 ± 42 7 
0 15 ± 0 07 
Ρ value 
< 0 0 4 
< 0 05 
< 0 03 
baseline 
177 ± 19 
5 8 ± 2 9 
0 33 ± 0 12 
2 mg ι ν 
day 1 
20 755 ± 10,310 
236 1 ± 132 2 
0 12 ± 0 05 
Ρ value 
< 0 01 
< 0 03 
<0004 
The selectivity index of the proteinuria (clearance IgG/clearance albumin) is also given 
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Fig. 7. Albumin excretion of two-hour urine specimens sampled dur­
ing the first 24 hours after ι ν iryeition of 500 pg mAb JM-403 Note 
that the increase of albumin excretion occurred immediately after 
ІДІССІІОП of mAb Statistical significance between urinary albumin 
excretion before and in the two-hour unne specimens after injection of 
mAb is indicated by **V < 0 001, '*P < 0 01, ·Ρ < 0 05 
Discussion 
In this report we describe the production of a nephntogenic 
mAb against GBM HS 1 he HS-spccificity of mAb JM-403 can 
be concluded from the following experimental data (a) in 
ELISA a strong reactivity was observed with HS, but not with 
chondroitin sulfate A or C, dermatan sultate, keratin sulfate or 
hepann, (b) mAb JM-403 bound in ELISA to isolated human 
GBM HSPG, but not to its core protein without HS-chains, (c) 
pretreatment of kidney sections with hepantmase prevented the 
binding of JM-403, whereas the binding of polyclonal antibodies 
against the core protein of GBM HSPG was unaffected Pre-
treatment with chondroitinase ABC and Hyaluronidase did not 
influence the binding of JM-403, (d) the binding of mAb JM-403 
to HS in ELISA as well as the binding to the kidney sections in 
indirect IF could be inhibited by human GBM HSPG and HS, 
but not by other GAGs or the HSPG core protein 
Besides binding to HS, mAb JM-403 also reacted with HA 
Interestingly, Füllt et al desenbed two mAbs against HA, from 
which one bound to HS [37] They also demonstrated in sera of 
patients with post-streptococcal glomerulonephritis the pres-
ence of antibodies against HS, which cross reacted with HA 
[38] Their and our findings indicate that HS and HA contain 
cross reactive epitopes Both HA and HS contain the same 
basic structure of repeating disacchande units of N-acetyl-
glucosamme and glucuronic acid Apparently the presence of 
O- and N-linked sulfate is not important for JM-403 binding 
since HA does not contain these components On the other 
hand, mAb JM-403 exhibits no affinity for hepann that has more 
iduronic acid and sulfate groups than HS The binding of mAb 
JM-403 to HS could not be inhibited by glucuronic acid or 
N-acetyl-glucosamme These findings suggest that the epitope 
may be located within a cluster of unsulfated glucuronic acid— 
N-acetyl-glucosamine disacchande units The fact that HA 
present in cryostat sections of skin and umbilical vein (tissues 
known to contain large amounts of HA) did not stain with mAb 
JM-403 in indirect IF and the absence of an effect of pretreat-
ment of these sections with hyaluromdase suggests that the 
epitope on HA, which is recognized by mAb JM-403, is hidden 
in vivo This could be due to the fact that in situ, HA is bound 
to proteoglycans and proteins, thereby forming large molecular 
complexes, which may result in the masking of the JM 403 
recognized epitope, which is set free after isolation of HA 
Compánson of the characteristics of mAb JM-403 with those 
of previously described mAbs against HS [25, 27) indicates 
differences in epitope specificity Kure and Yoshie [251 de-
scribed an anti-HS mAb directed against an epitope which is 
related to O-sulfated and N-acetylaled glucosamine present in 
cell surface-associated HS Snow et al [27) recently described 
an mAb against a glucosamine sulfate ul ->4 glucuronic acid in 
HS of mouse EHS HSPG Both mAbs did not bind to other 
GAGs, including HA and heparin 
In indirect IF on cryostat sections of rat kidneys, the GBM, 
Bowman's capsule and the basement membranes of endothelial 
cells and of smooth muscle cells in artenes and artenoles 
stained much more intensely than the TBMs The latter staining 
was variable and much weaker, some TBMs were even nega-
tive, which seemed to be related to the different segments of the 
nephron In indirect IEM, we observed that the whole width of 
the GBM was stained by mAb JM-403 At first glance this seems 
to be in contrast with the findings of Stow, Sawada and 
Farquhar [39], who found that the HS JO molecule was concen-
trated in both laminae rarae of the GBM However, their results 
were obtained after a short (2 to 4 hr) incubation of the sections 
with the anli-HSPG antibodies In accordance with our results, 
they also found a diffuse staining of the whole GBM after an 
overnight incubation Alternatively, differences in staining pat-
terns can also be explained by differences in epitope specificity, 
since their antiserum was directed against the core protein of 
GBM HSPG, whereas our mAb recognizes the HS chain 
The ι ν administration of mAb-403 induced an acute selec­
tive proteinuria This shortlasting albuminuria was paralleled by 
a transient binding of anti-HS mAb JM-403 along the GBM 
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Similar transient binding kinetics were found after i.v. admin-
istration of exogenous or endogenous cationic molecules |6, 12, 
13,40, 41]. Their binding to the anionic sites of the GBM is also 
accompanied by a short bout of albuminuria. Furthermore, 
injection of polycations led to a preferential leakage of albumin 
compared to IgG [12, 13], like we found with our mAb. These 
similarities suggest that, like polycations, mAb JM-403 neutral-
izes the HS-associated anionic sites of the GBM and decreases 
the charge-selective properties of the GBM, favoring the uri-
nary excretion of negatively-charged scrum proteins like albu-
min. Whether binding of mAb JM-403 to GBM HS can induce a 
local inflammatory response in addition remains to be investi-
gated. 
These in vivo experiments were done with unpurificd ascites 
containing mAb JM-403, since the procedures we used to purify 
the IgM mAb [42, 43] had a poor recovery and a substantial loss 
of anti-HS specificity. We performed control studies with 
ascites containing 2 mg of a nonrelevant IgM mAb. In these rats 
neither glomerular binding nor albuminuria was detected. 
It is tempting to speculate that the quick disappearance of the 
mAb from the GBM and the short period of albuminuria is 
related to the IgM isotype of the mAb. The large molecular 
mass of the IgM molecules (900 kDa) probably prevents pene-
tration into the GBM. and thereby restricts binding to HS 
present in the lamina rara interna of the GBM. This is exactly 
the localization of mAb JM-403 which we found with direct 
IEM after i.v. injection (Fig. 4B). In other models ofglomerular 
injury caused by subendothelial immune deposits, like the Con 
A-fcrritin/anti-ferritin model [44], the immune complexes dis-
appear within 24 hours, in contrast to subepithelial immune 
deposits which persist for a long time. The final proof has to 
come from the kinetics of intraglomerular binding and the 
course of albuminuria after administration of anti-HS mAbs of 
the IgG isotype, since one can expect that this isotype pene-
trates the GBM more easily and can induce subepithelial 
immune deposits in addition to subendothelial localization, as 
was observed for antibodies against the core protein of HSPG 
[22, 23]. The two other mAbs against HS that have been 
described [25, 27] were not tested for their nephritogenic 
potential. Two other studies have claimed a role for anti-HS 
antibodies in nephritis. Fillit el al [38] detected anti-HS ami-
bodies in sera of patients with acute post-streptococcal nephri-
tis. Whether these antibodies have a pathogenic significance for 
the glomerulonephritis is difficult to prove. In another study [45] 
Abrass and Cohen immunized rats with commercially available 
HS and investigated the role of anti-HS antibodies in the 
development ofglomerular injury. Binding of anti-HS antibod-
ies in the glomerulus induced a mild inflammatory reaction and 
a reduction of glomerular filtration rate, but no abnormal 
proteinuria. Unfortunately however, their HS preparation was 
contaminated with a 60 kDa protein, and the HS-specificity of 
the antibodies was not proven unequivocally. Antibodies 
against the core protein of HSPG are nephritogenic after 
intravenous injection. A mild form of anti-GBM-like nephritis 
occurred with [23] or without [22] the development of albumi-
nuria. 
In summary, our 'results show that antibodies to HS are 
nephritogenic and can induce a selective proteinuria, probably 
secondary to the neutralization of HS-associated anionic sites 
in the GBM. 
Acknowledgments 
This work was supported by Grant 86.616 from the Dutch Kidney 
Foundation. We thank Mr. Henri Dijkman for performing the IBM 
studies. Dr. R. van de Stadt (Dr. Jan van Breemen Institute, Amster-
dam, The Netherlands) for the gift ofkcralan sulfate, Mr. J. Koedam of 
the Central Animal Laboratory, University of Nijmegen, for taking care 
of the animals. Dr. A. Hoilsma for the statistical analysis and Prof. Dr. 
R.A.P. Koene and Dr. W.J.M. Tax for critically reading the manu-
script. 
Reprint requests to J. van den Born, M.Ü.. Division of Nephrology, 
University Hospital, P.O. Box 9101. 6500 HB Nijmegen, The Nether-
lands. 
References 
1. KANWAR YS: Biophysiology ofglomerular nitration and protein-
uria. Lab Invest 51:7-21, 1984 
2. COTRAN RS. RENNKE HG: Anionic sites and Ihe mechanisms of 
proleinuria. N Engl J Med 309:1050-1052, 1983 
3. KARQUHAR MG, LEMKIN MC, STOW JL: Role of proteoglycans in 
glomerular function and pathology, in Nephrology, edited by ROB-
INSON RR, New York, Springer-Verlag New York Inc., 1985, p. 
580 
4. PARTHASARATHY N, SPIRO RG: Effect of diabetes on the glycos-
aminoglycan component of the human glomerular basement mem-
brane. Diabetes 31:738-741, 1982 
5. VERNIER RL. KLEIN DJ, SISSON SI', MAHAN JD, OEGEMA TR, 
BROWN DM: Heparan sulfate-rich anionic sites in the human 
glomerular basemen! membrane; decreased concentralion in con-
genital nephrolic syndrome. N Engl J Med 309:1001-1009. 1983 
6. GROGOEL GC. STEVENSON J, HOVINOH P, LINKER A, BORDER 
WA: Changes in heparan sulfate correlate with increased glomeru-
lar permeability. Kidney Int 33:517-523, 1988 
7. SHIMOMURA H, SPIRO RG: Studies on macromolecular compo-
nents of human glomerular basement membrane and alterations in 
diabetes; decreased levels of heparan sulfate proteoglycan and 
laminin. Diabetes 36:374-381, 1987 
8. MAHAN JD, SISSON-ROSS S, VERNIER RL: Glomerular basement 
membrane anionic charge site changes in aminonucleoside nephro-
sis. Am J Pathol 125:393-^ 101, 1986 
9. MYNDERSE LA, HASSF.LL JR. KLEINMAN HK, MARTIN GR, MAR-
TINEZ-HERNANDEZ A: Loss of heparan sulfate proteoglycan from 
glomerular basement membrane of nephrolic rats. Lab Invest 
48:292-302, 1983 
10. ROSENZWEIO LJ. KANWAR YS: Removal of sulfated (heparan 
sulfate) or nonsulfaled (hyaluronic acid) glycosaminoglycans re-
sults in increased permeability of the glomerular basement mem-
brane to ,25-I-bovine serum albumin. Lab Invest 47:177-184, 1982 
11. KANWAR YS, LINKER A, FARQUHAR MG: Increased permeability 
of the glomerular basement membrane to ferritin after removal of 
glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell 
Biol 86:680-693, 1980 
12. VEHASKARI VM, ROOT ER, GERMUTH FG, ROBSON AM: Glomer-
ular charge and urinary protein excretion. Effects of systemic and 
intrarenal polycation infusion in the rat. Kidney Int 22:127-135, 
1982 
13. HUNSICKER LG, SHEARER TP, SHAFFER SJ: Acute reversible 
proteinuria induced by infusion of the polycation hexadimethrine. 
Kidney Int 20:7-17, 1981 
14. KELLEY VE, CAVALLO Τ: Glomerular permeability, transfer of 
native ferritin in glomeruli with decreased anionic sites. Lab Invest 
39:547-553, 1978 
15. ASSEL E, NEUMANN K-H, SCHUREK H-J, SONNENBURO С, STOLTE 
Η: Glomerular albumin leakage and morphology after neutraliza­
tion of polyanions; I. Albumin clearance and sieving coefficient in 
the isolated perfused rat kidney. Renal Physiol (Basel) 7:357-364, 
1984 
64 
16 SONNENBURG-HATZOPOUIOS С, ASSEL E, SCHUREK HJ. STOLTE 
H Glomerular albumin leakage and morphology after neutraliza­
tion of polyanions, [I Discrepancy of protamine induced albumin­
uria and fine structure of the glomerular nitration barrier J Submi-
croscCytol 16 741-7'il, 1984 
17 GROGCEL GC, HOVINGH P, BORDER WA, LINKI-R A Changes in 
glomerular heparan sulfate m puromycin aminonuclcosidc nephro­
sis Am J Pathol 128 521-527, 1987 
18 I.ELONCT B, MARINO H, KANWAR YS Status of glomerular 
proteoglycans in aminonucleoside nephrosis Kidney Ini 31 1299-
1310, 1987 
19 BERTOLATUSJA, HuNSlCKtRLG Polycation binding to glomerular 
basement membrane, effect of biochemical modification Lab In­
vest 56 170-179, 1987 
20 TEMPLETON DM Retention of glomerular basement membrane-
proteoglycans accompanying loss of anionic site staining in exper­
imental diabetes lablnve si 61 202-211, 1989 
21 MAKINO H, LELONGT B, KANWAR YS Nephnlogemcity of pro­
teoglycans 11 A model of immune complex nephntts Kidney Int 
34 195-208, 1988 
22 MAKINO H, GIBBONS JT, KUMUDAVALLI R E D D Y M, KANWAR YS 
Nephntogenicity of antibodies to proteoglycans of the glomerular 
basement membrane J Clin Invest 77 142-156, 1986 
23 MILTTINEN A, STOW JL, MENTONE S. FARQUHAR MG Antibodies 
to basement membrane heparan sulfate proteoglycans bind to the 
laminae rarae of the glomerular basement membrane (GBM) and 
induce subepithelial GBM thickening J txp Med 163 1064-1084, 
1986 
24. MAKINO H, LELONGT B, KANWAR YS Nephntogenicity of pro­
teoglycans 111 Mechanisms of immune deposit formation Kidney 
Int 34 209-219, 1988 
25 KURE S, YOSHIL О A syngeneic monoclonal antibody to murine 
meth-A sarcoma (HepSS-l) recognizes heparan sulfate glycos-
aminoglycan (HS-GAG) Cell density and transformation depen­
dent alteration m cell surface HS-GAG defìned by Hep-SSI J 
Immunol 137 3900-3908, 1986 
26 KOIKE Y, KATO M, SUZUKI S. КіМАіл К A monoclonal antibody 
against the heparan sulfate of EHS-tumor proteoglycan (abstract) 
¡X Int Symposium on Glyioconjugates B8, 1987 
27 SNOW AD, MAR H, NOCHI IN D, SFKIGUCHI RT, KIMATA К, 
KOIKE Υ, WIGHT TN Early accumulation of heparan sulfate in 
neurons and in the beta-amyloid protein-containing lesions of 
Alzheimern disease and Down's syndrome Am J Pathol 137 1253-
1270 1990 
28 SNOW AD, WIGHT TN, NOCHI IN D, KOIKE Y, KIMATA К, 
DEARMONO SJ, PRUSINER SB Immunolocalization of heparan 
sulfate proteoglycans to the prion protein amyloid plaques of 
Gerstmann-Straussler syndrome, Creutzfeld-Jakob disease and 
scrapie Lab Invest 63 601-611, 1990 
29 MFEZAN fc, HJELLE JT, BRENDEL К, CARLSON EC Л simple, 
versatile, nondisruptive method for the isolation of morphologically 
and chemically pure basement membranes from several tissues 
Ufe Sci 17 1721-1732. 1975 
30 FARNDAI E RW, SAVERS CA, BARRETT A J A direct spectrophoto-
metne microassay for sulfated glycosaminoglycans in cartilage 
cultures Connect Tiss Res 9 247-248, 1982 
31 VAN D E N HEUVEL LPWJ, VAN D E N BORN J. VAN D E VELDEN 
TJAM, VEERKAMP JH. M O N N E N S LAH, SCHRODER CH, BERDEN 
JHM Isolation and partial characterization of heparan sulfate 
proteoglycan from the human glomerular basement membrane 
Biochem J 264 457-465, 1989 
32 K O H L F R G , MILSTFIN С Continuous cultures of fused cells secret 
mg antibody of predefined specificity Nature 256 495-497, 1975 
33 MANCINI О, CARBONARA АО, HEREMANS JR Immunochemical 
quantitation of antigens by single radial immunodiffusion Immu-
nochem 2 235-254, 1965 
34 FAABER P, RIJKE GPM, VAN D E PUTTE L B A , CAPEL P J A , BERDFN 
JHM Crossreactivity of human and murine anti-DNA antibodies 
with heparan sulfate The major glycnsammoglycan in the glomer­
ular basement membrane J Clin Invest 77 1824-1830. 1986 
35 RFNNARD SI, BERG R, MARTIN GR, FOIDART JM, GFHRON ROBFY 
Ρ Enzyme linked immunoassay (ELISA) for connective tissue 
components Anal Biochem 104 205-210, 1980 
36 LAURLLL CB Quantitative estimation of proteins of electrophore­
sis in agarose gel containing antibodies Anal Biochem 15 45-52, 
1966 
37 Fu LIT ΗΜ, BLAKE M, M A C D O N A L D С MCCARTY M Immunoge-
nicity of liposome bound hyaluronatc in mice At least two different 
antigenic sites on hyaluronatc are identified by mouse monoclonal 
antibodies J Lxp Med 168 971-982. 1988 
38 biLLiT H, DAMLE SP, GREGORY JD, VOLIN C, POON-KING T, 
ZABRISKIE J Sera from patients with poststreptococcal glomerulo­
nephritis contain antibodies to glomerular heparan sulfate proteo­
glycan J txp Med 161 277-289, 1985 
39 STOW JL, SAWADA H, FARQUHAR MG Basement membrane 
heparan sulfate proteoglycans are concentrated m the laminae rarae 
and in the podocyles of the rat renal glomerulus Proi. Nail Acad 
Sa USA 82 3296-3300, 1985 
40 CAMUSSI G, T E ITA С, CODA R, SEGOIONI GP, VFRCCLLONE A 
Platelet activating factor-induced loss of glomerular anionic 
charges Ки/ло>/л/25 73-81. 1984 
41 SCHMIFDEKF TMJ, SiocKt FW, WEBFR R, SUGISAKI Y, BATS-
FORD R, VOGT A Histones have high affinity for the glomerular 
basement membrane J txp Med 169 1879-1894 1989 
42 GARCIA GONZALEZ M, B E T H N G L R S, O T T S, Οι IVIFR Ρ, KA-
DOUCHE J, POULFTTY Ρ Purification of murine lgG3 and IgM 
monoclonal antibodies by euglobulm precipitation J Immunol 
Meth 111 17-23 1988 
43 LIM P-L Isolation of specific IgM monoclonal antibodies by affinity 
chromatography using alkaline buffers Mol Immunol 24 11-15, 
1987 
44 FRIES JWU, MFNDRICK DL, RENNKF HG Determinants of im­
mune complex mediated glomerulonephritis Kidney int 34 333-
345 1988 
45 ABRASS CK, COHEN AH Characterization of renal injury initiated 
by immunization of rats with heparan sulfate Am J Pathol 130 103-
111, 1988 
65 

CHAPTER 4 
MONOCLONAL ANTIBODIES AGAINST THE 
CORE PROTEIN AND THE 
GLYCOSAMINOGLYCAN SIDE CHAIN OF 
GLOMERULAR BASEMENT MEMBRANE 
HEPARAN SULFATE PROTEOGLYCAN. 
CHARACTERIZATION AND IMMUNOHISTO-
CHEMICAL APPLICATION IN HUMAN TISSUES 
J. van den Bom, L.P.W.J. van den Heuvel, M.A.H. Bakker, 
J.H. Veerkamp, K.J.M. Assmann, and J.H.M. Berden 
Conditionally accepted for the J Histochem Cytochem 
67 

ABSTRACT 
Monoclonal antibodies (mAbs) were produced against both the core protein and the 
heparan sulfate (HS) side chain of heparan sulfate proteoglycan (HSPG) from glomerular 
basement membranes (GBM). Anti-HSPG-core mAbs were obtained after immunization of 
mice with HSPG purified from human GBM, the anti-HS mAb after immunization of mice 
with HSPG from rat glomeruli, which cross-reacted with human HS and GBM HSPG. The 
specificity of the mAbs was demonstrated by ELISA studies, Western blotting, inhibition 
experiments and indirect immunofluorescence (IF) on kidney cryostat sections pretreated with 
glycosaminoglycan degrading enzymes. Indirect IF on normal human kidney tissue showed 
prominent GBM staining for both mAbs with a variable staining of the other renal basement 
membranes (BMs). In the indirect immuno-electron microscopy (IEM), most intense staining 
was observed at the endothelial side of the GBM for both mAbs, although the staining 
patterns were not identical. Both mAbs were used to localize HSPG in human tissues by 
indirect IF. They bound to antigens, present in the BMs of most tissues examined, including 
those of epithelia and endothelia. Differences between both mAbs were observed for BMs 
of muscle cells, since the anti-HSPG core protein mAb (JM-72) staining was negative, 
whereas the anti-HS mAb (JM-403) clearly stained these structures. Comparison of our 
staining patterns in human tissues with the distribution of other anti-BM HSPG antibodies, 
suggests that there are at least two types of BM HSPG, which have common epitopes on the 
HS side chains recognized by JM-403. 
INTRODUCTION 
Proteoglycans are macromolecules with an ubiquitous tissue distribution. They are 
composed of glycosaminoglycan chains covalently attached via a linkage structure to a 
protein core [23,27,64]. One class of proteoglycans is formed by the heparan sulfate 
proteoglycans (HSPGs), which are found both on cell surfaces and in basement membranes 
(BMs) [21]. Cell surface-associated HSPGs are either integral plasma membrane proteins, 
or peripheral membrane components bound to the cell surface by specific receptors or 
through a glycosyl-phosphatidylinositol anchor [12,20]. They have been strongly implicated 
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with a role in cell recognition, cell adhesion, cell migration and cell growth 
[29,31,46,62,77]. HSPGs present in BMs, notably those found in the glomerular basement 
membrane (GBM), are thought to control the charge-dependent permeability of the GBM by 
virtue of their anionic charge provided by the HS side-chains [6,18,36]. After enzymatic 
removal of HS from the GBM, the glomerular capillary wall looses its ability to restrict the 
passage of albumin [63]. Moreover, clinically and experimentally, a reduction of (primarily 
HS-associated) anionic sites is characterized by the appearance of proteinuria 
[3,22,48,56,58,68,84]. Both classes of HSPGs, mentioned above, are immunologically and 
structurally completely different. Antibodies against one HSPG class do not cross-react with 
the other [33,72]. Moreover, the primary structures of cell surface-associated HSPGs like 
glypican [12] or members of the syndecan family [4,40,44,50,52,59,66] differ from that of 
the large BM HSPG [14,34,57]. Also the chromosomal localization is different, since the 
gene coding for the human cell surface HSPG fibroglycan is located on chromosome 8 [52], 
whereas the gene for the human BM HSPG has been localized on chromosome 1 [14,35,87]. 
For further characterization of function and distribution of HSPGs, monoclonal antibodies 
(mAbs) can provide important tools. Previously, we reported about the production of a mAb, 
recognizing the HS-side chain of HSPG [79]. 
In this report we describe the production and characterization of a mAb (JM-72) against 
the core protein of human GBM HSPG. The presence of HSPG-core protein was studied 
immunohistochemically in a variety of human tissues and was compared with a new anti-HS 
mAb JM-403, which we described recently [78]. The results of these studies indicate 
heterogeneity of the diverse tissue BMs and suggest the existance of several types of BM 
HSPGs. 
MATERIALS AND METHODS 
Proteoglycans and glvcosaminoglvcans 
Human GBM HSPG was isolated and characterized as described previously [82]. Briefly, 
GBM were prepared from human kidneys by the detergent method and HSPG was purified 
under dissociative conditions by 4 M guanidine extraction, ion-exchange- and gel permeation-
chromatography. The core protein of GBM HSPG was prepared according to the procedure 
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of Edge et al. [15] with some minor modifications [82] using trifluoromethanesulfonic acid 
(TFMS) as deglycosylating agent. Rat glomerular HSPG was partially purified under 
dissociative conditions by 4 M guanidine extraction and ion-exchange chromatography (78). 
Dermatan sulfate proteoglycan isolated from bovine lung [83] was kindly provided by Dr. 
A. van Kuppeveld (Dept. of Biochemistry, University of Nijmegen, The Netherlands). 
Chondroitin sulfate, dermatan sulfate and keratan sulfate proteoglycans isolated from bovine 
hyaline cartilage were a generous gift of Dr. R. van de Stadt (Jan van Breemen Institute, 
Amsterdam, The Netherlands). The following glycosaminoglycans were used: HS isolated 
from bovine kidney (Seikagaku, Tokyo, Japan); chondroitin sulfate A and С isolated from 
whale cartilage (Sigma, St. Louis, Mo., U.S.A.); dermatan sulfate isolated from porcine skin 
(Sigma); keratan sulfate isolated from calf cartilage (donated by Dr. R. van de Stadt), 
heparin (Thromboliquine, Organon Teknika, Oss, The Netherlands) and hyaluronic acid (HA) 
isolated from human umbilical cord (Sigma). Heparitinase (Seikagaku) was used at a 
concentration of 1 U/ml, chondroitinase ABC (Sigma) at 0.1 U/ml and hyaluronidase (Sigma) 
at 50 U/ml. 
Hybridoma production 
Female BALB/c mice were immunized intraperitoneally at days 0 and 30 with 50 μg 
human GBM HSPG or with 50 /ig of rat glomerular HSPG in 0.2 ml PBS emulsified with 
0.2 ml complete Freund's adjuvant. At days 60, 61 and 62 the mice were boosted 
intravenously with 15 μg HSPG in 0.15 ml PBS. At day 63 mice were sacrificed, blood was 
taken and the spleen cells were isolated and fused with the non-producing mouse myeloma 
cell line SP2/0 according to Köhler & Millstein [43] with some minor modifications. 
Syngeneic peritoneal macrophages (10,000 - 20,000 cells/well) were used as feeder layer. 
Wells with growing hybridomas were screened in ELISA for anti-HSPG and anti-HS 
reactivity, and by indirect IF on human or rat kidney cryostat sections. After HAT selection, 
cell cultures were grown in HEPES-buffered RPMI-1640 culture medium containing 10% 
fetal calf serum, gentamycin (40 jug/ml), pyruvate (110 /ig/ml) and glutamin (292 /ig/ml), 
and cultured in an humidified incubator at 370C with 95 % air and 5 % C02. Selected wells 
were recloned by limiting dilution until all subclones showed the same reactivity pattern. The 
antibody subclass was determined in ELISA using subclass-specific antibodies conjugated to 
peroxidase (Southern Biotechnology Associates Inc., Birmingham, AL, U.S.A.). Female 
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BALB/c mice, pretreated with pristane (2,6,10,14-tetramethylpentadecane 96%, Janssen 
Chimica, Beerse, Belgium), were injected intraperitoneally with 3 χ ΙΟ6 viable hybridoma 
cells. After 2 - 4 weeks ascites was drained, centnfuged to remove cells, clotted overnight 
at 40C, filtered through 0.2μπι filters and stored at -20^ until use. Antibody concentration 
in the ascites was determined by single radial immunodiffusion [51]. 
Characterization of mAbs 
ELISA studies. Anti-HS reactivity was measured in ELISA as described [17], using a 
protamine-chloride precoating to bind the negatively charged HS to the plates. Antibody 
reactivity against human GBM HSPG, rat glomerular HSPG, laminin from human placenta 
(Calbiochem, La Jolla, Ca. U.S.A.) or from the mouse Engelbreth-Holm-Swarm (EHS)-
tumor (Sigma, St. Louis, Mo., U.S.A.), collagen type IV from human placenta or from the 
mouse EHS-tumor (Sigma), fibronectin from human plasma (Sigma) or from rat plasma 
(Calbiochem, La Jolla, CA, U.S.A.) and several other proteoglycans was tested in ELISA 
according to Rennard [61]. Positive controls used in the ELISA studies were: m Ab against 
human laminin (Calbiochem), rabbit anti-mouse EHS-laminin (GIBCO Europe, Breda, The 
Netherlands), mAb against human collagen type IV [24] (kindly provided by Dr. J.P.M. 
Cleutjens, University of Limburg, Maastricht, The Netherlands), rabbit anti-mouse EHS-
collagen type IV (Collaborative Res. Inc., Bedford, Mass., U.S.A.), rabbit anti-human 
fibronectin (Calbiochem), goat anti-rat fibronectin (Calbiochem), rabbit anti-bovine dermatan 
sulfate proteoglycan [83] (kindly provided by Dr. A. van Kuppeveld, Dept. of Biochemistry, 
University of Nijmegen, The Netherlands) and rabbit anti-human GBM HSPG, prepared as 
described [82]. 
Inhibition experiments. A constant amount of mAb, giving 50% of the maximal ELISA 
signal, was added to an increasing concentration inhibitor (0.2 - 200 μg/ml) and incubated 
for 1 h at 370C, and subsequently for 1 h at 40C to optimize immune-complex formation. 
Thereafter this mixture was added to ELISA plates, precoated with GBM HSPG or HS. 
Bound antibodies were developed as described for the ELISA. Percentage inhibition was 
calculated as: [1 - (A450 + inhibitor / A450 - inhibitor)] χ 100%. 
Western blotting. Intact GBM HSPG or its core protein were run on 3-20% 
SDS-polyacrylamide gels and blotted overnight to nitrocellulose [76]. After incubation with 
the primary antibodies and development with peroxidase-conjugated goat anti-mouse IgG, 
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heavy and light chain specific (Nordic, Tilburg, The Netherlands), blots were stained with 
4-chloro-l-naphtol [25]. 
Immunohistochemical techniques 
Indirect immunofluorescence (IF). Human tissue specimens were obtained during autopsy 
or surgery, snap-frozen in liquid nitrogen and stored at -700C. Two μιη cryostat sections of 
these tissues were fixed for 5 min in aceton and washed with PBS. Thereafter, 100 μί of 
diluted ascites (1:200 for both JM-72 and JM-403 in PBS containing 1% BSA and 0.05% 
sodium azide) were applied to the sections for 30 min at room temperature. After washing 
with PBS, binding of JM-72 (anti GBM HSPG-core) and JM-403 (anti-HS) was visualized 
with F(ab)2-fragments of FITC-labeled sheep anti-mouse IgG, heavy and light chains (Cappel-
Organon Teknika, Turnhout, Belgium), 100 μί diluted 1:500 or FITC-labeled goat anti mouse 
IgM, Fc-specific, (Nordic, Tilburg, The Netherlands) 100 μ\ diluted 1:100 in PBS containing 
1% BSA and 0.05% sodium azide respectively. After incubation for 30 min at room 
temperature in the dark, sections were washed with PBS, embedded in Aqua Mount and 
examined with a Zeiss Axioskop microscope fitted for fluorescence microscopy. All 
incubations were done with the same batches of mAbs and secondary antibodies. Culture 
supernatant of a rat mAb against the large BM HSPG of the mouse (perlecan) which cross-
reacted with human HSPG, was a generous gift of Dr. John R. Couchman (University of 
Alabama, Birmingham, U.S.A.) and was applied undiluted to human kidney sections. 
Binding of mAb was visualized by FITC-labeled goat anti-rat IgG (Nordic) diluted 1:100 in 
IF buffer. 
Immuno-electron microscopy (IEM). A human cadaveric donor kidney, not suitable for 
transplantation because of ureteral damage, was perfused with Eurocollins solution and kept 
on ice for 36 hours. For indirect IEM the kidney was subsequently perfused with a mixture 
of periodate-lysine-2% paraformaldehyde (PLP) fixative for 15 min. Small pieces of renal 
cortex were further immersed in the same fixative for an additional 1.5 hour, cryoprotected 
in 2.3 M sucrose for 1 hour and snap frozen in liquid nitrogen. Twenty μτη cryostat sections 
were incubated with mAb JM-72, diluted 1:200 in PBS containing 1% BSA, or with mAb 
JM-403, diluted 1:170 in PBS/1% BSA, for 18 hour at 40C. After three washes in PBS-1% 
BSA, the sections were immunolabeled by incubation with a peroxidase labeled rabbit anti-
mouse Ig (Dakopatts, Copenhagen, Danmark), diluted 1:20 in PBS-1% BSA for 2 hours. 
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After several washes in PBS-1% BSA, the sections were incubated with 0.05% 
diaminobenzidine medium containing 0.6% TRIS for 10 min, followed by diaminobenzidine 
with addition of 7 μΐ of 30% Η202 for 7 min. After three washes in distilled water, the 
sections were post-fixed in 0.1 M phosphate buffered 1% OsO,,, pH 7.4 for 15 min at room 
temperature, dehydrated, and embedded in Epon 812. Thin sections were prepared on a LKB 
Ultratome, and examined in a Jeol 1200 EX II electron microscope. 
RESULTS 
Production and characterization of anti-human GBM HSPG mAbs 
After immunization of female BALB/c mice with human GBM HSPG, we obtained 18 
mAbs against this proteoglycan, of which the characteristics of one representative mAb of 
this group, mAb JM-72 is presented. This antibody is of the IgG, subclass. Ascites contained 
10 mg IgG^ml. In ELISA, mAb JM-72 bound to human GBM HSPG and to its core protein 
obtained after removal of HS by TFMS, but not to HS (Fig.lA). The reactivity towards the 
HSPG core protein was eight times stronger than to the total HSPG molecule. No reactivity 
could be observed in ELISA with other BM components like laminin, fibronectin and 
collagen type IV (all from human origin), nor was any reactivity detectable towards 
chondroitin sulfate, dermatan sulfate and keratan sulfate proteoglycans (Fig.lA). The binding 
of JM-72 to GBM HSPG in ELISA could specifically and dose-dependently be inhibited by 
GBM HSPG as well as by its core protein (Fig. IB). HS, laminin, fibronectin and collagen 
type IV, as well as chondroitin sulfate, dermatan sulfate and keratan sulfate proteoglycans 
had no effect on the binding of mAb JM-72 to GBM-HSPG in the inhibition ELISA . As in 
the direct ELISA, JM-72 displayed in the inhibition ELISA a greater affinity for the HSPG 
core protein than for the total HSPG molecule, since 50% inhibition was obtained 
respectively with 18 and 132 μg/ml. These results indicate that mAb JM-72 is directed 
against an epitope located on the core protein of human GBM HSPG. This specificity could 
be confirmed by Western blotting. With intact HSPG (Fig.2, panel A) one major broad band 
with a molecular mass between 200 - 400 kDa was revealed after staining. Treatment of the 
proteoglycan with TFMS resulted in several bands with a molecular mass of respectively 
160, 110, 90 and 60 kDa (Fig.2, panel B). The presence of core proteins with different 
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Fig. 1. Characteristics of mAb JM-72 in ELISA and inhibition-ELISA. Antigens used to coat 
the ELISA plates (A) or to inhibit the binding of mAb JM-72 to intact GBM HSPG (B) were: 
GBM HSPG ί-Δ-Λ the core protein of GBM HSPG obtained after removal of the HS-chains 
by TFMS (-*-), HS (-Π-) and other proteoglycans (chondroitin sulfate, dermatan sulfate or 
keratan sulfate proteoglycans) or BM components (collagen type IV, laminin or fibronectin) 
(- 0 -). The results are expressed in absorption units at 450 nm (A450) in the ELISA (A) and 
in % inhibition of the ELISA signal without inhibitor in the inhibition-ELISA (B). 
molecular masses after TFMS treatment of HSPG, indicates either the existence of core 
proteins with variable molecular masses or may be due to proteolytic cleavage of the 
precursor protein. These results are identical to those we reported previously (82). The intact 
HSPG as well as its core proteins stained clearly with mAb JM-72 (panel A, lane 2 and panel 
B, lane 2 respectively). A 1:50 dilution of the serum of the mouse, which was chosen for 
hybndoma production and known to be positive in ELISA and indirect IF, served as a 
positive control (both panels, lane 1). As can be seen in panel A, lane 1 the mouse serum 
reacts with 2 additional bands with a lower molecular weight. At present we do not know the 
identity of these bands, which are not visualized by mAb JM-72 or a previously prepared 
polyclonal rabbit anti-GBM HSPG antiserum [82] (data not shown). A non-relevant IgGi 
mAb with the same IgG, concentration served as a negative control (both panels, lane 3). 
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fig. 2. Characteristics ofmAbJM-72 by 
Western blotting. GBM HSPG (panel A) 
and its core protein (panel В) were 
separated on 3-20% SDS-PAGE and 
blotted overnight to nitrocellulose. Both 
panels, lane 1: incubated with the serum 
of the mouse used for the hybridoma 
production, dilution 1:50 (positive 
control); both panels, lane 2: incubated 
with mAb JM-72; both panels, lane 3: 
incubated with a non-relevant IgG, mAb 
(negative control). 
123 123 
Production and characterization of anti-HS mAb 
After immunization with a rat glomerular HSPG preparation, one anti-HS mAb of the IgM 
isotype (JM-403) was obtained [78]. Ascites obtained after intraperitoneal inoculation of 
hybridoma cells contained 6.5 mg IgM/ml. The reactivity pattern of mAb JM-403 in ELISA 
is shown in Fig.ЗА. A clear reactivity is observed with HS, but no binding occurred to 
chondroitin sulfate A and C, dermatan sulfate, keratan sulfate or heparin. Furthermore, the 
mAb bound to human GBM HSPG, but not to its core protein (Fig.ЗА). The specificity of 
mAb JM-403 was confirmed by the inhibition ELISA shown in Fig.3B. Both HS and intact 
GBM HSPG were able to inhibit the binding of mAb JM-403 to HS in a dose-dependent 
manner, whereas the HSPG core protein and the other glycosaminoglycans did not show any 
inhibition. Since the same GBM HSPG core protein preparation was used for this experiment 
as for the inhibition of JM-72 (Fig. IB), we could exclude denaturation or degradation of the 
core protein as a cause for the lack of inhibitory effects on JM-403 binding to HS. In 
addition to binding to HS, JM-403 showed a crossreactivity with hyaluronic acid (HA) in 
ELISA, which we have described previously [78]. With cellulose acetate electrophoresis we 
could exclude that the used HA preparation was contaminated with HS (data not shown), 
400 kDa -
В 
200 kDa -
*l 
1 
- 160 kDa 
-110 kDa 
- 90 kDa 
- 60 kDa 
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although a contamination with η-acetyl heparosan cannot be excluded formally. Our attempts 
to perform staining in a Western blot with JM-403 on intact HSPG and its core protein were 
unsuccesfull. Whether this is due to destruction of the JM-403 epitope by the SDS treatment 
is not yet known. 
A450 % Inhibition 
100 
I I I I I M 
0.01 0.1 1 10 
concentration mAb JM-403 hig/ml) concentration inhibitor fag/ml) 
Fig. 3. Characteristics of mAb JM-403 in ELISA and inhibition-ELlSA. Antigens to coat the 
ELISA plates (A) or to inhibit the binding of mAb JM-403 to HS (В) were: GBM HSPG (-ь-), 
the core protein of GBM HSPG obtained afier removal of the HS-chains by TFMS (-*-), HS 
(-Ώ-), and the other glycosaminoglycans (chondroitin sulfate A or C, dermatan sulfate, 
keratan sulfate or heparin) (- О -). The results are expressed in absorption units at 450 nm 
(A450) in the ELISA (A) and in % inhibition of the ELISA signal without inhibitor in the 
inhibition-ELISA (B). 
HSPG and HS distribution in human kidney tissue 
In the indirect IF mAb JM-72 (anti-HSPG core) showed in the glomerulus a brilliant, 
linear staining of the GBM, while the mesangial matrix was negative (Fig. 4A). A less 
intense, but also linear staining was seen along the other renal BMs (Bowman's capsule, 
tubular BMs, endothelial BMs of blood vessels and BMs of the smooth muscle cells in 
arterial walls, Fig. 4B). No interstitial staining was observed. 
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Fig. 4. Indirect IF ofmAb JM-72 (A and B) and mAb JM-403 (Cand D) on cryostat sections 
of a human kidney. A: glomerulus. Note the brilliant staining of the GBM and absence of 
mesangial staining. B: overview renal tissue. C: glomerulus. Note that the staining pattern 
corresponds well to that of anti-HSPG-core mAb JM-72 (A). D: overview renal tissue. Closed 
arrow indicate Bowman's capsule; open arrow tubular BMs; arrowhead BMs of peritubular 
capillaries; open triangle the BMs of vascular smooth muscle cells. Bar = 50 μm. 
The results of the indirect IEM on normal kidney tissue confirmed the findings of the indirect 
IF. Staining was observed throughout the whole GBM, but the reaction product was more 
prominently located at the endothelial side of the GBM (Fig. 5A and B). The mesangial 
matrix did not stain, although there was a slight staining at the border between the 
mesangium and the capillary endothelium (arrows Fig.5A). All tubular BMs were stained as 
well as the BMs of the peritubular capillaries (Fig. 5C). 
After indirect IF on human kidney tissue anti-HS mAb JM-403 displayed an homogeneous 
staining of the GBM (Fig.4C). Other renal BMs stained with variable intensity. The BMs of 
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Fig. 5. Immuno-electron micrographs of sections from a PLP perfusion-fixed human kidney 
incubated with mAb JM-72 (A,B and C) or mAh JM-403 (D,E and F). A: detail glomerulus. 
Most prominent staining was seen at the endothelial side of the GBM. Endothelium and 
epithelium were negative. Arrows indicate the staining between the mesangium and the 
capillary endothelium. B: detail GBM. Although the entire thickness of the GBM was 
positive, most staining was at the inner side of the GBM. C: detail tubuli. All tubular BMs 
(arrows) were positive as well as the BMs of the peritubular capillary. D: detail glomerulus. 
E: detail GBM. Attend the irregular and somewhat segmental subendothelial staining of the 
GBM. Endothelium and epithelium were negative. F: detail tubuli. Although the tubular BM 
(solid triangle) of the proximal tubule (brush border indicated by asteriks) was unstained, the 
other tubular BM (arrow) and the BM of the peritubular capillary were positive. 
En=endothelium, Ep=epithelium, M=mesangium, Ptc= peritubular capillary, US=urinary 
space. Bar is 2 μ/η. 
peritubular capillaries and those of vascular smooth muscle cells were strongly positive, 
endothelial BMs of venules and arteries and Bowman's capsule were moderately positive, 
tubular BMs ranging from negative to positive (Fig.4D). Pretreatment of cryostat sections 
with 1 U/ml heparitinase prevented all JM-403 staining, whereas pretreatment of the sections 
with chondroitinase ABC and hyaluronidase did not influence the binding of the mAb. This 
was also found in tissues known to contain large amounts of HA (skin and umbilical cord), 
indicating that HÀ was not recognized in situ (results not shown). In indirect IEM, 
incubation with mAb JM-403 revealed an irregular (sometimes segmental) staining of the 
subendothelial side of the GBM (Fig.5D and E). As in the indirect IF the BMs of the 
peritubular capillaries were positive, the tubular BMs were negative (proximal tubules) or 
positive (Fig.SF). 
HSPG and HS distribution in non-renal human tissues 
To localize the expression of GBM HSPG and HS throughout the body, a panel of human 
tissues were investigated with both anti-HSPG mAbs (anti-HSPG-core mAb JM-72 and anti-
HS mAb JM'403). The results are summarized in Table 1. Both mAbs recognized antigens 
essentially limited to the BMs of most tissues examined, including those of epithelia and 
endothelia. However, subtle differences in immunostaining were observed (Table 1). Whereas 
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Table 1. BM staining of human tissues with anti-HSPG core mAb JM-72 and anti-HS mAb JM-403 
Cell type Tissue JM-72 JM-403 
Epithelium 
Endothelium 
Kidney 
GBM 
TBM 
Bowman's capsule 
Liver 
sinusoids 
biliary ducts 
Skin 
Salivary glands 
Gingiva 
Esophagus 
Stomach 
Small intestine 
Colon 
Trachea 
Lung 
Urinary bladder 
Prostate 
Testis 
Vagina 
Thyroid 
Pancreas 
Artenes 
Venes 
Capillaries 
Sinusoids 
+ + + 
+ 
+ 
± 
+ + 
+ + 
-/+ 
+ + 
+ + 
+ 
J> 
+ 
+ + 
+ 
+ 
+ 
+ + 
+ 
+ + + 
+ + 
+ 
+ 
+ + 
+ 
+ + + 
-/+ + 
-/+ 
+ + +· 
± 
+ + + 
+ +• 
+ + + 
+ + 
+ 
+ + 
+ + 
+· 
+ + + 
+ + 
+ + 
+ + 
+ + 
+ + + 
+ + 
+ + + 
+ + 
+ + 
+ 
Muscle striated 
smooth 
in arterial wall 
in other tissues 
cardiac 
+ +' 
+ + + 
+ + 
+ + + 
Schwann cell Peripheral nerves 
'^segmental staining 
b
=positive with polyclonal anti-HSPG core antiserum 
81 
anti-HSPG core mAb JM-72 showed always a linear staining pattern of the various BMs, 
anti-HS mAb JM-403 staining was variable from fine granular to linear. The epithelial BMs 
from skin, gastrointestinal tract except for the small intestine (gingiva, esophagus, stomach 
and colon), urinary bladder, trachea and lung, testis and vagina, exocrine glands including 
salivary glands, pancreas and prostate, and endocrine glands like the thyroid stained with 
both anti-HSPG-core mAb JM-72 and anti-HS mAb JM-403, although JM-403 staining was 
in general more intensive (Table I and Fig.6 Α-D and A'-D'). The staining pattern that we 
observed in tissues of the lower gastro-intestinal tract was variable. We analysed tissue 
specimens of the stomach, small intestine and colon from three different sources. Only one 
specimen of the stomach and one of the colon clearly stained with mAb JM-72, whereas in 
all three occasions the staining in the small intestine was negative. However, all these tissues 
(including the small intestine) clearly stained with a polyclonal antiserum against human 
GBM HSPG core protein and by anti-HS mAb JM-403, pointing to the presence of HSPG 
in these tissues. This indicates that the epitope recognized by JM-72 on the HSPG core 
protein is either absent or has a variable expression. In the liver, anti-HS mAb JM-403 bound 
to the sinusoidal wall (sometimes in a segmental fashion), whereas mAb JM-72 staining was 
very weak (Fig.6 E and E'). In the same sections, the BMs of the blood vessels and bile 
ducts were positive with both mAbs. All endothelial BMs of blood vessels, ranging from 
large to small sized, arterial as well as venous, capillaries and sinusses stained with both 
mAbs, although mAb JM-403 staining was much more prominent (Table 1 and Fig.6). 
Although mAb JM-403 clearly recognized basal lamina-associated HS of myocardial muscle 
cells as well as those of all skeletal and smooth muscle cells throughout the body, anti-
HSPG-core mAb JM-72 stained only the basal laminae of smooth muscle cells belonging to 
the arterial wall. Basal laminae of smooth muscle cells elsewhere in the body (for instance 
in the gastrointestinal tract, skin, prostate and urinary bladder), and those of skeletal and 
myocardial muscles were not recognized by mAb JM-72 (Fig.6F and G, F' and G')· The 
basal laminae of Schwann cells in the peripheral nerves (as observed in the skeletal muscle) 
were positive with mAb JM-72, but very weakly with mAb JM-403. In the brain (cerebrum 
and cerebellum) only immunostaining of the blood vessels was obtained. In lymphatic tissue 
(spleen, thymus, tonsil, lymph node) the BMs of blood vessels, sinusses and the interlobulary 
connective tissue stained with both mAbs. No staining of the sections was observed by using 
non-relevant IgG, and IgM mAbs, developed with their respective FITC-labeled conjugates. 
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Fig. 6. Indirect IF on a panel of human tissues incubated with anti-HSPG core mAb JM-72 
(Α-G) or anti-HS mAb JM-403 (A '-G'). A-A ': skin. A positive staining could be observed of 
the junction between the epidermis and the dermis. B-B ': esophagus. The BM between the 
stratified squamous epithelium of the mucous membrane and the underlying submucosa was 
clearly stained by both mAbs. C-C: trachea. Note the linear staining of the BM of the 
ciliated columnar epithelium by mAb JM-72, whereas a weak and somewhat segmental 
staining was observed by mAb JM-403 (capillaries in the same section stained in a normal 
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fashion). D-D': thyroid. Both mAbs stained the BMs of the epithelium of the follicles. E-E': 
liver. Whereas mAb JM-72 weakly stained the sinusoids, mAb JM-403 heavily stained these 
structures in a segmental fashion. F-F': skeletal muscle. The basal laminae surrounding the 
myofibrils were negative by mAb JM-72, but clearly stained by mAb JM-403. The basal 
laminae of Schwann cells surrounding peripheral nerves were positive by mAb JM-72, but 
almost negative with mAb JM-403 (arrowhead). G-G': cardiac muscle. The basal laminae 
surrounding the myocardial cells were negative with mAb JM-72 (although the capillaries 
were positive), but heavily stained by mAb JM-403. Arrows in all photographs of this figure 
indicate the staining of capillary BMs. D=dermis, E=epithelium, F=follicle, S=submucosa. 
Bar is 50 μm. 
Taken together, these results indicate that both mAbs stained exclusively BM-associated 
HSPG throughout the body, although JM-72 distribution is more limited compared to JM-
403, especially in muscle tissues. The staining of the BMs in the tissues could be completely 
inhibited, when the sections were incubated by the mAbs in the presence of purified GBM 
HSPG. Cell surface-associated HSPG was not recognized by both mAbs, indicating that the 
epitopes recognized by these mAbs are not present on cell surface-associated HSPG core 
protein and HS chains. 
DISCUSSION 
In this study the production and characterization of mAbs reacting with the core protein 
(JM-72) or the HS chains (JM-403) of human GBM HSPG is described. These mAbs were 
used to study immunohistochemically the co-localization of GBM HSPG-core protein and 
GBM HS in human tissues. 
Characteristics of the mAbs 
The results obtained in the ELISA, the inhibition studies and the Western blotting indicate 
that mAb JM-72 is directed against the core protein of GBM HSPG. In the ELISA and in the 
inhibition experiments, JM-72 showed a higher reactivity with the HSPG core protein than 
with the total HSPG molecule, which suggests that glycosylation of the core protein decreases 
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the binding of mAb JM-72 to its epitope. Similar results were obtained by Couchman and 
Ljubimov with m Abs against EHS derived HSPG-core protein [7]. The HS-specificity of 
mAb JM-403 was demonstrated in ELISA, inhibition experiments and in indirect IF after 
pretreatment with glycosaminoglycan degrading enzymes. Interestingly, JM-403 also 
displayed reactivity towards HA in ELISA, although tissues rich in HA (like skin and 
umbilical cord) were not stained by JM-403, except for the HS-containing BMs. This 
suggests that the JM-403 epitope in HA is hidden in vivo. That HS and HA contain cross-
reactive epitopes is also suggested by the work of Fillit et al [19], who found that a mAb 
against HA cross-reacted with HS. Our findings, showing binding of mAb JM-403 to HS and 
HA but not to other glycosaminoglycans, suggest that the epitope may be located within a 
cluster of unsulfated glucuronic acid - N-acetyl glucosamine disaccharide units. At present, 
we try to unravel the epitope specificity at the molecular level. 
HSPG core protein distribution in human tissues 
We observed a variable staining intensity with mAb JM-72 in the different BMs (Table 1). 
This may be due to differences in the HSPG content, to differences in the accessibility of the 
JM-72 epitope by steric hindrance of other BM components or to variations in the degree of 
glycosylation of the HSPG-core protein. The IF pattern that we observed with our anti-GBM 
HSPG core mAb JM-72 resembles those reported by other investigators in rat and human 
tissues, using anti-HSPG antibodies [8,39,49,54,67,82] (Table 2). As can be seen in Table 
2 this distribution pattern is observed with antibodies obtained after immunization with a 
small, high density HSPG, mainly of glomerular or GBM origin. This is in contrast to the 
staining pattern observed with antibodies directed against a large, low density HSPG, mainly 
derived from the mouse EHS tumor or against HSPG derived from other sources, but 
immunologically related to EHS HSPG [7,16,28,38]. With these latter antibodies the most 
prominent staining in the kidney is seen in the mesangium and the TBMs, whereas the GBM 
stains less intensely (Fig.7). Outside the kidney all BMs, including those of endothelium, 
epithelia, all types of muscle cells and liver sinusoids, stained positively with these antibodies 
(Table 2). These data suggest that there are (at least) two antigenic different types of BM 
HSPGs: a large HSPG present in all BMs and a small HSPG present in most epithelial and 
endothelial BMs, but absent in especially the BMs of most types of muscle cells. It has been 
suggested by Klein et al. [41] that the small HSPG is derived from the large HSPG by 
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Table 2. Stauung patterns of antibodies against BM HSPGs from different sources as desenbed by several investigators. 
Ref.no. Source HSPG Anti­
bodies 
Mr HSPG 
intact core 
Staining pattern kidney 
GBM TBM mesangium 
Stauung 
liver 
sinusoids 
staining muscle cells 
smooth striated 
vascular non­
vascular 
cardiac 
54 
49 
39 
67 
82 
this study 
8 
16 
38 
7 
28 
Rat glomeruli 
Rat GBM 
Bovine glomeruli 
Porcine GBM 
Human GBM 
Human GBM 
Mouse PYS-2 
ECM 
Rat Schwann ECM 
Mouse EHS tumor 
Mouse EHS tumor 
Human fibr. ECM 
Ρ 
Ρ 
m 
Ρ 
Ρ 
m 
Ρ 
m 
m 
m 
m 
ND 
150 
210 
>400 
200^*00 
200-400 
200 
>450 
>500 
>500 
>450 
130 
18 
130 
230 
60-160 
60-160 
200 
400 
450 
450 
400 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
+ + 
ND 
+ 
± 
+ 
ND 
+ 
+ 
+ 
+ 
+ 
ND 
ND 
ND 
± 
± 
ND 
ND 
ND 
± 
± 
ND 
ND 
± 
± 
ND 
ND 
+• 
+ 
+ 
ND 
+ 
ND 
ND 
ND 
+ 
+ 
+ 
+ 
+ 
ND 
ND 
+ 
+ 
ND 
71 Rat hver 150-300 40 + + + + ND ND ND 
•=4 of the 9 mAbs were positive 
ECM=extracellular matrix 
EHS=Engelbreth Holm Swarm 
fibr. = fibroblast 
GBM=glomerular basement membranes 
HSPG=heparan sulfate proteoglycan 
m=monoclonal antibodies 
ND=not determined 
ρ=polyclonal antibodies 
TBM = tubular basement membranes 
Fig. 7. Indirect immunofluorescence on human kidney cryostat sections with mAbs against 
(A) the large mouse EHS HSPG, which cross-react with human HSPG or against (B) the 
small human GBM HSPG (mAb JM-72). Note the differences, especially in the glomerular 
staining pattern, in (A) predominantly a mesangial staining and in (B) a strong GBM 
staining. Bar is 50 μη. 
proteolysis. However, the differences in distribution patterns obtained with antibodies against 
either type of BM HSPG (Table 2 and Fig.7) argue against this assumption and suggest that 
both types of BM HSPG are unrelated. Mohan and Spiro [55] also suggested this, since they 
found a limited cross-reactivity between GBM HSPG and EHS HSPG. Moreover, Rada et 
al [60] found different distribution patterns with anti-GBM HSPG than with anti-EHS HSPG 
antibodies within the GBM. Very recently Soroka and Farquhar [71] described a novel HSPG 
produced by hepatocytes, which is present in the extracellular matrix of liver sinusoids and 
in BMs. Whether this type of HSPG represents a third type of BM HSPG remains to be 
elucidated. However, antibodies against this liver BM HSPG do not cross-react with GBM 
HSPG and its staining pattern in kidney, liver, cardiac muscle, pancreas and small intestine 
is fully identical to those observed with antibodies against EHS HSPG. Further experiments 
are needed whether or not this novel liver BM HSPG is a member of the EHS HSPG family. 
At present, it is not clear whether the BM HSPG diversity is due to differential processing 
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of a common precursor, to differential splicing of mRNA, or to different genes encoding for 
HSPG. Conclusive data to solve this problem has to come from cloning of the genes coding 
for the various core proteins of BM HSPGs. Very recently, the complete sequence of a 
human BM HSPG has been published [34], showing a great homology with the large mouse 
EHS HSPG, called perlecan [57]. Future comparison of mAbs raised against peptides 
encoded by different domains of perlecan with our mAbs raised against GBM HSPG, will 
provide some more conclusive data about the relationship between both types of HSPG. 
The tissue distribution of anti-GBM HSPG core protein m Ab JM-72 is different from those 
observed with antibodies against core proteins of other proteoglycans, like anti-BM 
chondroitin sulfate proteoglycan [53], anti-cell surface-associated HSPG [26] and anti-
chondroitin/dermatan sulfate proteoglycan [85]. 
With the indirect IEM we also found that the binding of JM-72 in the human kidney was 
restricted to the various renal BMs, most prominently in the GBM. Interestingly, there was 
also some reaction product located between the mesangium and the capillary endothelium. 
Since all other parts of the mesangium were negative, this suggests an endothelial origin of 
HSPG at this special location. Within the GBM the staining was most prominent at the 
endothelial side of the GBM. Using the same procedure (indirect immunoperoxidase) Stow 
et al [73] also found the highest binding of anti-GBM HSPG antibodies in the lamina rara 
interna of the GBM. However, using different techniques (indirect immunogold on ultrathin 
frozen sections or a direct immunoperoxidase procedure after i.v. injection of the antibodies) 
they localized HSPG in both laminae rarae of the GBM [73], which was also found by Rada 
and Carlson [60] using the immunogold technique. Whether the staining pattern of JM-72 is 
the result of a preferential expression in the lamina rara interna of the recognized HSPG-
epitope, or of a lesser accessibility of these HSPG epitopes in the lamina rara externa is not 
known yet. An alternative explanation may be that the indirect immunoperoxidase technique 
that we used is not sensitive enough to localize precizely antigens within layers of the GBM, 
as suggested before [10]. 
HS distribution in human tissues 
In indirect IF with mAb JM-403 on human kidney sections, we could demonstrate a fine 
granular to linear binding to the GBM and most other but not all renal BMs. This pattern is 
somewhat different from the JM-72 staining in the kidney, especially with respect to the 
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tubular BM staining (see Fig.4B and D). In contrast to JM-403, mAb JM-72 stained all 
tubular BMs, which indicates that HSPG is present in all tubular BMs. Moreover, in a 
previous study [81] we were not able to demonstrate any differences between HSPG from 
tubular BM or GBM origin, suggesting that both molecules are identical. For that reason, 
we think that the heterogeneity of tubular BM staining as observed for mAb JM-403 can be 
explained by variations in the macro-molecular compositions of these BMs. HS-binding 
domains have been demonstrated on collagen type IV, laminin as well as fibronectin [75]. 
It is conceivable that binding of the HS-chains of HSPG to one or more of these BM 
components interferes with the binding of mAb JM-403 to its epitope. Such a selective 
epitope expression or accessibility within BMs is not unique, since it has been described 
previously for another anti-HS mAb [79] and for other BM components like laminin, S-
laminin, merosin, and the NCI segment of the different a chains of collagen type Г 
[1,13,30,32,42,47,65,86]. Our finding, showing a variable tubular BM staining with anti-HS 
mAb JM-403 confirms this concept of BM heterogeneity [11]. This heterogeneity in BMs is 
also thought to be responsible for the subtle differences in staining patterns between both 
mAbs observed in the tissues tested in this study (Table 1). 
The indirect IEM shows an irregular, segmental binding of mAb JM-403 to the inner side 
of the GBM. This staining pattern does not correspond to the distribution pattern of cationic 
probes, which detect regular arranged clusters of anionic sites in both laminae rarae of the 
GBM [37]. Although HS is a thought to be a major determinant of anionic sites in the GBM, 
other molecules are also involved [2,74], which may explain the difference. Another 
possibility could be that the JM-403 epitope is preferentially expressed in the lamina гага 
interna of the GBM, since also JM-72, recognizing a different epitope of the HSPG 
molecule, also localizes predominantly at the inner side of the GBM. Alternatively, the 
relative absence of staining at the outer side of the GBM by both mAbs, could be the result 
of the cold ischemia time and/or the absence of fluid flow across the GBM of the cadaveric 
kidney used in these experiments. 
The HS-epitope, recognized by mAb JM-403 is present in most BMs throughout the body. 
Since JM-403 bound to the GBM as well as to basal laminae of all muscle cell types and 
liver sinusoids, it recognizes an HS-epitope carried by both suggested types of BM HSPG. 
This idea is substantiated further by our finding that mAb JM-403 bound equally well in 
ELISA to purified GBM HSPG (the small HSPG), as to the large HSPG purified from the 
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mouse EHS tumor, whereas antibodies against the core protein of GBM HSPG (polyclonal 
and mAbs) bound to GBM HSPG but did not recognize the EHS HSPG (unpublished 
observations). 
Although mAbs against HS have been described [45,69], they were not used for tissue 
distribution studies of HS by immunohistochemical methods. Comparison of the distribution 
of anti-HS mAb JM-403 with the findings of others, using mAbs against chondroitin sulfate 
[9], dermatan sulfate [70] and keratan sulfate [88], confirmed the uniqueness and HS-
specificity of mAb JM-403. 
Antibodies recognizing different epitopes of the HSPG molecule can be of value in the 
elucidation of the function of HSPG in human BM assembly and function as well as its role 
in many pathological conditions, such as tumor invasion and several renal diseases like 
diabetic nephropathy [58,68], the congenital nephrotic syndrome [80,84] and adult polycystic 
kidney disease [5]. 
ACKNOWLEDGMENTS 
We would like to thank Henri Dijkman for assistance in the IEM experiments, Monique 
Link for assistance in the IF experiments, and Dr. John R. Couchman (University of 
Alabama, Birmingham, U.S.A.) for the generous gift of the anti-mouse perlecan mAb. 
91 
LITERATURE CITED 
1. Abrahamson DR, Irwin MH, St John PL, Perry EW, Accavitti MA, Heck LW, 
Couchman JR: Selective immunoreactivities of kidney basement membranes to monoclonal 
antibodies against laminin: localization of the end of the long arm and the short arms to 
discrete microdomains. J Cell Biol 109:3477, 1989 
2. Bertolatus JA, Hunsicker LG: Polycation binding to glomerular basement 
membrane; effect of biochemical modification. Lab Invest 56:170, 1987 
3. Brenner BM, Hostetter TH, Humes HD: Glomerular permselectivity; barrier 
function based on discrimination of molecular size and charge. Am J Physiol 234:F455, 1978 
4. Carey DJ, Evans DM, Stahl RC, Asundi VK, Conner KJ, Garbes P, 
Cizmeci-Smith G: Molecular cloning and characterization of N-Syndecan, a novel 
transmembrane heparan sulfate proteoglycan. J Cell Biol 117:191, 1992 
5. Carone FA, Makino H, Kanwar YS: Basement membrane antigens in renal 
polycystic disease. Am J Pathol 130:466, 1988 
6. Cotran RS, Rennke HG: Anionic sites and the mechanisms of proteinuria. New Engl 
J Med 309:1050, 1983 
7. Couchman JR, Ljubimov AV: Mammalian tissue distribution of a large heparan 
sulfate proteoglycan detected by monoclonal antibodies. Matrix 9:311, 1989 
8. Couchman JR: Heterogeneous distribution of a basement membrane heparan sulfate 
proteoglycan in rat tissues. J Cell Biol 105:1901, 1987 
9. Couchman JR, Caterson B, Christner JE, Baker JR: Mapping by monoclonal 
antibody detection of glycosaminoglycans in connective tissues. Nature 307:650, 1984 
10. Courtoy PJ, Hunt Picton D, Farquhar MG: Resolution and limitations of the 
immunoperoxidase procedure in the localization of extracellular matrix antigens. J Histochem 
Cytochem 31:945, 1983 
11. Damjanov I: Heterogeneity of basement membranes in normal and pathologically 
altered tissues. Virchows Arch A (Anat Pathol) 416:185, 1990 
12. David G, Lories V, Decock B, Marynen P, Cassiman J-J, van den Berghe H: 
Molecular cloning of a phosphatidylinositol-anchored membrane heparan sulfate proteoglycan 
from human lung fibroblasts. J Cell Biol 111:3165, 1990 
92 
13. Desjardins M, Gros F, Wieslander J, Gubler M-C, Bendayan M: Heterogeneous 
distribution of monomeric elements from the globular domain (NCI) of type IV collagen in 
renal basement membranes as revealed by high resolution quantitative immunocytochemistry. 
Lab Invest 63:637, 1990 
14. Dodge GR, Kovalszky I, Chu M-L, Hassell JR, McBride OW, Fang Yi H, lozzo 
RV: Heparan sulfate proteoglycan of human colon: partial molecular cloning, cellular 
expression, and mapping of the gene (HSPG2) to the short arm of human chromosome 1. 
Genomics 10:673, 1991 
15. Edge ASB, Spiro RG: Selective deglycosylation of the heparan sulfate proteoglycan 
of bovine glomerular basement membrane and identification of the core protein. J Biol Chem 
262:6ê93, 1987 
16. Eldridge CF, Sanes JR, Chiù AY, Bunge RP, Cornbrooks CJ: Basal 
lamina-associated heparan sulphate proteoglycan in the rat PNS: characterization and 
localization using monoclonal antibodies. J Neurocytol 15:37, 1986 
17. Faaber P, Щке GPM, van de Putte LBA, Capel PJA, Berden JHM: 
Crossreactivity of human and murine anti-DNA antibodies with heparan sulfate: the major 
glycosaminoglycan in the glomerular basement membrane. J Clin Invest 77:1824, 1986 
18. Farquhar MG. Lemkin MC. Stow JL: Role of proteoglycans in glomerular function 
and pathology. In Robinson RR, ed. Nephrology, Vol.1. New York, Springer-Verlag New 
York Inc., 1985, 580 
19. Fillit HM, Blake M, MacDonald C, McCarty M: Immunogenicity of 
liposome-bound hyaluronate in mice. At least two different antigenic sites on hyaluronate are 
identified by mouse monoclonal antibodies. J Exp Med 168:971, 1988 
20. Fransson L-Â: Structure and function of cell-associated proteoglycans. TIBS 12:406, 
1987 
21. Gallagher JT, Lyon M, Steward WP: Structure and function of heparan sulphate 
proteoglycans. Biochem J 236:313, 1986 
22. Groggel GC, Stevenson J, Hovingh P, Linker A, Border WA: Changes in heparan 
sulfate correlate with increased glomerular permeability. Kidney Int 33:517, 1988 
23. Hascall VC. Kimura JH: Proteoglycans: isolation and characterization. In 
Cunningham LW, Frederiben DW, eds. Methods in Enzymology. Structural and contractile 
Proteins. Part A: Extracellular Matrix. New York, Academic Press, 1982, 769 
93 
24. Havenith MG, Cleutjens JPM, Beek C, van der Linden E: Human specific 
anti-type IV collagen monoclonal antibodies, characterization and immunohistochemical 
application. Histochem 87:123, 1987 
25. Hawkes R, Niday E, Gordon J: A dot-immunobinding assay for monoclonal and 
other antibodies. Anal Biochem 119:142, 1982 
26. Hayashi K, Hayashi M, Jalkanen M, Firestone JH, Trelstad R, Bernfield M: 
Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light 
and electron microscopic study. J Histochem Cytochem 35:1079, 1987 
27. Heinegârd D. Paulsson M: Structure and metabolism of proteoglycans. In Piez AP, 
Reddi AH, eds. Extracellular matrix biochemistry. New York, Amsterdam, Oxford, Elsevier, 
1984, 277 
28. Heremans A, Schueren van der В, Cock de В, Paulsson M, Cassiman J-J, Berghe 
van den H, David G: Matrix-associated heparan sulfate proteoglycan: core protein-specific 
monoclonal antibodies decorate the pericellular matrix of connective tissue cells and the 
stromal side of basement membranes. J Cell Biol 109:3199, 1989 
29. Höök M: Cell-surface glycosaminoglycans. Ann Rev Biochem 53:847, 1984 
30. Horikoshi S, Koide H, Shirai T: Monoclonal antibodies against laminin A chain and 
В chain in the human and mouse kidneys. Lab Invest 58:532, 1988 
31. lozzo RV: Cell surface heparan sulfate proteoglycan and the neoplastic phenotype. 
J Cell Biochem 37:61, 1988 
32. Jaffe R, Bender B, Santamaria M, Chung Α,Ε.: Segmental staining of the murine 
nephron by monoclonal antibodies directed against the GP-2 subunit of laminin. Lab Invest 
51:88, 1984 
33. Jalkanen M, Rapraeger A, Bernfield M: Mouse mammary epithelial cells produce 
basement membrane and cell surface heparan sulfate proteoglycans containing distinct core 
proteins. J Cell Biol 106:953, 1988 
34. Kallunki P, Tryggvason K: Human basement membrane heparan sulfate proteoglycan 
core protein: A 467 kD protein containing multiple domains resembling elements of the low 
density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth 
factor. J Cell Biol 116:559, 1992 
94 
35. Kallunki Ρ, Eddy RL, Byers MG, Restila M, Shows ТВ, Tryggvason К: Cloning 
of human heparan sulfate proteoglycan core protein, assignment of the gene (HSPG2) to 
lp36. l-p35 and identification of a BamHI restriction fragment length polymorphism. 
Genomics 11:389, 1991 
36. Kanwar YS: Biology of disease, biophysiology of glomerular filtration and 
proteinuria. Lab Invest 51:7, 1984 
37. Kanwar YS, Farquhar MG: Presence of heparan sulfate in the glomerular basement 
membrane. Proc Natl Acad Sci USA 76:1303-1307, 1979 
38. Kato M, Koike Y, Suzuki S, Rimata К: Basement membrane proteoglycan in 
various tissues: characterization using monoclonal antibodies to the Engelbreth-Holm-Swarm 
mouse tumor low density heparan sulfate proteoglycan. J Cell Biol 106:2203, 1988 
39. Kemeny Б, Fillit HM, Damle S, Mahabir R, Refalides NA, Gregory JD, 
Antonovych T, Sabnis S, Zabriskie JB: Monoclonal antibodies to heparan sulfate 
proteoglycan: development and application to the study of normal tissue and pathologic 
human kidney biopsies. Connect Tiss Res 18:9, 1988 
40. Kiefer MC, Stephans JC, Crawford К, Okino К, Barr Ρ: Ligand-affinity cloning 
and structure of a cell surface heparan sulfate proteoglycan that binds basic fibroblast growth 
factor. Proc Natl Acad Sci USA 87:6985, 1990 
41. Klein DJ, Brown DM, Oegema TR, Brenchley PE, Anderson JC, Dickinson MAJ, 
Horigan EA, Hassel! JR: Glomerular basement proteoglycans are derived from a large 
precursor. J Cell Biol 106:963, 1988 
42. Kleppel MM, Santi PA, Douglas Cameron J, Wieslander J, Michael AF: Human 
tissue distribution of novel basement membrane collagen. Am J Physiol 134:813, 1989 
43. Köhler G, Milstein С: Continuous cultures of fused cells secreting antibody of 
predefined specificity. Nature 256:495, 1975 
44. Kojima T, Shworak NW, Rosenberg RD: Molecular cloning and expression of two 
distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell 
Une. J Biol Chem 267:4870, 1992 
45. Kure S, Yoshie O: A syngeneic monoclonal antibody to murine meth-A sarcoma 
(HepSS-1) recognizes heparan sulfate glycosaminoglycan (HS-GAG): cell density and 
transformation dependant alteration in cell surface HS-GAG defined by Hep-SSI. ƒ Immunol 
137:3900, 1986 
95 
46. Leppä S, Mali M, Miettinen HM, Jalkanen M: Syndecan expression regulates cell 
morphology and growth of mouse mammary epithelial tumor cells. Proc Natl Acad Sci USA 
89:932, 1992 
47. Leu F-J, Engvall E, Damjanov I: Heterogeneity of basement membranes of 
genitourinary tract revealed by sequential immunofluorescence staining with monoclonal 
antibodies to laminin. J Histochem Cyiochem 34:483, 1986 
48. Mahan JD, Sisson-Ross S, Vernier RL: Glomerular basement membrane anionic 
charge site changes in aminonucleoside nephrosis. Am J Pathol 125:393, 1986 
49. Makino H, Gibbons JT, Kumudavalli Reddy M, Kanwar YS: Nephritogenicity of 
antibodies to proteoglycans of the glomerular basement membrane. J Clin Invest 77:142, 
1986 
50. Mali M, Jaakkola P, Arvilommi Α-M, Jalkanen M: Sequence of human syndecan 
indicates a novel gene family of integral membrane proteoglycans. J Biol Chem 265:6884, 
1990 
51. Mancini О, Carbonara АО, Heremans JR: Immunochemical quantitation of 
antigens by single radial immunodiffusion. Immunochem 2:235, 1965 
52. Marynen P, Zhang J, Cassiman J-J, van den Berghe H, David G: Partial primary 
structure of the 48- and 90-kilodalton core proteins of cell surface-associated heparan sulfate 
proteoglycans of lung fibroblasts. Prediction of an integral membrane domain and evidence 
for multiple distinct core proteins at the cell surface of human lung fibroblasts. J Biol Chem 
264:7017, 1989 
53. McCarthy KJ, Couchman JR: Basement membrane chondroitin sulfate 
proteoglycans: Localization in adult rat tissues. J Histochem Cytochem 38:1479, 1990 
54. Miettinen A, Stow JL, Mentone S, Farquhar MG: Antibodies to basement 
membrane heparan sulfate proteoglycans bind to the laminae rarae of the glomerular 
basement membrane (GBM) and induce subepithelial GBM thickening. J Exp Med 163:1064, 
1986 
55. Mohan PS, Spiro RG: Characterization of heparan sulfate proteoglycan from calf 
lens capsule and proteoglycans synthesized by cultured lens epithelial cells. J Biol Chem 
266:8567, 1991 
96 
56. Mynderse LA, Hassell JR, Kleinman HK, Martin GR, Martinez-Hernandez A: 
Loss of heparan sulfate proteoglycan from glomerular basement membrane of nephrotic rats. 
Lab Invest 48:292, 1983 
57. Noonan DM, Fülle A, Valente Ρ, Cai S, Horigan E, Sasaki M, Yamada Y, 
Hassell JR: The complete sequence of perlecan, a basement membrane heparan sulfate 
proteoglycan, reveals extensive similarity with laminin A chain, low density 
lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem 266:22939, 1991 
58. Parthasarathy N, Spiro RG: Effect of diabetes on the glycosaminoglycan component 
of the human glomerular basement membrane. Diabetes 31:738, 1982 
59. Pierce A, Lyon M, Hampson IN, Cowling GJ, Gallagher JT: Molecular cloning 
of the major cell surface heperan sulfate proteoglycan from rat liver. J Biol Chem 267:3894, 
1992 
60. Rada JA, Carlson EC: Electron microscopic histochemical and immunochemical 
analysis of heparan sulfate proteoglycan distribution in renal glomerular basement 
membranes. Histol Histopath 6:149, 1991 
61. Rennard SI, Berg R, Martin GR, Foidart JM, Gehron Robey P: Enzyme-linked 
immunoassay (ELISA) for connective tissue components. Anal Biochem 104:205, 1980 
62. Roberts R, Gallagher J, Spooncer E, Allen TD, Bloomficld F, Dexter TM: 
Heparan sulphate bound growth factors: a mechanism for stromal cell mediated 
haemopoiesis. Nature 332:376, 1988 
63. Rosenzweig LJ, Kanwar YS: Removal of sulfated (heparan sulfate) or nonsulfated 
(hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular 
basement membrane to 125-I-bovine serum albumine. Lab Invest 47:177, 1982 
64. Ruoslahti E: Structure and biology of proteoglycans. Ann Rev Cell Biol 4:229,1988 
65. Sanes JR, Engvall E, Butkowski R, Hunter DD: Molecular heterogeneity of basal 
laminae: Isoforms of laminin and collagen IV at the neuromuscular junction and elsewhere. 
J Cell Biol 111:1685, 1990 
66. Saunders S, Jalkanen M, O'Farell S, Bernfield M: Molecular cloning of syndecan, 
an integral membrane proteoglycan. J Cell Biol 108:1547, 1989 
67. Schleicher ED, Wagner Ε-M, Olgemöller В, Nerlich AG, Gerbitz KD: 
Characterization and localization of basement membrane-associated heparan sulfate 
proteoglycan in human tissues. Lab Invest 61:323, 1989 
97 
68. Shimomura H, Spiro RG: Studies on macromolecular components of human 
glomerular basement membrane and alterations in diabetes; decreased levels of heparan 
sulfate proteoglycan and laminin. Diabetes 36:374, 1987 
69. Snow AD, Mar H, Nochlin D, Sekiguchi RT, Rimata К, Koike Y, Wight TN: 
Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing 
lesions of Alzheimer's disease and Down's syndrome. Am J Pathol 137:1253, 1990 
70. Sobue M, Takeuchi J, Fukatsu T, Nagasaka T, Nakashima N, Ogura T, Katoh 
T, Yoshida K: Immunohistochemical techniques for detection of dermatan sulfate 
proteoglycan in tissue sections. Stain Technol 64:43, 1989 
71. Soroka CJ, Farquhar MG: Characterization of a novel heparan sulfate proteoglycan 
found in the extracellular matrix of liver sinusoids and basement membranes. J Cell Biol 
113:1231, 1991 
72. Stow JL, Farquhar MG: Distinctive populations of basement membrane and cell 
membrane heparan sulfate proteoglycans are produced by cultured cell lines. J Cell Biol 
105:529, 1987 
73. Stow JL, Sawada II, Farquhar MG: Basement membrane heparan sulfate 
proteoglycans are concentrated in the laminae rarae and in the podocytes of the rat renal 
glomerulus. Proc Natl Acad Sci USA 82:3296, 1985 
74. Templeton DM: Retention of glomerular basement membrane-proteoglycans 
accompanying loss of anionic site staining in experimental diabetes. Lab Invest 61:202,1989 
75. Timpl R, Dziadek M: Structure, development, and molecular pathology of basement 
membranes. Int Rev Exp Pathol 29:1, 1986 
76. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from 
Polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl 
Acad Sci USA 76:4350, 1979 
77. Trautman MS, Kimelman J, Bernfield M: Developmental expression of syndecan, 
an integral membrane proteoglycan, correlates with cell differentiation. Development 
111:213, 1991 
78. Van den Born J, van den Heuvel LPWJ, Bakker MAH, Veerkamp JH, Assmann 
KJM, Berden JHM: A monoclonal antibody against GBM heparan sulfate induces an acute 
selective proteinuria in rats. Kidney Int 41:115, 1992 
98 
79. Van den Born J, van den Heuvel LPWJ, Bakker MAH, Veerkamp JH, Assmann 
KJM, Berden JHM: Production and characterization of a monoclonal antibody against 
human glomerular heparan sulfate. Lab Invest 65:287, 1991 
80. Van den Heuvel LPWJ, van den Born J, Jalanko H, Schröder CH, Veerkamp 
JH, Assmann KJM, Berden JHM, Holmberg С, Rapóla J, Monnens LAH: The 
glycosaminoglycan content of renal basement membranes in the congenital nephrotic 
syndrome of the Finnish type. Pediatr Nephrol 6:10, 1992 
81. Van den Heuvel LPWJ, van den Born J, Veerkamp JH, van de Velden TJAM, 
Schenkels L, Monnens LAH, Schroder CH, Berden JHM: Heparan sulfate proteoglycan 
from human tubular basement membrane. Comparison with this component from the 
glomerular basement membrane. Biochim Biophys Acta 1025:67, 1990 
82. Van den Heuvel LPWJ, van den Born J, van de Velden TJAM, Veerkamp JH, 
Monnens LAH, Schroder CH, Berden JHM: Isolation and partial characterization of 
heparan sulfate proteoglycan from the human glomerular basement membrane. Biochem J 
264:457, 1989 
83. Van Kuppevelt THMSM, Janssen HMJ, van Beuningen HM, Cheung K-S, 
Schijen MMA, Kuyper CMA, Veerkamp JH: Isolation and characterization of a collagen 
fibril-associated dermatan sulphate proteoglycan from bovine lung. Biochim Biophys Acta 
926:296, 1987 
84. Vernier RL, Klein DJ, Sisson SP, Mahan JD, Oegema TR, Brown DM: Heparan 
sulfate-rich anionic sites in the human glomerular basement membrane; decreased 
concentration in congenital nephrotic syndrome. New EnglJ Med 309:1001, 1983 
85. Voss В, Glossi J, Cully Ζ, Kresse Η: Immunocytochemical investigation on the 
distribution of small chondroitin sulfate-dermatan sulfate proteoglycan in the human. J 
Histochem Cytochem 34:1013, 1986 
86. Wan Y-J, Wu T-C, Chung AE, Damjanov I: Monoclonal antibodies to laminin 
reveal the heterogeneity of basement membranes in the developing and adult mouse tissues. 
J Cell Biol 98:971, 1984 
87. Wlntle RF, Kisilevsky R, Noonan D, Duncan AMV: In situ hybridization to human 
chromosome 1 of a cDNA probe for the gene encoding the basement membrane heparan 
sulfate proteoglycan (HSPG). Cytogenet Cell Genet 54:60, 1990 
99 
88. Zanetti M, Ratcliffc A, Watt FM: Two subpopulations of different chondrocytes 
identified with a monoclonal antibody to keratan sulfate. J Cell Biol 101:53, 1985 
100 
CHAPTER 5 
EVALUATION OF THE DISTRIBUTION OF GBM 
HEPARAN SULFATE PROTEOGLYCAN 
CORE PROTEIN AND SIDE CHAINS 
IN HUMAN GLOMERULAR DISEASES 
BY MONOCLONAL ANTIBODIES 
J. van den Bom, L.P.W.J. van den Heuvel, M.A.H. Bakker, 
J.H. Veerkamp, K.J.M. Assmann, J.J. Weening, and J.H.M. Berden 
Kidney Int 1993; 43: in press 
101 

ABSTRACT 
Evaluation of the distribution of heparan sulfate proteoglycan core protein and 
side chains in human glomerular diseases by monoclonal antibodies. Using monoclo-
nal antibodies (mAbs) recognizing either the core protein or the heparan sulfate (HS) side 
chain of human GBM heparan sulfate proteoglycan (HSPG), we investigated its glomeru-
lar distribution on cryostat sections of human kidney tissues. The study involved 95 
biopsies comprising twelve different glomerulopathies. Four normal kidney specimens 
served as controls. A homogenous to linear staining of the GBM was observed in the 
normal kidney with anti-HSPG-core m Ab (JM-72) and anti-HS m Ab (JM-403). In human 
glomerulopathies the major alteration was a segmental or total absence of GBM staining 
with anti-HS m Ab JM-403, most pronounced in lupus nephritis, membranous glomerulo-
nephritis (GN), minimal change disease and diabetic nephropathy, whereas the HSPG-
core staining by m Ab JM-72 was unaltered. In addition we found HSPG-core protein in 
the mesangial matrix when this was increased in membranoproliferative GN Type I, 
Schönlein-Henoch GN, IgA nephropathy, lupus nephritis, diabetic nephropathy and in 
focal glomerulosclerosis. Also staining with the anti-HS mAb JM-403 became positive 
within the mesangium, although to a lesser extent. Furthermore, amyloid deposits in AL 
and AA amyloidosis clearly stained with anti-HSPG-core mAb JM-72, and to a lesser 
degree with anti-HS mAb JM-403. Finally, in membranous GN (stage II and III), the 
GBM staining with anti-HSPG-core mAb JM-72 became irregular or granular, probably 
related to the formation of spikes. In conclusion, major alterations were observed in the 
glomerular distribution of HS and HSPG-core in various human glomerulopathies. The 
mAbs can be useful to delineate further the significance of HSPG and HS for glomerular 
diseases. 
INTRODUCTION 
The biochemical and biophysical properties of the glomerular capillary wall (GCW), 
which functions both as a size and a charge selective filter are, in addition to hemodyna-
mic and oncotic factors, important determinants of glomerular ultrafiltration [1]. The 
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physicochemical basis for the charge-selective filtration is thought to be an electrostatic 
repulsion of the negative charge of albumin and other plasma proteins by the fixed 
negative charge of the GCW [2,3]. Initially it was thought that sialoglycoproteins, located 
on the cell membranes of glomerular endothelial and epithelial cells, were mainly 
responsible for the negative charge of the GCW. Later on it became clear that also the 
anionic glycosaminoglycan heparan sulfate (HS), which is the side chain of heparan 
sulfate proteoglycan (HSPG), present in the glomerular basement membrane (GBM), was 
a major determinant of the charge-dependent permeability of the GCW [4-7]. Enzymatic 
digestion of HS in the GCW causes an increased passage of native ferritin and albumin 
into the urinary space [4,5]. Furthermore, intrarenal or intravenous injection of 'cationic 
molecules leads to an increased GBM permeability due to the neutralization of primarily 
HS-associated anionic sites of the GCW [8-12]. Recently, we could demonstrate the 
induction of an acute selective proteinuria after intravenous injection of a monoclonal 
antibody (mAb) against GBM HS [13]. 
In many types of glomerular disease, major alterations occur in the permeability of the 
GBM, resulting in proteinuria. For that reason several investigators have tried to relate 
the status of GBM HSPG to the onset or existence of proteinuria in many types of 
glomerulopathy [14]. Firstly, using cationic probes, both in humans and in experimental 
animals, a reduction of GBM anionic sites was found in systemic lupus erythematosus 
[15-17], aminonucleoside nephropathy [18], minimal change disease [19], membranous 
glomerulonephritis (GN) [20-24], congenital nephrotic syndrome [25], IgA nephropathy 
[26,27] and diabetic nephropathy [28-30]. Secondly, with biochemical and immunoche-
mical methods HSPG alterations were observed in membranous GN [31], polycystic 
kidney disease [32] and diabetic nephropathy [33-37]. However, in many of these studies 
the methods used (cationic probes, "S-sulfate incorporation) are not specific for HS and a 
number of controversies still exists, that hamper a clear interpretation [38-44]. Finally, 
some reports have described changes in the immunohistochemical distribution of HSPG-
core protein in several glomerulopathies [45-51]. However, an immunohistochemical 
analysis of the distribution of glomerular HS has not been performed so far. 
Recently, we developed mAbs against the core protein of human GBM HSPG [52] and 
against the HS-side chain of GBM HSPG [13]. In this paper, we describe the glomerular 
distribution of HSPG and HS in twelve different types of human glomerular diseases 
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using these mAbs in indirect immunofluorescence (IF) on cryostat sections of kidney 
biopsies. One major alteration that we observed, was a strong decrease or even absence 
of GBM staining with anti-HS mAb JM-403 in several glomerular diseases, whereas the 
HSPG-core staining by mAb JM-72 was unaltered. These results indicate an impaired HS 
expression or accessibility in several types of human glomerular diseases. 
MATERIALS AND METHODS 
Kidnev tissue specimens. 
This study includes 99 renal tissue specimens. Four of them were control tissues 
obtained during - operation or taken from cadaveric donor kidneys, not suitable for 
transplantation. The remaining 95 renal biopsies originates from the Depts. of Pathology 
of the University Hospitals of Nijmegen and Groningen and were either obtained by 
percutaneous renal biopsy or at autopsy from patients suffering from various renal 
diseases. The tissue specimens were snap-frozen in liquid nitrogen and stored at -70oC. 
Classification of glomerular disease was established using routine light, immunoflu-
orescence (IF) and if possible electron microscopy. 
Antibodies. 
The two mAbs recognizing different epitopes of human GBM HSPG used in this study 
have been described previously [13,52]. One of them (JM-72) is directed against the core 
protein, the other (mAb JM-403) recognizes the HS-side chain of GBM HSPG. The major 
characteristics of these mAbs are summarized in Table I. Immunohistochemical detection 
of AA amyloidosis was done with mAb REU 86.2 against AA amyloid (Immuno Quality 
Products, Groningen, The Netherlands). 
Inhibition ELISA. 
Inhibition ELISA's were performed as described previously [13]. Briefly, a constant 
amount of mAb (JM-72 or JM-403) was added to an increasing amount of the following 
inhibitors: HS (from bovine kidney; Seikagaku, Tokyo, Japan), human GBM HSPG and 
its core protein, isolated as described previously [53]. These mixtures were tested in 
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ELISA's with GBM HSPG (for JM-72) or HS (for JM-403) as coated antigens. Results 
are expressed as % inhibition of the ELISA signal calculated as [1-(A450 + inhibi­
tor/A450 -inhibitor)] χ 100%. 
Indirect IF. 
Initially, kidney biopsies were analysed with JM-72 alone. Two ¿tm cryostat sections 
were fixed in acetone for 5 min. Thereafter, 100 μΐ of JM-72 ascites, diluted 1:200 in 
PBS containing 1% BS A and 0.05% sodium azide (IF buffer) were applied to the sections 
for 30 min at room temperature. Incubations of the sections with non-relevant mAbs with 
an IgG] isotype served as negative controls. After washing with PBS, binding of JM-72 
(anti GBM HSPG-core) was visualized with Ftab^-fragments of FITC-labeled sheep 
anti-mouse IgG, heavy and light chains (Cappel-Organon Teknika, Turnhout, Belgium), 
100 μΐ diluted 1:500 in IF buffer. After incubation for 30 min in the dark at room 
temperature, the sections were washed with PBS and embedded in Aquamount. Later on, 
when the anti-HS mAb JM-403 became available, renal biopsies were double-stained with 
anti-HS mAb JM-403 and mAb JM-72 (anti-HSPG-core). Sequential incubations were 
done as follows: (a) mAb JM-403 (1:200 dilution of ascites fluid in IF buffer); (b) FITC-
labeled goat anti-mouse IgM, Fc-specific (Nordic, Tilburg, The Netherlands, 1:100 in IF 
buffer); (c) mAb JM-72 (1:200 dilution of ascites fluid in IF buffer containing 5% normal 
human serum); (d) TRITC-labeled goat anti-mouse IgG, (Nordic, 1:25 in IF buffer 
containing 5% normal human serum and 10 /tg/ml mouse IgM to prevent any cross-
reactivity with mAb JM-403). The double staining experiments included the following 
controls: (a) omitting mAb JM-403 or JM-72 or both; (b) incubating mAb JM-403 or JM-
72 with the conjugate used for the detection of the other mAb in the double staining. 
Sections were examined on a Leitz ortholux microscope equipped with a Ploemopak epi-
illuminator. 
RESULTS 
Characteristics of the anti-HSPG mAbs. 
The two mAbs used in this study recognize different epitopes of GBM HSPG (Table I 
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and Fig.l). The mAb JM-72 is directed against an epitope on the core protein of human 
GBM HSPG (Fig.lA), whereas mAb JM-403 recognizes an epitope on the HS-side chain 
of HSPG (Fig. IB). 
Table I. Characteristics of anti-human GBM HSPG-core mAb JM-72 
and anti-HS mAb JM-403. 
Characteristic 
Isotype 
Immunogen 
Species specificity 
Binding to" 
human GBM HSPG 
human GBM HSPG-core 
HS-side chain 
Staining of the GBMb 
Staining sensitive for 
heparitinase0 
anti-HSPG-core 
mAb JM-72 
IgGl 
human GBM 
HSPG 
human 
yes 
yes 
no 
yes 
no 
anti-HS 
mAb JM-403 
IgM 
rat glomerular 
HSPG 
rat, mouse, human 
yes 
no 
yes 
yes 
yes 
* Binding was studied in ELISA, inhibition ELISA and Western blot 
ь
 In indirect immunofluorescence and immuno-electron microscopy 
c
 Pretreatment of cryostat kidney sections with heparitinase and 
subsequent indirect immunofluorescence 
Although mAb JM-403 was obtained after immunization with rat glomerular HSPG, 
this mAb cross-reacts with the HS-side chain of human GBM HSPG in ELISA and 
indirect IF on human kidney sections. The glomerular staining patterns of these mAbs in 
normal human kidney are shown by a double staining technique in the indirect IF in 
Fig.2. A strong linear staining of the GBM is observed with mAb JM-72 (Fig.2A). A 
homogeneous, fine granular staining was seen along the GBM with anti-HS mAb JM-403 
(Fig.2B). In normal kidney biopsies of young individuals a very faint staining of the 
mesangium was observed with both mAbs, but this staining increased with advanced age 
if paralleled by an expansion of the mesangium. 
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% inhibition % inhibition 
100 
Ί I I I I I 
10 100 
concentration inhibitor (ug/ml) 
1 0 0 -
1 10 100 
concentration inhibitor (ng/ml) 
Fig. 1. Antigen specificity of mAb JM-72 (A) and mAb JM-403 (B), demonstrated in the 
inhibition ELISA . Human GBM HSPG was used as coated antigen in (A), HS in (В). A 
dose-dependent inhibition of mAb JM-72 (A) was found with intact GBM HSPG (-A-) and 
its core protein (-*-), but not by HS (-Ώ-). MAb JM-403 (B) was inhibited in a dose-
dependent manner by intact GBM HSPG (-Δ-) and HS (-Ώ-), but not by the core protein 
of GBM HSPG (-*-). 
Alterations in HSPG distribution in glomerular diseases. 
The various types of glomerulopathies and the number of biopsies that were analyzed 
for their HSPG distribution are listed in Table II. Less biopsies were available for the 
evaluation of JM-403 staining (n=74) compared to mAb JM-72 (n=95), since JM-403 
was produced and characterized later, and for some biopsies, tissue was not available 
anymore. The alterations in glomerular HSPG immunolocalization can be categorized in 
four major items: (a) the most important finding was a segmental or total absence of 
GBM staining with anti-HS mAb JM-403 in various glomerulopathies; in addition (b) the 
presence of HSPG in expanded mesangial matrix in several glomerulopathies; (c) the 
presence of HSPG in glomerular amyloid deposits; and (d) an irregular GBM staining in 
stage II and III membranous GN with anti-HSPG-core mAb JM-72. 
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Fig. 2. HSPG localization in the normal human kidney. Indirect IF on normal human 
kidney cryostat sections with anti-HSPG-core mAb JM-72 (A) and anti-HS mAb JM-403 
(B) in a double staining technique. In this control kidney there is also positive staining of 
the mesangium, due to age-related expansion of the mesangial matrix. Insert in (B) 
demonstrates the GBM staining of mAb JM-403 at a higher magnification (A and Β χ 
260, insert χ 450). 
Decreased anti-HS mAb JM-403 staining. The majority of biopsies investigated in 
this study with anti-HS mAb JM-403 showed a segmental or total absence of GBM 
staining (Table II). This phenomenon was most pronounced in SLE nephritis, membra­
nous GN, minimal change disease and diabetic nephropathy and was not observed in IgA 
nephropathy and Alport's syndrome. In all other glomerulopathies listed in Table II, a 
lesser degree of reduced GBM staining with JM-403 was observed. Although the decrease 
or absence of anti-HS staining may be related to the nature and progression of the 
disease, we were not able to correlate the GBM staining pattern with anti-HS mAb JM-
403 to the severity of the disease. No differences were observed between patients with 
focal (n=3) or diffuse (n=3) crescentic GN, patients with WHO class III (n=2), class IV 
(n=8) or class V (n=3) lupus nephritis, patients with stage II (n=4) or stage III (n = l) 
membranous GN, and patients with nodular (n=4) or diffuse (n=6) diabetic nephropathy. 
We also did not observe an association between the GBM staining for HS and the degree 
of proteinuria. The most striking observation in this respect is that in patients with 
minimal lesions glomerulopathy who were in remission (n=4) the decrease in HS staining 
was identical to those who were still nephrotic (n=2). In spite of the clear decrease in 
JM-403 staining, all biopsies showed a normal staining of the GBM with the anti-HSPG-
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Table II. Types of glomerulopathies studied with anti-HSPG-core mAb 
JM-72 and anti-HS mAb JM-403 together with the GBM staining pattern 
of mAb JM-403. 
Glomerulopathy 
Proliferative: 
Membranoproliferative GN0 
Type! 
Crescentic GN 
Diffuse endocapillary GN 
(post-infectious) 
Schönlein-Henoch purpura 
IgA nephropathy 
JM-72'I> 
6 
7 
2 
4 
4 
normal 
2 
2 
1 
3 
JM-403'C 
segmental 
4 
1 
1 
absent 
1 
Lupus nephritis 
(WHO class III, IV and V) 13 1 12 
Non-proliferative: 
Minimal change disease 7 3 3 
Focal glomerulosclerosis 8 1 3 1 
Membranous GN 
(Stage II and III) 6 I 4 
Other: 
Diabetic nephropathy 
(nodular and diffuse) 
Alport's syndrome 
Amyloidosis 
AL 
AA 
13 
2 
7 
16 
2 
1 
1 
3 
5 
4 
10 
3 
1 
• The numbers of biopsies examined with each mAb are given 
ь
 For JM-72 the GBM staining was normal in all biopies studied 
c
 For anti-HS mAb JM-403 biopsies were categorized according to their GBM 
staining pattern 
d
 GN=glomerulonephritis 
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core mAb JM-72 as can be seen in the double staining shown in Fig.3 for respectively 
lupus nephritis, minimal change disease, and diabetic nephropathy. 
Fig. 3. HSPG localization in some glomerulopathies. Double staining of anti-HSPG-core 
mAb JM-72 (A,C and E) and anti-HS mAb JM-403 (B,D and F) in indirect IF on kidney 
sections of lupus nephritis (A and B), minimal change disease (C and D) and diabetic 
nephropathy (E and F). Note the strongly decreased anti-HS staining, accompanied with 
an unaltered anti-HSPG-core staining. Arrows in A and asteriks in E indicate the staining 
of the expanded mesangium with anti-HSPG-core mAb JM-72 (A and Β χ 360; С and D χ 
440; Ε and F χ 220). 
I l l 
HSPG in expanded mesangial matrix. The HSPG-core protein could be demonstrated 
in mesangial areas of kidney specimens showing expansion of mesangial matrix (Table 
III). 
Table III. Staining of the mesangial matrix with anti-HSPG core 
mAb JM-72 and anti-HS mAb JM-403. 
Glomerulopathy 
Membranoproliferative GN 
Type I 
Schönlein-Henoch GN 
IgA nephropathy 
Lupus nephritis 
Focal glomerulosclerosis 
Diabetic nephropathy 
anti-HSPG-core 
mAb JM-72 
5/6' 
1/4 
2/4 
9/13 
4/8 
11/13 
anti-HS 
mAb JM-403 
2/3 
0/4 
1/3 
0/13 
1/5 
2/8 
'Number of positive specimens / specimens studied are given. 
This presence of HSPG in the mesangium was seen in membranoproliferative GN type 
I (Fig.4A), Schönlein-Henoch GN, IgA nephropathy, lupus nephritis (Fig.3A), diabetic 
nephropathy, mostly in the noduli (Fig.3E) and in focal glomerulosclerosis (Fig.4B). 
However, not in all biopsies of the forementioned glomerular diseases an increase in 
mesangial matrix was observed and in these biopsies HSPG could not be demonstrated in 
the mesangium (Table III). The mesangial HS staining with mAb JM-403 was less clear 
than for the HSPG-core (Table III). The intensity of the mesangial staining paralleled the 
intensity of the HS-staining in the GBM; if the GBM staining was decreased or negative, 
the mesangium showed also a decreased or negative staining despite the expansion, as 
illustrated for lupus nephritis in Fig.3B and the diabetic nephropathy in Fig.3F. However, 
in biopsies showing expansion of mesangial matrix in combination with an unaffected HS-
staining in the GBM, HS could be demonstrated in the mesangial areas. This relation 
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between GBM and mesangial HS staining is illustrated in Fig.4C in a biopsy with focal 
glomerulosclerosis, although in the majority of cases with focal glomerulosclerosis (see 
Table II) the HS staining of the GBM and the mesangium was reduced. 
Fig. 4. Presence of HSPG in expanded mesangial matrix. Indirect IF with anti-HSPG-
core mAb JM-72 (A and B) or anti-HS mAb JM-403 (C) demonstrates the presence of 
HSPG in mesangial matrix in membranoproliferative GN Type I (A), and focal glomeru­
losclerosis (B and С). В and С were carried out by a double staining, arrows indicate the 
increased mesangial matrix (A χ 310; В and С χ 260). 
HSPG in glomerular amyloid. A brilliant staining was observed with anti-HSPG-core 
mAb JM-72 of the amyloid deposits, localized within the mesangial areas and sometimes 
also along the capillary wall in AL (Fig.5A) as well as in AA (Fig.53) amyloidosis 
(Table IV). These forms of amyloidosis were distinguished on clinical features and/or the 
use of an anti-A A amyloid mAb. The GBM staining with anti-HSPG-core mAb JM-72 
was unaltered in these biopsies. In 10 out of 19 biopsies with amyloidosis, staining of the 
amyloid deposits was seen with anti-HS mAb JM-403 (Fig.5C), although the staining was 
sometimes weak. Although the numbers were small, it seemed that a positive HS staining 
was more prevalent in AA amyloidosis than in AL. 
Membranous GN. An irregular, granular staining of the GBM was observed with anti-
HSPG-core mAb JM-72 in all biopsies with stage II and III membranous GN (Fig.6). 
This irregular, moth-eaten pattern was not seen in every capillary loop and was in all 
probability related to the formation of spikes. Since the anti-HS staining was negative in 4 
out of 5 cases with membranous nephropathy (Table II), this suggests that also the newly 
formed basement membrane matrix at the sites of spike formation is negative for HS. 
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Table IV. Staining of the amyloid deposits with anti-HSPG-core mAb 
JM-72 and anti-HS mAb JM-403. 
Type anti-HSPG-core anti-HS 
mAb JM-72 mAb JM-403 
AL amyloidosis 7/7' 1/5 
AA amyloidosis 16/16 9/14 
" Number of positive specimens / specimens studied are given. 
Fig. 5. Presence ofHSPG in amyloid deposits. Indirect IF with anti-HSPG-core mAb JM-
72 (A and B) or anti-HS mAb JM-403 (C) demonstrating the presence ofHSPG in AL (A) 
and AA (B and C) amyloidosis (A χ 190; Β χ 290; С χ 230). 
Fig. 6. Distribution of HSPG-core protein in membranous GN. Indirect IF with anti-
HSPG-core mAb JM-72. Overview of a glomerulus (A). Magnification of a part of a 
glomerulus (B), demonstrating the irregular, moth-eaten GBM staining as indicated by 
arrows (A χ 330; Β χ 1180). 
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Normal distribution of HSPG and HS. 
A normal glomerular staining with anti-HSPG-core mAb JM-72 (linear GBM and in 
general no mesangial staining) was observed in crescentic GN, minimal change disease 
and Alport's syndrome. No alterations in GBM staining with anti-HS mAb JM-403 were 
observed in IgA nephropathy and Alport's syndrome and in some kidney biopsies 
belonging to other glomerulopathies (Table II). 
All control experiments (see Materials and Methods) we performed in the indirect IF 
and the double staining experiments were negative. 
DISCUSSION 
In this study, the glomerular HSPG distribution was analyzed in human glomerulopa-
thies by indirect IF, using mAbs specific for the HSPG-core protein and for the strongly 
anionic HS-side chains of HSPG, which are thought to be a main determinant of the 
charge selective filter of the GCW. Although other reports have described the distribution 
of the HSPG-core protein in several glomerular diseases [45-51], in the present study, we 
used an unique combination of mAbs, which enabled us to compare the HS-staining with 
that for the HSPG-core protein. Since the anti-HSPG-core mAb JM-72 had a different 
isotype compared to anti-HS mAb JM-403 (IgGl versus IgM), biopsies could be studied 
using a double staining technique. 
The most remarkable finding was a segmental or global decrease or even absent 
staining of anti-HS mAb JM-403 accompanied by a normal staining for HSPG-core 
protein in various glomerular diseases, most notably in lupus nephritis, membranous GN, 
minimal change disease, and diabetic nephropathy, while it was normal in IgA nephropa-
thy and Alport's syndrome. This decrease can be due firstly to a decreased HS expression 
in the GBM as a consequence of an impaired synthesis or enhanced degradation of HS. 
Alterations in GBM HS have been described for diabetic nephropathy [33-37] and for an 
experimental model of membranous GN [31]. However, in all glomerulopathies, showing 
a segmental or complete absence of JM-403 staining, anti-HSPG-core staining was 
normal, which indicates that the HSPG-core expression was unaltered. Secondly, the 
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decrease of JM-403 staining might be due to a blocking effect of cationic molecules or 
immune complexes, that become bound to the GBM by charge-charge interactions. With 
cationic probes, various investigators found an impaired anionic charge of the GCW in 
experimental and human nephropathies [15-30]. In addition, a number of studies 
[15,54-63] showed the involvement of endogeneous cationic molecules in the pathogenesis 
of glomerular diseases. In one study the GBM binding of basic proteins was accompanied 
by a decrease of the anionic charge of the GBM and onset of proteinuria [60]. It is 
tempting to speculate that our results, demonstrating specifically a decrease or absence of 
GBM HS staining may be related to GBM binding of cationic proteins or immune 
complexes, leading to a decrease of the net negative charge of the GBM, as suggested for 
SLE nephritis [15-17,54-56], minimal change disease [58,64] and membranous GN 
[20-24]. The relevance of the JM-403 HS-epitope for the charge-selective properties of 
the GBM is suggested by our recent observation that JM-403 is able to induce an acute 
selective proteinuria in rats after a single intravenous injection [13]. Recent work from 
our laboratory [65,66] and that of others [54] points towards a role of histones in lupus 
nephritis. Recently, the glomerular localization of histones was demonstrated in human 
SLE kidney biopsies [55]. The binding of histones to the GBM might explain our 
immunohistochemical findings in the SLE kidney biopsies showing a complete absence of 
JM-403 staining, accompanied by an unaltered JM-72 binding. Preliminary data from our 
laboratory show that cationic molecules like histones are indeed able to inhibit the binding 
of JM-403 to HS in ELISA, but not the binding of JM-72 to HSPG (abstract Kidney Int. 
1992, in press). Whether a similar mechanism is also true for other glomerular diseases 
remains to be elucidated and is under current investigation. 
In the present study, we were not able to correlate the GBM staining pattern with anti-
HS mAb JM-403 to clinical parameters of the patients, especially proteinuria. This may 
be due to the retrospective character of this study. However, we have preliminary data in 
the adriamycin model in the rat demonstrating a significant correlation between the GBM 
staining with mAb JM-403 and the fractional urinary excretion of albumin in course of 
time. It is attractive to hypothesize that an increase in urinary albumin excretion may be 
the result of an altered HS expression/accessibility in the GBM. An alternative explanati-
on for the decreased HS staining of the GBM could be an altered HS metabolism as a 
consequence of the high levels of proteinuria. In that case, a decreased anti-HS staining 
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would be an aspecific phenomenon related to the presence of proteinuria. An argument 
against the latter explanation is the fact that we found a normal HS staining in IgA 
nephropathy, Alport's syndrome and some biopsies from several other glomerular 
diseases with increased proteinuria. 
A second alteration we observed in glomerular HSPG distribution deals with the 
presence of HSPG in areas with increased mesangial matrix production, suggesting the 
production of HSPG by mesangial cells in these glomerular diseases (Table III). Normal-
ly, chondroitin sulfate proteoglycan appears to be concentrated in the mesangial matrix 
[67] and is the major proteoglycan produced by mesangial cells in culture [68-70]. 
However, in several experimental and human glomerular diseases, an expansion of the 
mesangium is accompanied by an altered composition of the mesangial matrix [71-75], 
one of them showing the presence of HSPG [71]. 
In amyloidosis we observed a brilliant staining of the amyloid deposits with anti-HSPG-
core mAb JM-72 and in some, but not all cases with anti-HS mAb JM-403. The presence 
of HSPG in various forms of amyloid has been known for several years (reviewed in 
[76]) and was recently demonstrated for neural and renal AA amyloidosis by immunohis-
tochemical methods using antibodies specific for the HS-side chain and the core protein of 
HSPG [77-81]. Our study confirms and extends these data, since we also demonstrated 
the presence of HSPG in AL amyloidosis. In amyloidosis, the presence of intrinsic 
basement membrane components is not restricted to HSPG, since several other basement 
membrane components like collagen type IV, fibronectin and laminin, have been found in 
amyloid deposits [76]. 
The irregular, moth-eaten GBM staining that we observed in stage II and III membra-
nous GN with our anti-HSPG-core mAb JM-72 is in agreement with the findings of 
others, showing the presence of HSPG in the spikes, whereas the immune deposits were 
negative [46,50], and suggests that HSPG is a constituent of the newly formed basement 
membrane material in this disease. 
Except for membranous GN, we found in all glomerulopathies an unaltered linear GBM 
staining with the anti-HSPG-core mAb JM-72. The unaltered HSPG-core expression in 
the GBM in various glomerulopathies has been found by others [46,47], although some 
reports described a reduced HSPG-core staining of the GBM in experimental nephrotic 
syndrome [45] and in diabetic nephropathy [51]. These differences may be due to 
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differences in HSPG source and specificity of the antibodies. 
The unique combination of mAbs against the HSPG-core protein and the HS-side 
chains, can be useful to delineate further the involvement of HSPG and HS in renal 
pathology, and maybe also in other basement membrane disorders and cell-matrix 
interactions in vitro and in vivo. 
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Abstract. A decrease in the concentration of heparan sul-
phate proteoglycan (HSPG) in the glomerular basement 
membrane (GBM) is supposed to cause the increased 
GBM permeability in the congenital nephrotic syndrome 
(CNS) Therefore, we analysed the glycosaminoglycan 
(GAG) content and composition of the GBM and tubular 
basement membrane (TBM) from 3 patients with CNS of 
the Finnish type (FCNS) and 16 control infants The GAG 
content, determined by spectrophotometnc assay after 
papain digestion, was not significantly different in FCNS 
patients compared with controls In addition, the GAG 
composition was comparable in the two groups, with hepa-
ran sulphate (HS) constituting at least 75% of the total 
GAG content The urinary GAG content (expressed as mg 
GAG/mmol creatinine) was age dependent, but similar in 
both groups Indirect immunofluorescence studies on kid-
ney tissue from normal human infants, using monoclonal 
or polyclonal antibodies against the core protein of human 
GBM HSPG, showed linear staining of almost all renal 
basement membranes A monoclonal antibody directed 
against the HS chain of HSPG showed strong GBM and a 
weak TBM staining Kidney tissue from three patients with 
FCNS displayed no discernible differences in the distribu-
tion or quality of staining with the same antibodies These 
biochemical and immunohistochemical results are in con-
trast to the decrease in anionic sites (by polyethyleneirmne 
staining) and the replacement of GBM HS by chondroitin 
sulphate, observed by others in CNS of the diffuse 
mesangial sclerosis type. 
Key words: Congenital nephrotic syndrome - Finnish type 
- Glomerular basement membrane - Heparan sulphate -
Heparan sulphate proteoglycan 
Introduction 
Congenital nephrotic syndrome (CNS) is usually a fatal 
disorder in which heavy proteinuria and the nephrotic syn-
drome are present from birth or early infancy The main 
subgroups are the Finnish type (FCNS) and diffuse 
mesangial sclerosis [1] FCNS is an autosomal recessive 
renal disease which is characterized, even in utero, by 
elevated levels of α-fetoprotein both in the maternal circu­
lation and in the amniotic fluid [2, 3] After birth, patients 
with FCNS have massive proteinuria resistant to treatment, 
and renal transplantation is the only therapeutic option [2] 
The precise pathogenesis of FCNS is unknown It has 
been assumed that the proteinuria is due to faulty structure 
of the glomerular filtration bamer, probably m the glomer­
ular basement membrane (GBM) itself [4] Electron-mi­
croscopic studies of kidneys from fetuses and infants with 
FCNS have generally revealed a normal GBM [5] How­
ever, on morphometnc analysis a thinner GBM lamina 
densa has been demonstrated in FCNS compared with age-
matched controls [6] A number of biochemical studies of 
the collagen composition of the GBM have failed to show 
conclusive evidence of any basic abnormalities in FCNS 
[7]. In addition, immunohistochemical studies for lamimn, 
type IV collagen, fibronectin, brush border antigens, 
Tamm Horsefall protein and binding of wheat germ agglu­
tinin have not revealed changes in FCNS compared with 
age-matched controls [8], except for an accumulation of 
lamimn, fibronectin and type IV collagen in the mesangial 
matnx [9] This mesangial change is, however, regarded as 
a secondary phenomenon 
Alterations in the charge as well as the size bamer have 
been suggested as a cause of the proteinuria Changes in 
the charge bamer have been observed in aminonucleoside 
nephrosis [10-13], IgA nephropathy and membranous ne­
phropathy [14-18] Vemieretal [14] reported a decrease 
in heparan sulphate(HS)-nch anionic sites in the GBM in 
five patients with CNS, revealed by a decreased staining 
with polyethylemmine However, none of the patients in 
this study had CNS of the Finnish type In a recent study 
Vermylen et al. [17] found no change in the total gly-
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cosaminoglycan (GAG) content of the GBM, but a total 
replacement of HS with chondroitin sulphate in one patient 
with diffuse mesangial sclerosis. The urinary excretion of 
HS was significantly increased in two patients with FCNS 
(expressed both in relation to creatinine and to chondroitin 
sulphate) compared with normal children, but it was nor­
mal or only slightly increased in two patients with diffuse 
mesangial sclerosis and in nine with acquired nephrotic 
syndrome [17]. 
To ascertain whether changes in proteoglycans are in­
volved in the pathogenesis of FCNS, we analysed the GAG 
content and composition of the GBM and tubular basement 
membrane (TBM) in 3 children with FCNS and in 16 chil­
dren of comparable age who died from unrelated disorders 
The availability of specific polyclonal and monoclonal an­
tibodies against human GBM HS proteoglycan (HSPG) 
[19-21] enabled us to investigate more extensively the 
changes in HS content in FCNS We also determined the 
unnary GAG excretion of patients with FCNS and of agc-
matched controls 
Materials and methods 
Materials 
Kidnev tissue BicKhemical dnd immunohistochemical investigations 
were performed on kidneys from 1 infants with FCNS (between 4 and 
12 months) and 16 controls ranging from premature neonates to children 
up to 4 years old All the patients with FCNS had typical clinicdl features 
[2], with proteinuria in excess of 5 0 g/24 h In all patients glomerular 
changes consisted of mesangial proliferation Kidneys were obtained at 
nephrectomy and the diagnosis was confirmed by routine pathological 
investigation Control kidneys were obtained at autopsy within 20 h of 
death During life, there was no clinical evidence of any renal disease in 
any of these subjects 
Urine Complete 24 h unnc samples were collected (and preserved with 
sodium azide) from 39 healthy children with normal renal function 
ranging from premature infants to children up to 4 years old, and from 
14 patients with FCNS During the collection penod the unne was kept at 
4"С and frozen at -7(ГС within a few hours 
Other materials All other chemicals have been desenbed in detail else­
where [ 191, or were of analytical grade 
Methods 
Isolation of basement membranes Isolation of glomeruli and tubules 
from renal cortex was earned out following established procedures [22] 
which included the use of ethylCnediaminetetra-acetic acid (hDTA), a 
temperature below 6° C, mincing of the cortical tissue through a stainless 
steel screen and sieving To obtain sulficicntly pure glomerular prepara­
tions, repeated sieving of glomerular fractions was necessary Punty 
control was performed by light microscopy, which showed that glomeru­
lar preparations had a purity of at least 90% and tubular preparations of 
at least 95% 
Basement membranes were isolated from glomeruli and tubules by 
the detergent procedure [22, 231 which required lysis in water, extraction 
with 1 M sodium chloride (NaCl), extraction with 4% sodium deoxycho-
late (for 5 h at room temperature) followed by digestion with ribonu-
clease and deoxynbonuclease (for 2 h at room temperature 'S mg each 
en/ymc/100 ml 50 mM Tns-HCI/7 5 mM MgCh, pH 7 3) The final 
basement membrane preparations were lyophihzed and dned above 
phosphorus pentoxidc 
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Fig. 1. Glycosaminoglycan {GAG) content of A individual glomerular 
basement membrane (GBM) and В tubular basement membrane (TBM) 
preparations from patients with congenital nephrotic syndrome of the 
Finnish type (FCNS) ( β ) and controls (O) as a function of age 
Assay of GAG content of basement membranes Basement membranes 
were digested with papain (300 μg/ml) at 56" С for 16 h in 50 mM 
phosphate buffer (pH 6 5) containing 2 mM EDTA and 2 mM ^-acetyl­
cysteine The digest was centnfuged at 7,000 g for 15 mm To 100 μΙ of 
digest or standard HS solution, I ml dimethyl methylene blue reagent was 
added The colour reagent was prepared by dissolving 16 mg dimethyl-
methylene blue in 1 1 water containing 3 04 g glycine, 2 37 g NaCl and 
95 ml 0 1 M hydrochlonc acid, to give a solution at pH 3 0 with an 
absorbance at 525 nm of 0 31 [24] The absorbance of samples was 
measured immediately after mixing at 525 nm GAG concentrations 
were calculated from a standard curve for HS. since the relative absor­
bance of the main GAGs, HS and chondroitin sulphates A and С are 
similar [25] The recovery of GAGs added to basement membranes was 
95%-100% [25] 
Identification of GAGs Basement membranes were digested with papain 
(300 μg/ml) at 5 6 Τ for 16 h m 0 1 M sodium acetate buffer (pH 7 0) or 
in 0 1 M Tns-HCl buffer (pH S 0) To remove papain, the samples were 
heated at 100' С for 10 mm and centnfuged at 10,000 g for 2 mm To the 
digest m 0 1 M sodium acetate buffer, calcium acelate up lo a final 
concentration of 10 mM and 1 unit hepantinase were added, before in-
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Fig. 2. Enzyme-linked immunosorbent assay with A monoclonal anti­
body (mAb) 72 or В mAb 403 against intact GBM heparan sulphate 
proteoglycan (HSPG) ( · ) , its core protein obtained after tn-
) Dilution 
fluoromethanesulphomc acid treatment (X) or its HS (GAG) chains 
obtained by alkaline sodium borohydnde treatment of HSPG (0) 
cubation at 43°C for 16 h The digest in 0 1 M Tns-HCI buffer (pH 8 0) 
was incubated wiih 0 25 umis chondroiUnase ABC for 16 h at 37' С The 
GAG content was determned before and after incubation 
a limited time penod. using the same batches of primary and secondary 
antibody 
Quantification of urinary G AGs Unne samples were dialysed against 
7 M urea/10 mM Tns-HCI (pH 6 8) Diethylaminoethyl (DEAE)-
Sepharose CL-4B chromatography was performed batchwise in a centn-
fuge tube Urinary GAGs were bound to DEAE-Sepharose (1 0 ml 
gel/10 ml urine in 7 M urea/0 1 M NaCl/10 mM Tns-Hcl, pH 6 8) The 
DFAE-Sepharose was washed twice with the same buffer and the GAGs 
were eluted with 7 M urea/1 5 M NaCl/10 mM Tns-HCI, pH 6 8 This 
procedure was repeated for all samples The GAG content was deter­
mined by spectrophotometry after staining with dimethylmethylene blue 
[24] As an internal standard, 15sulphur (S) labelled rat glomerular pro­
teoglycans was used Values for the GAG content were corrected for loss 
dunng the batchwise purification The recovery of the 35S-label was 
always more than 75% 
Preparation and characterization of antibodies Rabbit anlisera against 
human GBM HSPG were prepared using a schedule of multiple intrader­
mal injections [19] The isolation of the antigen, GBM HSPG, has also 
been previously desenbed [19] Monoclonal antibodies (mAbs) were 
obtained according to established procedures after immunizing mice with 
human GBM HSPG (mAb 72) or rat glomerular HSPG (mAb 403) 
[19-21, 26] The specificity and the titre of the antisera or mAbs were 
determined by enzyme-linked immunosorbent assay (ELISA) 
[19,27,28] 
Indirea immunofluorescence microscopy Indirect immunofluorescence 
(IIF) microscopy was performed on 2-μπι cryostat sections of human 
kidneys Sections were fixed for I min in acetone and washed with 
phosphate buffered sahne (PBS) Thereafter, 100 μΙ primary anubody 
(polyclonal antibody, mAb 72 or mAb 403), diluted in PBS containing 
1% bovine scrum albumin (BSA) and 0 05% sodium azide, were applied 
to the section for 30 mm at room temperature After washing with PBS, 
binding was visualized by incubating the sections for 30 mm at room 
temperature in the dark with 100 μ! fluorescein isothiocyanalc-labelled 
secondary antibody goat anti rabbit IgG for the polyclonal antibody 
(Nordic, Tilburg, The Netherlands), sheep anti-mouse IgG, heavy and 
light chains (Cappel-Organon Tekmka, Turnhout, Belgium) for mAb 72, 
goat anü-mouse IgM Fc-spccific (Nordic) for mAb 403 These antibod-
ies were also diluted in PBS containing 1% BSA and 005% sodium 
azide Sections were washed with PBS, embedded in Aqua Mount and 
examined with a Leitz Ortholux 2 microscope fitted for fluorescence 
microscopy All incubations were performed by the same person within 
Results 
Biochemical studies on GBM and TBM GAGs 
The total GAG content of the GBM or TBM from normal 
control subjects showed a large variation, but the values 
did not differ from those obtained from patients with FCNS 
(Fig 1 ). In addition, the GAG composition of the GBM or 
TBM preparations from patients with FCNS and controls 
were comparable (Table 1). HS was the predominant GAG 
in the GBM and TBM, and constituted at least 75% of the 
total GAG content. These data are in the range of earlier 
desenbed results for controls [25,29]. 
Total urinary excretion of GAG 
The total unnary excretion of GAG was age dependent in 
control children (Table 2) in that there was a decrease in 
the unnary GAG/creatmine ratio with increasing age, as 
also observed by Vermylen et al. [ 171. The unne of patients 
Table I. Glycosammoglycan (GAG) composition of glomerular base 
ment membrane (GBM) and tubular basement membrane (TBM) from 
patients with congenital nephrotic syndrome of the Finnish type (FCNS) 
and age-matched controls" 
GAG 
Heparan sulphate 
Chondromn sulphate 
GBM 
FCNS 
76±6 
18±5 
Controls 
75±6 
23 + 6 
TBM 
FCNS 
82±4 
16±4 
Controls 
82 + 6 
15±5 
* ComposiUon was determined by degradation with heparitmase and 
chondroitinase ABC Values are given as percentage (mean ± SD) for 
3 patients and 6 controls 
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Table 2. Urinary GAG excretion by patiems with FCNS and age-
matched controls3 
Age Controls FCNS patients'1 
Premature 65±21(II) 
0-3 months 46 + 17(10) 56 (1) 
4-12months 35±14(10) 28±9 (5) 
l-4years 17±5 (8)* 22±11(8) 
* P<0.01 compared with other control groups 
a
 Values are mean ± SD for the number of children in parentheses and 
are expressed in milligrams GAG per millimole creatinine 
b
 The values for patients with FCNS were not significantly different 
from control values 
with FCNS had comparable GAG/creatinine ratios to age-
matched controls. 
Immunological studies 
Polyclonal rabbit antiserum against human GBM HSPG 
and mAbs against human GBM HSPG (mAb 72) or rat 
glomerular HSPG (mAb 403) were used for immunohisto-
chemical studies on cryostat sections of kidneys from 
patients with FCNS and controls. The polyclonal antibody 
[19] and mAb 72 (Fig. 2 A) [20] are directed against the 
core protein of GBM HSPG. mAb 403 is directed against 
the HS chain of GBM HSPG (Fig. 2B) [21]. In the ELISA 
these antibodies showed no activity against mouse or 
human laminin or human type IV collagen, albumin or 
fibronectin. 
In kidney tissue from normal children the polyclonal 
antibody stained all renal basement membranes (GBM, 
TBM, peritubular capillaries and Bowman's capsule) in an 
intense linear pattern by IIF (Fig. ЗА). mAb 72 displayed a 
brilliant linear staining of the GBM in the same sample 
(Fig. 3B). A less intense, but also linear staining was seen 
along Bowman's capsule, the TBM, the basement mem­
branes of the peritubular capillaries and the basement 
membranes of smooth muscle cells in the arterial wall; the 
mesangial matrix was negative. By IIF on cryostat sections 
of normal infant kidney, the antibody against the HS chain 
(mAb 403) showed a strong linear staining of the GBM 
(Fig. 3C). mAb 403 also stained all renal basement mem­
branes, but the fluorescence in the GBM was more pro­
nounced. All these staining patterns could be inhibited by 
preincubation of the antibodies with human GBM HSPG. 
IIF on kidneys from patients with FCNS revealed a 
microcystic dilatation of proximal convoluted tubules 
(Fig. 4) [2]. No discernible differences in staining intensity 
were noted between the 3 patients with FCNS and the 
age-matched controls when the same set of antibodies 
against the core protein or the HS side chain of GBM 
HSPG were used (Fig. 5 Α-C). In general, the distribution 
was also identical, although in some glomeruli there was an 
increased staining of mesangial areas with the anti-HS 
mAB403(Fig. 5C). 
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Fig. 3. Indirect immunofluorescence staining of human infant kidney 
cortex with: A polyclonal anti-human GBM HSPG serum (dilution 
1:500); В mAb against GBM HSPG core protein (mAb 72); С mAb 
against HS (mAb 403) ( χ 100) 
Discussion 
Despite the therapeutic advances made by dialysis and 
renal transplantation allowing survival of patients with 
FCNS, the precise pathogenesis of this condition is still 
unknown. It has been postulated that a gene defect in­
volved in proteoglycan metabolism is responsible for a 
decrease in anionic charges in the glomerular capillary 
wall. However, in this study we found no biochemical 
differences in the GAG content and composition of the 
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Fig, 4. indirect immunofluorescence staining of FCNS kidney cortex 
with polyclonal anti-human GBM HSPG serum (dilution 1:500) ( χ 25) 
An arrow indicates a glomerulus 
GBM and TBM of FCNS patients compared with age-
matched controls. These data are substantiated by immuno-
histochemical studies using mAbs and polyclonal antibod­
ies against human GBM HSPG and HS. These results are 
in contrast to the decrease in anionic sites of the GBM or 
the replacement of GBM HS by chondroitin sulphate 
shown by others [14, 17]. Vernier et al. [14] demonstrated 
a decrease in the number of anionic sites in the GBM in 
five patients with CNS using the cationic probe polyethy-
leneimine. It is difficult, however, to classify these patients 
since light microscopy revealed focal mesangial prolifera­
tion in most glomeruli in patients 1 -4 and focal segmental 
sclerosis and hyalinosis in many glomeruli in patient 5. 
The biochemical study performed by Vermylen et al. [17] 
was of an infant with CNS due to diffuse mesangial sclero­
sis, a different form of CNS from that studied here. 
The absence of any change in urinary GAG excretion in 
our patients with FCNS is in contrast to the increase in two 
patients described by Vermylen et al. [17]. Experimental 
differences may explain this since these investigators did 
not isolate the urinary GAG before measurement with al­
elan blue. Moreover, the alcian blue assay gives an over-
estimation of the urinary GAG content [30]. Staprans et al. 
[31] also used DEAE-chromatography to isolate the uri­
nary GAGs, but found that patients with nephrotic syn­
drome (not further characterized) excreted much less GAG 
in the urine than controls. 
The main molecular structures responsible for the 
anionic sites in the glomerular barrier are the proteoglycans 
of the basement membrane and the sialoglycolipids and 
sialoglycoproteins present on the cell surface of the podo-
cytes of the epithelial cells [32]. A reduced sialation of 
glomerular capillary wall components has also been re­
ported in nephrotic conditions [33, 34]. Speri et al. [35] 
observed a nephrotic syndrome due to a disturbance of 
lysosomal membrane transport in siblings with infantile 
sialic acid storage disease. Normal levels of HS, but an 
altered structure, particularly a decrease in the negative 
Fig. 5. indirect immunofluorescence staining of FCNS kidney cortex 
with: A polyclonal anti-human GBM HSPG serum (dilution 1:500); 
В mAb against GBM HSPG core protein (mAb 72): С mAb against HS 
(mAb403)(xlOO) 
charge density of this molecule, were observed in amino-
nucleoside nephrosis [36-38]. The congenital nephrotic 
syndrome is an uncommon, diverse disorder [1, 2] and 
may, therefore, be caused by various genetic abnormalities 
which lead to different structural GBM aberrations. This 
may explain the discrepancies between our results in FCNS 
and those reported in the literature in other forms of CNS. 
In summary, both biochemically and immunohistologi-
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cally, we observed no quantitative or structural abnormali-
ties of HSPG in renal basement membranes in FCNS 
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CHAPTER 7 
SUMMARY AND PERSPECTIVES 
FOR FURTHER INVESTIGATION 

SUMMARY 
Heparan sulfate (HS) is the side chain of heparan sulfate proteoglycan (HSPG), the 
major proteoglycan present in the glomerular basement membrane (GBM). By its negative 
charge, HS is thought to play a crucial role in the permselective properties of the 
glomerular capillairy wall (GCW), especially in the charge-selective permeability. An 
increased glomerular permeability for proteins is found in many glomerular diseases. To 
evaluate the role of HSPG in glomerular filtration and renal disease, monoclonal 
antibodies (mAbs) against epitopes on the HSPG-core protein as well as on the HS-side 
chains might be of great value. In this thesis the production, characterization and some 
applications of mAbs against the HSPG core protein and the HS side chain are described. 
Chapter 2 deals with an anti-HS mAb (JM-13), that was obtained after immunization 
with human glomerular HSPG. The HS specificity of this mAb was demonstrated by 
enzyme-linked immunosorbant assay (ELISA), Western blotting, inhibition studies and 
indirect immunofluorescence (IF) using specific glycosaminoglycan-degrading enzymes. 
In indirect IF on human kidney sections, a restricted staining of tubular basement 
membranes (BMs) was observed along with staining of the vascular BMs. The precise 
localization of the restricted tubular BM staining was defined by double staining with 
mAb JM-13 and antibodies that identify specific segments of the nephron. We could 
locate the epitope in the BMs of the distal convoluted tubule, the thick ascending limb of 
Henle's loop, the medullary collecting tubule, and to a lesser extent, the proximal tubule. 
In the glomerulus, a weak, fine granular staining was seen along the capillary wall and in 
the mesangium, without a clear staining of the GBM. MAb JM-13 bound also to the baso-
lateral cell membranes of proximal tubular cells, to the cell membranes of cultured human 
and rat glomerular visceral epithelial cells, rat mesangial cells, human hepatocytes in 
culture and in liver cryostat sections, indicating also a recognition of cell surface-
associated HS. 
In Chapter 3 a second anti-HS mAb (JM-403) is described. It was produced after 
immunization of mice with partially purified rat glomerular HSPG. The HS-specificity of 
the mAb was demonstrated by ELISA studies, inhibition experiments and indirect IF in 
combination with specific glycosaminoglycan degrading enzymes. In indirect IF, mAb 
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JM-403 displayed a brilliant staining of the GBM, Bowman's capsule and the arterial 
wall. Other renal BMs also stained but somewhat weaker. Indirect immuno-electron 
microscopy demonstrated staining throughout the whole GBM. Intravenous injection of 
this mAb into rats resulted into a transient binding to the glomerular capillary wall and 
into a dose-dependent immediate, transient and selective proteinuria. This result 
underlines the important role for HS in the charge-selective properties of the GBM. 
Comparison of both anti-HS mAbs JM-13 and JM-403 indicates recognition of different 
epitopes on HS. Besides HS and HSPG, mAb JM-13 also recognizes heparin, but no 
other glycosaminoglycans and BM components. Moreover, this antibody fails to recognize 
human GBM HSPG treated with HNO2 on Western blot. This demonstrates that the 
epitope is located in the N-sulfated parts of HS. On the other hand, anti-HS mAb JM-403 
recognizes HS as well as hyaluronic acid, but did not bind to heparin and other 
glycosaminoglycans. Both hyaluronic acid and HS contain the same basic structure of 
repeating disaccharide units of N-acetyl glucosamine and glucuronic acid. Apparently, the 
presence of N- and O-linked sulfate is not important for JM-403 binding, since hyaluronic 
acid does not contain these components. On the other hand, mAb JM-403 exhibits no 
affinity for heparin that has more iduronic acid and sulfate groups than HS. These data 
suggest that the epitope may be located within a cluster of unsulfated glucuronic acid - N-
acetyl glucosamine disaccharide units. 
Besides mAbs against different epitopes of the HS-side chain of HSPG, we also 
developed mAbs against the core protein of human GBM HSPG (Chapter 4). One mAb 
(JM-72) out of 18 was characterized in detail by ELISA studies, inhibition experiments 
and Western blotting. The renal localization of its epitope on the core protein of HSPG 
was demonstrated ultrastructurally and by indirect IF. A brilliant linear staining of the 
GBM was observed in the indirect IF, while the other renal BMs stained to a lesser 
extent, but also linear. Indirect immuno-electron microscopy demonstrated the epitope to 
be present throughout the whole width of the GBM, although mostly pronounced in the 
subendothelial region. Moreover, its localization in many other human tissues was studied 
by indirect IF and compared with anti-HS mAb JM-403. Whereas anti-HS mAb JM-403 
stained all BMs throughout the body, anti-HSPG-core mAb JM-72 did not stain the BMs 
of all types of muscle cells (striated, smooth and heart), although all other BMs were 
positive. Our data suggest that GBM HSPG, to which JM-72 is directed, differs from the 
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large EHS HSPG. Anti-HS mAb JM-403 in all probability recognizes the HS chains 
present in both types of HSPGs. The results with our three m Abs (anti-HS m Abs JM-13 
and JM-403 and anti-HSPG-core mAb JM-72) underlines the heterogeneity of HSPGs in 
BMs. 
The anti-HSPG-core mAb JM-72 and anti-HS mAb JM-403 were also used to study 
alterations in the distribution of the HSPG-core protein and HS in human glomerular 
diseases. The study was carried out on sections of kidney biopsies involving twelve 
different glomerulopathies. The results of this study are presented in Chapter 5. The 
major alteration was a segmental or total absence of GBM staining with anti-HS mAb JM-
403, most pronounced in lupus nephritis, membranous glomerulonephritis (GN), minimal 
change disease and diabetic nephropathy, whereas the HSPG-core staining remained 
unaltered. The decreased HS-staining in the GBM may be the result of an impaired 
metabolism of HS or to a blocking effect by cationic molecules or immune-complexes, 
thereby masking the JM-403 epitope. In addition, we found HSPG to be present within 
the mesangial matrix when this was increased and in amyloid deposits in AL and AA 
amyloidosis. Furthermore, in membranous GN (stage II and III), the GBM staining with 
anti-HSPG-core mAb JM-72 became irregular or granular, probably related to the 
formation of spikes. The results of this study indicate that changes in HS and HSPG core 
protein staining may be involved in many different types of glomerulopathies. 
Since a decrease in HS content of the GBM is supposed to cause the increased GBM 
permeability in the congenital nephrotic syndrome, we analysed the glycosaminoglycan 
content and composition of the GBM, of the tubular BMs and in the urine from 3 patients 
with the congenital nephrotic syndrome of the Finnish type and 16 control infants 
(Chapter 6). Moreover, in both groups the presence of the HSPG-core protein and HS 
was studied immunohistochemically using the m Abs JM-72 and JM-403. No differences 
between the 3 children suffering from the Finnish type of the congenital nephrotic 
syndrome and 16 control infants were observed for the glycosaminoglycan content and 
composition of the GBM, the tubular BMs and the urine, and for the 
immunohistochemical staining of the kidney tissues with anti-HSPG-core mAb JM-72 and 
anti-HS mAb JM-403. These results indicate that the increased glomerular permeability in 
this particular disease is not due to a HSPG abnormality. 
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PERSPECTIVES FOR FURTHER INVESTIGATION 
Future studies will be focussed on the glomerular HSPG-core and HS content in 
relation to renal hemodynamics and glomerular protein excretion in different animal 
models of renal disease (streptozotocin-induced diabetic nephropathy, adriamycin 
nephrosis, PAN nephrosis, protein-overload proteinuria, the remnant kidney model, 
experimental membranous GN and anti-GBM nephritis). Furthermore, we will try to 
elucidate the precise localization of the different epitopes on the HS-side chain and the 
core protein of HSPG, recognized by our different mAbs. Finally, the cloning of the 
cDNA encoding for the HSPG molecule, present in the GBM, will allow the production 
of domain-specific antibodies, that can be used in functional assays to unravel the 
significance of the different domains of the HSPG molecule in renal physiology and 
pathology. Moreover, such studies may demonstrate the possible relationship between 
GBM HSPG and other types of HSPG like the large EHS HSPG. 
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SAMENVATTING 
Eén van de belangrijkste funkties van de nieren is de filtratie van het bloed. Dit heeft 
tot doel de afvalstoffen van het lichaam uit het bloed te verwijderen en uit te scheiden in 
de urine. Dit proces vindt plaats in de 2,5 miljoen nefronen in beide nieren. Aan het 
begin van ieder nefron bevindt zich het filterorgaantje, de glomerulus (bij de mens 
ongeveer 0,1 mm in doorsnede). Het aanvoerende bloedvat vertakt zich in de glomerulus 
in een groot aantal haarvaatjes, ook wel capillairen genoemd, die een zeer dunne wand 
hebben, waardoor het ultrafiltratie proces plaats vindt. Het ultrafiltraat (de door de 
capillairwand heengeperste vloeistof) noemt men de voorurine. Zo'n capillairwand is 
opgebouwd uit 3 lagen: twee cellagen, te weten de binnenbekleding (het endotheel) en de 
buitenbekleding (het epitheel), met daartussen een membraan, de zogeheten glomerulaire 
basaal membraan (GBM), het eigenlijke filter. De samenstelling en structuur van de 
GBM is erg belangrijk voor de wijze waarop de ultrafiltratie plaats vindt. Onderzoek 
heeft aangetoond dat de GBM zowel een grootte- als een ladings-afhankelijke 
doorlaatbaarheid vertoont. Dat wil zeggen dat naarmate deeltjes (meestal eiwitten) in het 
bloed groter zijn, deze moeilijker de GBM kunnen passeren. Tegelijkertijd is het echter 
zo dat positief geladen deeltjes beter geklaard worden dan negatief geladen deeltjes. Dit 
laatste is gevolg van het feit dat de GBM zelf sterk negatief geladen is. De negatieve 
lading van de GBM wordt voor een groot gedeelte veroorzaakt door één component, het 
zogeheten heparan sulfaat proteoglycan (HSPG). Proteoglycanen zijn opgebouwd uit een 
eiwitketen (core proteine), waaraan bepaalde negatief geladen suikerketens, 
(glycosaminoglycan ketens) gebonden zijn. In GBM HSPG bestaan die ketens uit heparan 
sulfaat (HS). Monoklonale antilichamen (mAb's), d.w.z. antistoffen met één 
specificiteit, gericht tegen of het core proteine of de HS zijketens van HSPG kunnen van 
grote betekenis zijn bij de bestudering van de rol van HSPG bij de glomerulaire 
ultrafiltratie en bij nieraandoeningen. In dit proefschrift worden de ontwikkeling, 
karakterisering en enkele toepassingen beschreven van mAb's gericht tegen het core 
proteine en tegen de HS zij keten. 
Hoofdstuk 2 beschrijft een mAb (JM-13) tegen HS, die werd verkregen na immunisatie 
met humaan glomerulair HSPG. De HS-specificiteit van deze mAb kon worden aange-
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toond in een enzymgekoppeld immunosorbens analyse (ELISA), in Western blotting, bij 
remmingsexperimenten en in indirecte immunofluorescentie (IF) in combinatie met 
specifieke glycosaminoglycan afbrekende enzymen. De indirecte IF, uitgevoerd op 
humane niercoupes liet een aankleuring zien van een beperkt aantal tubulaire 
basaalmembranen (BM's), met daarbij een aankleuring van alle vasculaire BM's. De 
exacte localisatie van de tubulaire BM aankleuring werd onderzocht met behulp van 
dubbelkleuringen met JM-13 en antistoffen gericht tegen specifieke segmenten van het 
nefron. Uit deze studie bleek dat JM-13 de BM's van het distale convoluut van de 
tubulus, van het dikke opstijgende deel van de lis van Henle, van de médullaire 
verzamelbuis en in mindere mate van de proximale tubulus aan te kleuren. In de 
glomerulus was een zwakke aankleuring te zien langs de glomerulaire liswand en in de 
mesangiale gebieden, evenwel zonder duidelijke GBM aankleuring. MAb JM-13 herkende 
ook het celoppervlak geassocieerde HS aanwezig op de basolaterale celmembranen van 
proximale tubulus epitheelcellen, op de celmembranen van gekweekte humane en ratte 
glomerulaire viscerale epitheelcellen, van rat mesangiumcellen en van humane levercellen 
in kweek en in coupes. 
In hoofdstuk 3 wordt een ander anti-HS m Ab (JM-403) beschreven, die werd verkregen 
na immunisatie met gedeeltelijk opgezuiverd rat glomerulair HSPG. De specificiteit van 
deze mAb voor HS werd aangetoond met ELISA studies, remmingsexperimenten en 
indirecte IF in combinatie met specifieke glycosaminoglycaan afbrekende enzymen. In de 
indirecte IF werd een duidelijke homogene, fijn granulaire aankleuring gezien van de 
GBM, het kapsel van Bowman en de arteriewanden. De andere BM's in de nieren 
(tubulaire BM's en de BM's van de peritubulaire capillairen) kleurden aanzienlijk zwakker 
aan. De indirecte immuno-electronenmicroscopie liet een kleuring zien van de gehele 
breedte van de GBM. Wanneer mAb JM-403 intraveneus werd ingespoten in ratten, werd 
een kortdurende binding langs de glomerulaire capillair wand gevonden en ontstond 
onmiddelijk een dosisafhankelijk, kortdurende en selectieve Proteinurie. Deze resultaten 
demonstreren de belangrijke funktie van HS bij de handhaving van de ladingsafhankelijke 
permeabiliteit van de GBM. 
Vergelijking van de bindingspatronen van beide anti-HS mAb's JM-13 en JM-403 geeft 
aan dat deze antistoffen verschillende epitopen op HS herkennen. MAb JM-13 herkent 
naast HS en HSPG tevens héparine, maar geen andere glycosaminoglycanen of BM 
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componenten. Bovendien herkent deze antistof op de Westem blot HSPG niet meer na 
behandeling met HNO2. Dit toont aan dat het epitoop is gelocaliseerd in het N-
gesulfateerde deel van HS. JM-403 daarentegen herkent zowel HS als hyaluronzuur, maar 
bindt niet aan héparine of andere glycosaminoglycanen. Hyaluronzuur en HS zijn beiden 
opgebouwd uit dezelfde disaccharide eenheden N-acetyl-glucosamine en glucuronzuur. De 
aanwezigheid van N- of O-gebonden sulfaatgroepen is kennelijk niet van belang of storend 
voor de JM-403 herkenning. Deze gegevens suggereren dat het JM-403 epitoop gelocali-
seerd is binnen een cluster van ongesulfateerde glucuronzuur-N-acetyl-glucosamine 
eenheden. 
Naast de hierboven beschreven mAb's tegen verschillende epitopen van HS, werden 
ook m Abs ontwikkeld tegen het core proteine van humaan GBM HSPG (Hoofdstuk 4). 
Van de . 18 m Abs tegen het HSPG-core eiwit werd er één (JM-72) in detail 
gekarakteriseerd met behulp van ELISA studies, Western blotting en 
remmingsexperimenten. De localisatie van het HSPG-core eiwit werd bestudeerd in de 
indirecte IF en met behulp van indirecte immuno-electronenmicroscopie. Het blijkt dat de 
GBM het sterkst aankleurt in een lineair patroon, terwijl alle andere renale BM's een 
zwakkere lineaire aankleuring vertonen. Immuno-elektronenmicroscopische opnamen 
tonen de localisatie van het epitoop in de gehele GBM, het meest uitgesproken in de 
lamina rara interna. 
De distributie van HSPG werd met behulp van indirecte IF in een groot aantal humane 
weefsels bestudeerd met m Ab JM-72 en m Ab JM-403. Terwijl anti-HS m Ab JM-403 alle 
BM's aankleurt, blijkt anti-HSPG-core proteine mAb JM-72 alleen de BM's van 
dwarsgestreepte-, gladde- en hart-spiercellen niet aan te kleuren, terwijl alle andere BM's 
positief zijn. De distributie patronen van het core proteine van GBM HSPG (waartegen 
mAb JM-72 is gericht) verschilt in de diverse weefsels van die in de literatuur beschreven 
voor antistoffen tegen EHS HSPG. MAb JM-403 herkent naar alle waarschijnlijkheid de 
HS ketens van beide typen BM HSPG's. De resultaten van de drie hierboven beschreven 
mAb's (anti-HS mAb's JM-13 en JM-403 en anti-HSPG-core proteine mAb JM-72) 
wijzen in de richting van BM heterogeniteit met betrekking tot HSPG. 
De combinatie van de mAb's JM-72 en JM-403 werd ook gebruikt om eventuele 
veranderingen in HSPG-core proteine of HS distributie te bestuderen bij humane 
glomerulonefritiden. Dit onderzoek werd uitgevoerd op coupes van nierbiopten, afkomstig 
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van 95 patiënten lijdend aan 12 verschillende glomerulopathiën (Hoofdstuk 5). Het meest 
opvallende was een sterk verminderde of zelfs geheel afwezige aankleuring van de GBM 
met anti-HS mAb JM-403, die het meest uitgesproken was bij de lupus nefritis, de 
membraneuze glomerulonefritis (GN), de minimal lesions en de diabetische nefropathie. 
De kleuring met anti-HSPG-core mAb JM-72 was echter in al deze biopten onveranderd. 
De afname van de HS kleuring in de GBM zou het gevolg kunnen zijn van een verstoord 
HS metabolisme of van een maskering van de HS epitoop door positief geladen moleculen 
of immuuncomplexen. Tevens kon HSPG worden aangetoond in de mesangiale matrix, 
wanneer deze was toegenomen, en in glomerulaire amyloidneerslagen bij AL en AA 
amyloidose. Tenslotte werd in de stadia II en III van membraneuze GN een onregelmatige 
tot granulaire aankleuring van de GBM gevonden met anti-HSPG-core proteine mAb JM-
72, waarschijnlijk in samenhang met de vorming van spikes. De resultaten van deze 
studie tonen aan dat veranderingen in HS betrokken zijn bij verschillende glomerulaire 
ziekten. 
Omdat verondersteld werd dat een afname van HSPG in de GBM verantwoordelijk zou 
zijn voor de verhoogde permeabiliteit van de GBM in het congenitaal nefrotisch syndroom 
(CNS), hebben we de glycosaminoglycan hoeveelheid en -samenstelling bepaald van de 
GBM en de tubulaire BM's en in de urines van 3 patientjes lijdende aan het Finse type 
van het CNS en deze waarden vergeleken met die van 16 controlekinderen in dezelfde 
leeftijdsgroep. Bovendien werd de glomerulaire HSPG-core proteine en HS expressie 
immunohistochemisch bestudeerd met de mAb's JM-72 en JM-403. Zowel de 
glycosaminoglycanbepalingen als de immunohistochemische analysen lieten geen 
verschillen zien tussen de patiënten met het Finse type van het CNS en de controle groep. 
Deze resultaten geven aan dat de verhoogde glomerulaire doorlaatbaarheid bij deze ziekte 
niet het gevolg is van HSPG afwijkingen. 
Met behulp van de in dit proefschrift beschreven en gekarakteriseerde anti-HS(PG) 
mAb's is het mogelijk om de rol van HSPG, in relatie tot de renale hemodynamiek en 
glomerulaire eiwituitscheiding, in verschillende diermodellen van nierziekten te 
onderzoeken. 
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CURRICULUM VITAE 
Jacob van den Bom werd op 30 mei 1960 geboren te Utrecht. In mei 1979 werd het 
eindexamen Atheneum В behaald aan het Chr. Lyceum te Zeist. Aansluitend werd van 
sept. 1979 tot mei 1980 het propädeutisch jaar aan de Evangelische Hogeschool te 
Amersfoort met goed gevolg doorlopen, waama in datzelfde jaar de studie Biologie aan 
de R.U. te Utrecht werd aangevangen. Het kandidaatsexamen B5* (Medische Biologie) 
werd in sept. 1983 behaald, het doctoraal examen in februari 1987. De 
afstudeerrichtingen waren: immunologie (eerste hoofdvak; prof. Ballieux, AZU), neuro-
endocrinologie (tweede hoofdvak; prof. Swaab, Ned. Inst, voor Hersenonderzoek, 
Amsterdam) en moleculaire celbiologie (bijvak; prof. Voorma, RUU). 
Vanaf 1 maart 1987 is de schrijver aangesteld als wetenschappelijk onderzoeker op het 
Laboratorium voor Nierziekten in het Radboud Ziekenhuis te Nijmegen. Het in dit 
proefschrift beschreven onderzoek kon worden uitgevoerd dankzij een subsidie van de 
Nier Stichting Nederland. Vanaf 1 maart 1991 is een eveneens door de Nier Stichting 
Nederland gesubsidieerd onderzoek van start gegaan, waarin, voortbouwend op de 
resultaten van het eerste onderzoek, de mogelijke rol van heparan sulfaat proteoglycan bij 
de diabetische nefropathie wordt uitgediept. 
De schrijver is gehuwd met Jeanette Roks en zij ontvingen drie kinderen, Daan, Joost 
en Geert. 
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Stellingen behorend bij het proefschrift 
MONOCLONAL ANTIBODIES 
AGAINST 
GLOMERULAR BASEMENT MEMBRANE 
HEPARAN SULFATE PROTEOGLYCAN 
1. Het is zeer aannemelijk dat veranderingen in de funktionele beschikbaarheid van 
de negatief geladen sulfaat en/of carboxyl groepen van heparan sulfaat in de 
glomerulaire basaal membraan directe gevolgen heeft voor de ultrafiltratie van 
serum eiwitten, met name van albumine. 
2. De locale produktie van reactieve zuurstofradicalen door ontstekingscellen en/of 
glomerulaire cellen zou een goede verklaring kunnen zijn voor de door ons 
waargenomen verminderde heparan sulfaat aankleuring in de glomerulaire basaal 
membraan bij diverse humane glomerulopathiën. (Kishihara et al. Proc Natl Acad 
Sci USA 1992; 89: 6309-6313) 
3. De selectieve basaal membraan aankleuring, die door ons wordt waargenomen met 
verschillende anti-heparan sulfaat antistoffen, is te verklaren door een "blocking 
effect" als gevolg van een locale interactie van heparan sulfaat met één of 
meerdere heparan sulfaat bindende eiwitten. 
4. Basaal membranen zijn heterogeen met betrekking tot heparan sulfaat proteoglyca-
nen. 
5. Er zijn geen overtuigende aanwijzingen voor een rol van heparan sulfaat proteo-
glycaan in de Pathogenese van het Finse type van het congenitaal nefrotisch 
syndroom. 
6. Ondanks een verhoogde albumine excretie in de urine is de glomerulaire hoeveel-
heid heparan sulfaat niet afgenomen bij experimentele diabetes in de rat. 
7. De Nederlandse Spoorwegen maken het ruimschoots mogelijk om dagelijks 
voldoende afstand van het werk te nemen. 
8. De naam "Verenigde Reformatorische Kerk in Nederland" is wel de meest 
verwarringscheppende naam die bedacht kan worden voor de toekomstige "Samen 
Op Weg" kerk. 
9. Een promotie aan een Katholieke Universiteit wordt ruimschoots gecompenseerd 
door een feest 's avonds in gebouw "Calvijn". 
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